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Protein kinases are enzymes that promote phosphorylation – transferring a phosphate group from ATP to 
a substrate protein. Due to the central involvement of kinases in growth factor signaling, cell cycle 
control, apoptosis and angiogenesis, they have been linked to cancer development and are attractive drug 
targets for cancer therapeutics. Staurosporine is a natural, potent kinase inhibitor, initially isolated from 
the bacterium Streptomyces staurosporeus. It does not serve as a viable therapeutic drug since it exhibits 
poor selectivity. However, this natural product has been widely used in research and serves as a 
“structural muse” for the design of protein kinase inhibitors with improved specificity and selectivity.  
 
This project involved the synthesis of potential reversible and irreversible kinase inhibitors inspired by the 
natural product staurosporine. A primary objective was to develop compounds with improved selectivity, 
while maintaining the potency of staurosporine. The design strategy incorporated a driving portion, 
resembling the structural features of staurosporine, carrying a specific warhead to form a reversible or 
irreversible interaction within the kinase domain. This project comprises of two main parts – the design of 
pyrrolocarbazole structures and the generation of structures based on the “open” form of the 
indolocarbazoles. The development of the pyrrolocarbazole compounds was motivated by the 
encouraging results exhibited by 6-(3-hydroxypropyl)pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione (29), 
previously synthesized in our group.  
 
The major steps involved in the synthesis were the reduction, oxidation, Wittig, Diels-Alder and 
aromatization reactions. Introducing different warheads, allowed for the generation of unaromatized and 
aromatized pyrrolocarbazole target compounds having an N-tether hydroxyl, propargyl and nitrile 
functionality. The synthesis of the “open” form structures utilized click chemistry. The synthetic 
methodology towards the bisaryl maleimide structures involved a “double click” approach, which 
presented various challenges. In addition, the synthesis of indolyl maleimide click products also proved to 
be difficult. Finally, a promising route towards bisamino maleimide compounds led to the development of 
two target compounds containing the acryloyl and propargyl warhead functionality respectively.  
 
Biochemical screening by German collaborators against the wild type, and two mutant forms of the EGFR 
kinase, was undertaken with the target compounds, utilizing the HTRF KinEASE-TK assay. Overall, only 
the aromatized pyrrolocarbazole N-two carbon linker hydroxyl target compound exhibited inhibitory 
activity in the μM range. Finally, a number of optimization measures are described to potentially improve 
the inhibitory activity of both the pyrrolocarbazole compounds and bisamino maleimides.  




Proteïn kinase is ensieme wat fosforilasie bevorder – deur ń fosfaat groep van ATP na ń substraat proteïn 
oor te plaas. As gevolg van die sentrale betrokkenheid van kinase in groei-faktor seine, beheer oor sel 
siklus, apoptosis asook angiogenesis, is hulle gekoppel aan kanker sel toename en is ń aantreklike middel 
vir kanker-terapie. Staurosporine is ń natuurlike, sterk kinase onderdrukker, aanvanglik geïsoleer van die 
bakterium Streptomyces staurosporeus. Ongelukkig dien dit nie as ń bruikbare geneesmiddel nie as 
gevolg van die tekort aan selektiwiteit – vele kinases word geteiken. Nietemin, word die natuurlike 
produk algemeen gebruik in navorsing en dien as ń “strukturele muse” vir die ontwerp van proteïn kinase 
onderdrukkers met verbeterde selektiwiteit en meer spesifiek.  
 
Die projek behels die sintese van potensiёle omkeerbare en onomkeerbare kinase onderdrukkers wat 
geïnspireer is deur die natuurlike produk staurosporine. ń Primêre doel was om verbindings te ontwikkel 
met beter selektiwiteit, wat die effektiwiteit van staurosprine behou. Die ontwerp strategie inkorporeer ń 
dryfdeel wat ooreenstem met die struktuur van staurosporine en ń spesifieke aanvalpunt wat hopelik ń 
omkeerbare of onomkeerbare interaksie binne die kinase-omgewing sal vorm. Die projek bestaan 
hoofsaaklik uit twee dele nl. die ontwerp van pyrrolokarbasoolstrukture, asook strukture wat die “oop” 
vorm van die indolokarbasole namaak.  
 
Die ontwikkeling van die pyrrolokarbasool samestellings was gemotiveer deur die bemoedigende 
resultate vertoon deur 6-(3-hydroxypropyl)pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione (29) wat voorheen 
in ons navorsings-groep gesintiseer was. Die hoofsaaklike stappe betrokke gedurende die sintese was 
reduksie, oksidasie, Wittig, Diels-Alder en aromatisering reaksies. Die bekendstelling van verskeie 
aanvalpunte, maak die ongearomatiseerde en aromatiseerde pyrrolokarbasool teikenprodukte met ń N-
koolstof binding met hidroksiel, propargiel en nitriel funksionele groepe moontlik. Die sintese van die 
“oop” vorm strukture gebruik “click” chemie. Die metode om die sintese van die bisariel-malimied 
strukture na te streef behels ń “dubbele click” wyse, wat baie uitdagings gehad het. Verder het die sintese 
van die indolyl-malimied “click” produkte ook verskeie problem opgelewer. Uiteindelik het ń baie 
belowende roete na bisamino-malimied verbindings gelei, en die ontwikkeling van twee teiken produkte, 
met ń akryloyl en propargiel aanvalpunt funktionele groepe, was bereik. 
 
Biochemiese keuring deur Duitse medewerkers teen die wilde tipe, asook twee mutant vorms van die 
EGFR kinase, was onderneem teen die teiken verbindings, met gebruik van die HTRF KinEASE-TK 
toets. Oor die algeheel, was die aromatiese pyrrolokarbasool met die N-koolstof verbinding met die 
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hidroksiel groep, die enigste verbinding wat onderdrukkende aktiviteit in die μM grens getoon het. 
Verskeie optimisering strategieё was bespreek om die potentiёle onderdrukkings aktiwiteit van die 
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A note to the reader regarding the interpretation of NMR spectra  




C NMR spectra. The 
indole moiety was labeled first in an alphabetical order and an anti-clockwise manner. Hence, once an 
atom received a label, the label remained constant for the subsequent intermediates, with only the 
transforming functional groups changing. This assignment was applied to ease the analysis of spectra and 
improve the ease of reading when referring to the same atom in different substrates.  
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CHAPTER 1 – CANCER 
1.1 Cancer 
1.1.1 Definition and statistics 
In 1889 the word ‘cancer’ was defined by the Oxford English Dictionary (OED) as “a malignant growth 
or tumor in different parts of the body that tends to spread indefinitely and to reproduce itself and also to 
return after removal; it eats away or corrodes the part in which it is situated and generally ends in 
death.”
[1]
 This term has embedded itself in our thought patterns, notorious for its uncontrollable, lethal 
and devastating process.
[2]
 Metaphors of decay, destruction and hideous consumption have been 
associated with the word ‘cancer’. These implications account for its use not only when referring to the 
pathological condition, but when talking about insidious, uncontrollable and frightening things.
[2]
 
According to the definition, the outcome of cancer is mortality. Extensive research and progress in the 
field of cancer has led to the definition being changed for the first time in 111 years. The OED now 
defines cancer as “what happens when a group of cells grow in a disorderly and uncontrollable way and 
invade neighboring tissues. They may or may not later spread into distant parts of the body. The cancer 




Despite the rapid developments and enormous amount of research over the past 20 years, cancer 
continues to be a leading cause of death and a worldwide killer.
[3]
 Globally, one in five men and one in six 
women will develop cancer before the age of 75. Furthermore, one in eight men and one in twelve women 
will die from this disease.
[4]
 According to the World Health Organization (WHO) a global ‘tidal wave’ of 
cancer is on the horizon, warning that by 2035 approximately 24 million people will have the disease 
(figure 1).
[5]
 The International Agency for Research on Cancer (IARC) reported that in 2012 there were 
14.1 million new cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 
years of diagnosis) worldwide. The number of cancer cases is expected to rise to 22 million annually 
within the next two decades, while deaths are predicted to rise to 13 million per year.
[6]
 Previously 
thought of as a first world disease, statistics show an alarming increase of cancer cases and mortality in 
developing countries. More than 60% of global cancer cases occur in Africa, Asia and Central and South 
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Graph illustrating the predicted cancer cases worldwide. Image reproduced from following reference.
[5]
 
This global cancer burden is attributed mainly to population growth and increasing lifespan, placing 
further strain on developing countries due to the lack of early detection and access to treatment.
[6]
 In 
addition, the costs spent on treatment, together with the economic and social inactivity from premature 
death and disability has damaging effects on economies worldwide.
[4]
 WHO reported an approximate total 
annual economic cost of cancer reaching US $ 1.16 trillion in 2010.
[6]
 According to the IARC, primary 
prevention is essential to address the alarming rise of the cancer burden.
[5]
 Efficient strategies towards 
prevention and early detection are crucial to complement the crucial research carried out over the last few 
decades to develop improved cancer treatments.
[6]
 
Over the past two centuries, significant discoveries in the cancer field have established a rich and 
complex body of knowledge of this remarkably diverse neoplastic disease. New observations and findings 
lead to more questions, adding further layers of complexity to understanding cancer. In 1971, President 
Nixon signed the National Cancer Act, declaring “war” on cancer and providing funds for the support of 
cancer research and application of research results – fuel for the revolution in molecular biology.
[7]
 
Although cancer remains an extremely complicated pathologic condition and challenging questions 
persist, many scientists foresee cancer research developing into a logical science where the intrinsic 
complexity of the disease will become understandable.
[8]
 
1.1.2 Hallmarks of cancer 
In cancer research, a logical framework of organizing principles, known as hallmarks, have been 
proposed, in order to have a better understanding of the biology of this disease.
[9]
 Before discussing these 
hallmarks, a simple explanation of tumorigenesis is given. As mentioned in the introductory paragraph, 
cancer is a term given to a group of diseases that can develop in virtually any of the body’s tissues. Each 
form of cancer has its unique features, but the basic processes that generate cancer are similar.
[10]
  
Stellenbosch University  https://scholar.sun.ac.za
Chapter 1 – Cancer 
3 
 
A representation of the progression of cancerous cells is illustrated in figure 2. All cancers start in the 
body’s fundamental unit of life - when cells’ genetic material become damaged or changed, producing 
mutations. These mutations affect the orderly manner of cell proliferation, transcription, growth, 
migration, differentiation and death.
[11]
 Cells generated from the abnormal ancestral cell and its offspring 
also display uncontrollable activity. These abnormal cells form a mass of tissue known as a tumor which 
may be cancerous or benign. An in situ tumor is formed when the tumor remains in the tissue of origin, 
while malignant tumors invade nearby tissue generating new tumors (metastases) in the body.
[10]
 Tumor 
formation and progression however, is not dependent on cancer cells alone, but consists of an intricate 















Representation of the progression of cancerous cells. Image reproduced from following reference.
[10]
 
The transformation of normal human cells into malignant derivatives is a multistep process that develops 
over time, reflecting a long and complex succession of genetic changes.
[10]
 Hanahan and Weinberg 
enumerated six biological capabilities acquired during this multistep development, known as the 
hallmarks of cancer. They include sustaining proliferative signaling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and 
metastasis (Figure 3). These six hallmarks are used to explain and rationalize the ability of cancer cells to 
overcome the anticancer defense mechanism hardwired into cells and tissues.
[8-9]
 Here follows a brief 
explanation of each acquired capability: 
A) Sustaining proliferative signaling 
There are two main classes of genes which play a critical role in controlling the cell cycle, namely: proto-
oncogenes (encourage cell division) and tumor-suppressor genes (inhibit cell division). Proto-oncogenes 
code for proteins that receive and process growth-stimulating signals from other cells.
[10]
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The signaling starts with the production of mitogenic growth signals (GS) which are transmitted into the 
cell by specific transmembrane receptors. These GS convey a stimulatory signal to different proteins 
thereby activating genes to promote growth.
[8]
 When proto-oncogenes become mutated they are called 
oncogenes. Oncogenes cause the proteins involved in the growth-promoting pathways to be overactive or 
oversensitive.
[10]
 Tumor cells show reduced dependence on stimulation form their normal tissue 
microenvironment by generating their own GS.
[8]
 In this manner proliferative signaling is sustained.  
B) Evading growth suppressors 
In a similar manner to stimulatory messages, inhibitory messages are transmitted to the cell’s nucleus by 
tumor-suppressor genes. When these antigrowth signals are not received, the growth promoting pathways 
operate without restraint, leading to uncontrolled cellular growth.
[8, 10]
 
C) Resisting cell death 
Programmed cell death (apoptosis) is crucial when abnormalities are detected. Cancer cells can acquire 
resistance to apoptosis though a variety of strategies. Mutation of the p53 tumor-suppressor gene which 




D) Enabling replicative immortality 
Acquired deregulation of cell-to-cell signaling (abnormal proliferation and apoptosis) does not account 
for the enormous cell population that makes up macroscopic tumors. This introduces the fourth hallmark 
known as replicative immortality. Cells carry an intrinsic cell-autonomous program that prevents them 
from proliferating indefinitely. This system is controlled by a counting device involving DNA segments 
at the end of chromosomes, known as telomeres. With each chromosome replication the telomeres 
become shorter and eventually reach a limit that causes the cell to stop dividing, resulting in cellular 
death. An enzyme known as telomerase, enables cancer cells to proliferate endlessly, by systematically 
replacing the telomeric segments which restrict replicative immortality.
[8, 10]
 
E) Inducing angiogenesis 
The process of angiogenesis generates tumor-associated neovasculature to supply the cancer cells with 
nutrients and oxygen. In adults, angiogenesis is only transiently turned on, but during tumor progression 
an “angiogenic switch” remains on to continually sprout new vessels and sustain growth.
[9]
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This angiogenic switch is governed by counterbalancing positive or negative factors that either encourage 
or block angiogenesis.
[8]
 Angiogenesis is induced by factors such as vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF).  
Pericytes which support blood vessel growth express PDGF receptors, while VEGF receptors are 
expressed on the endothelial cells of tumor vessels. Pericytes produce VEGF and endothelial cells 
produce both VEGF and PDGF. Each cell type is therefore able to promote proliferation and survival of 
the other cell type, by producing the specific growth factor.
[12]
 Tumors threaten human life when they 
invade and disrupt the tissues and organs needed for survival. 
F) Activating invasion and metastasis 
Malignant tumors are capable of shedding abnormal cells into the blood and lymph systems, establishing 
new tumors throughout the body. This invasion to adjacent tissue and formation of new cancer colonies is 
known as metastases and is the cause of 90% of cancer deaths.
[8]
 The mechanisms underlying invasion 
and metastasis are complex and are not fully understood. Both processes involve changes in the physical 
coupling of cells to their microenvironment and activation of extracellular protease. The affected proteins 
include cell-cell adhesion molecules (CAMs) and integrins, which link cells to extracellular matrix 
substrates. E-cadherin is an example of a CAM which undergoes mutational inactivation when invasion 
and metastasis is observed.Over the past few years a number of advances have been made in delineating 
the features of this hallmark, but representation of these advances are yet to be completed.
[8-9]
 
It is believed that almost all cancer cells will acquire these hallmark capabilities in a manner which differs 
both mechanistically and chronologically.
[8]
 An enabling characteristic associated with the acquisition of 
these hallmarks is genome instability. Defects in genome maintenance and repair encourage tumor 
progression, by accelerating the rate of accumulative favorable genotypes in evolving neoplastic cells.
[8-
9]
Another enabling characteristic is contributed to the tumor-associated inflammatory response, which 
enhances tumerogenesis. Inflammation can supply the tumor microenvironment with bioactive molecules, 
survival factors, proangiogenic factors, invasion/metastasis and many other hallmark facilitating 
programs.
[9]
 Recent research suggests two additional emerging hallmarks of cancer. Firstly, deregulating 
cellular energies involves altering and reprogramming of cellular metabolism to support neoplasmic 
growth. The second emerging hallmark is the defective immunological monitoring of tumors that evade 
immunological destruction. This capability involves deficiencies in the development and function of T 
and B lymphocytes, macrophages, and natural killer cells. A representation of the six hallmarks, the 
emerging hallmarks and enabling characteristics is displayed below in figure 3.
[9]
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The six hallmarks of cancer are illustrated in the left diagram. Two new emerging hallmarks and enabling 





The remarkable progress of research into the mechanisms of cancer pathogenesis provided scientists a 
mode to devise new strategies and generate effective weaponry to combat cancer.
[13]
 In this respect, 
cancer treatment has evolved from nonspecific, high-dose chemotherapy to targeted treatment.
[14]
 The first 
tool available for treatment was surgical removal of the tumor. For this method of treatment, the 
introduction of radical mastectomy and en bloc resection in 1894 by William Halsted, had a profound 
influence, leading to the application of en bloc resection to remove all other cancers. Surgery was the only 
option for cancer treatment in the first era of the 20
th
 century, but only a minority of patients could be 
cured by this type of treatment alone. Together with the discovery of X-rays came the era of radiation 
therapy. In 1928, fractional radiation treatments were shown to cure neck and head cancers.The 
introduction of cobalt teletherapy initiated the modern era of radiation treatments in 1950.
[7]
 Surgery and 
radiotherapy dominated the field of cancer therapy into the 1960s, but sadly only 33% of all cancers could 
be cured by these two approaches - alone or combined - due to the presence of micro-metastases.
[7, 15]
 
In the early 1900s, Paul Ehrlich made a concerted effort to develop drugs to treat infectious diseases. His 
interests involved creating chemicals to cure cancer, a term he coined “chemotherapy”. Another major 
contribution Ehrlich made to cancer drug development was the discovery of using animal models to 
screen drugs for their anticancer activity.
[15]
 The first half of the 20
th
 century was dedicated to model 
development for screening of various drugs for their potential activity against cancer cells.
[7]
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The start of the modern era of chemotherapy can be traced back to World War II when an accidental spill 
of sulfur mustards on troops led to depleted bone marrow and lymph nodes of the men exposed to the 
gases. This observation encouraged Louis Goodman and Alfred Gilman to use nitrogen mustard to treat a 
patient with non-Hodgkin’s lymphoma. For the first time it was proved that chemotherapy could induce 
tumor regression. Another important event that provided encouragement for the use of anticancer drugs 
was the use of antifolates by Sydney Farber to induce remission in children with acute lymphoblastic 
leukemia (ALL).
[15-17]
 These discoveries lead to a national screening effort at the NCI and the use of 
chemotherapy became more popular.
[16]
 Still, the controversy and hostile attitude towards chemotherapy 
remained. The main concern was whether the drugs caused more harm than good.
[15]
 A major 
breakthrough in the mid-1960s gave evidence that combination chemotherapy (combination of drugs, 
each with a different mode of action) could cure childhood leukemia and Hodgkin’s disease. This led to 
remarkable advances in the field of chemotherapy and the use of combination treatment and 
chemotherapy as an adjuvant to surgery and radiation therapy.
[15-16]
 The various pivotal events in cancer 





Pivotal events in the treatment of cancer. Image reproduced from following reference.
[7]
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1.2.2 Targeted treatment 
Paul Ehrlich’s ideas and bold assumptions inspired generations of scientists to devise powerful molecular 
cancer therapeutics. His postulate of creating “magic bullets” paved the way for targeted therapy and 
today Ehrlich’s ideal of “aiming precisely” using drugs with high efficacy dominates modern drug 
discovery.
[15]
 The revolutionary insights in cell biology and the mechanisms associated with the hallmarks 
of cancer initiated the era of targeted therapy.
[9, 16]
 A milestone in the targeted revolution was the 
development and clinical success of Imatinib (Gleevec) for chronic myeloid leukemia (CML).
[13]
 
Imatinib inhibits the kinase activity of all proteins that contain ABL, ABL-related genes (ARG) protein, 
or platelet-derived growth factor receptor (PDGFRs), as well as the KIT tyrosine kinase.
[17]
 The ABL 
gene is found on chromosome 9 of the Philadelphia chromosome and encodes for a tightly regulated 
tyrosine kinase. The Philadelphia chromosome is the product of the translocation between chromosome 9 
and chromosome 22. Chromosome 22 carries the breakpoint cluster region (BCR) gene. The principle 
target of Imatinib is this BCR-ABL fusion protein which involves the pathogenesis of CML.
[14, 16, 18]
 
Proof-of-principle was now established that targeted therapy towards specific molecular abnormalities 
could possibly convert certain cancers into manageable chronic illnesses.
[7]
 This led to numerous efforts 
to develop and test small-molecule inhibitors targeting effectors in the acquired biological capabilities of 
cancer cells.
[15]
 Most of these hallmark-targeting cancer drugs have been directed towards specific 
molecular targets as seen in figure 5. This type of specificity was thought to be advantageous as it 
presents targeted inhibitory activity without harming healthy tissue. Despite the remarkable achievements 




Clinical responses have frequently been temporary, being followed by almost-inevitable relapse.
[9]
 In the 
case of Imatinib, in the acute leukemic phase, treatment leads to drug-resistant cells that display mutations 
in the catalytic kinase domain of ABL. The presence of drug-resistant cells before drug exposure has 
proven the fact that cancers possess a range of drug-resistant mutant sub-clones, even before treatment.
[16]
 
Similarly to the development of resistance, the target protein governs whether the drug will work and 
which patients will respond to treatment. This is illustrated by the kinase inhibitor, gefitinib, which blocks 
the activity of epidermal growth factor receptor (EGFR), which is overexpressed in 40-80% of lung 
cancers. However, gefitinib causes partial remissions in only 10-15% of patients. This response was 
attributed to the presence of mutations around the ATP binding pocket of the EGFR proteins. Patients that 
responded to gefitinib tend to carry these specific mutations.
[13, 16] 
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Illustrative examples of inhibitors which target the specific hallmarks of cancer and enabling characteristics. Image 
reproduced from following reference.
[9]
 
For many years Ehrlich’s “magic bullet” was interpreted by scientists as a compound that specifically 
targets a single oncoprotein. Knowing that cancer is a multi-factorial disease that has a number of parallel 
signaling pathways which support core hallmark capabilities, has changed the interpretation of Ehrlich’s 
vision to a “ multiple magic bullet”.
[15]
 Targeting crucial signaling proteins that regulate the hallmarks of 
cancer cells will potentially result in more effective and durable therapies.
[9]
 Furthermore, as a result of 
the resistance towards single agents, Ehrlich’s idea of combination therapy is essential for tumor 
eradication.
[15-16]
 Therefore, network-targeted combination therapy is a promising strategy for the future 
development of more efficacious weaponry against cancer.
[15]
 The discovery of small molecule kinase 
inhibitors has attracted growing interest for novel drug development and targeting protein kinases has 
been the subject of intensive study.
[19-20]
 Thus, an understanding of protein kinases is necessary and will 
be discussed in the following section. It must be noted that small molecule kinase inhibitors are not the 
only type of targeting therapeutic agent. Numerous drugs have been investigated and developed for 
targeted therapies and have been approved for the use in cancer treatment. These include monoclonal 
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1.3.1 Kinases and their relation to cancer 
The reversible phosphorylation of proteins is the most general regulatory device adopted by eukaryotic 
cells and represents a key step in many crucial cellular processes including metabolism, growth, division, 
differentiation, motility, organelle trafficking, membrane transport, muscle contraction, immunity, 
learning and memory.
[23-25]
 Protein phosphorylation is the most prominent post-translational modification 
to both intracellular and extracellular signals.
[20, 24]
 In addition, perturbed signal transduction is a major 
cause of deregulated cell growth in both benign and malignant neoplasms.
[26]
 Protein kinases are enzymes 
that phosphorylate their substrate proteins by catalyzing the transfer of the terminal γ-phosphate of 
adenosine triphosphate (ATP), to the hydroxyl acceptor group on the side chains of serine, threonine, or 
tyrosine residues (in eukaryotes) of the substrate protein (Scheme 1).
[19]
 Due to the central involvement of 
kinases in growth factor signaling, cell cycle control, apoptosis and angiogenesis, they have been linked 





General scheme for the phosphorylation of a serine residue by a kinase. 
1.3.2 The kinase superfamily 
An ultimate purpose of research into signal transduction is to obtain a full understanding of protein 
phosphorylation in normal and disease states.
[25, 27]
 An ambitious goal to achieve this knowledge, pursued 
by Hanks and Hunter, was to determine the number of protein kinases encoded by eukaryotic genomes 
and assess the structures, functions and evolutionary relationships.
[27-29]
 The advent of gene cloning and 
sequencing techniques led to an exponential rise in the number of unique members in the protein kinase 
family being identified. An immense amount of progress in the pregenomic and genomic era has 
contributed to the completion of the first draft of the human genome, allowing the identification of almost 
all human protein kinases. 
[25, 27-29]
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The human kinome comprises of 518 protein kinases (478 eukaryotic protein kinases and 40 atypical 
protein kinases), approximately 1.7% of all human genes.
[27]
 Protein kinases constitute one of the largest 
human gene families and the relationships between the members of the complete superfamily is depicted 
in a phylogenic tree shown in figure 6. The most widely used human protein kinase classification 
phylogenic tree is constructed based on public and proprietary genomic, complementary DNA, and 
expressed sequence tag (EST) sequences.
[25, 27-28]
 The tip of each branch represents a kinase and similarity 
is inversely related to the distance between positions on the tree.
[30]
 This similarity among various kinases 
is the sequence and structure of their catalytic domain. The feature of a conserved catalytic domain was a 
main attribute used in the identification of the protein kinase family.
[28-29]
 There are 7 major groups, 
consisting of smaller kinase families with highly related sequences and biological function. The grey 
branches in the center of the tree represent other kinases. According to Manning’s classification of protein 
kinases, the major groups are: TK (tyrosine kinases); TKL (tyrosine kinase-like); AGC; CAMK 
(Calcium/calmodulin-dependant protein kinase); CKI (Casein kinase 1); CMGC; STE (Homologs of yeast 





The phylogenic tree depicting the human kinome. Image reproduced from following reference.
[31]
 For enlarged 
image visit kinase.com/human/kinome/. 
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One of the most commonly targeted families for the development of cancer therapeutics is the receptor 
tyrosine kinases (RTKs), which include the epidermal growth factor receptors (EGFRs), the vascular 
endothelial growth factor receptors (VEGFRs) and the platelet-derived growth factor receptors 
(PDGFRs).
[20]
 The RTK class comprises 58 known members that are distinguished among 20 subfamilies. 
The fact that more than half of these cell-surface receptors are known to be mutated or overexpressed in 
diseases make them attractive candidates as targets. The EGFR family has four members: EGFR, human 
EGRF-related 2 (HER2) and the kinase impaired HER3 and HER4.
[32]
 For the purpose of this project 
particular interest is directed towards the inhibition of EGFRs. 
Cloning and sequencing of EGFR cDNA in the 1980s provided insight into its molecular architecture. 
EGFR is a large flexible glycoprotein with a modular structure containing an extracellular ligand-binding 
domain, a transmembrane region, and a cytoplasmic tyrosine-kinase region flanked by regulatory regions 
which are non-catalytic (tail).
[32]
 When a ligand binds to this RTK, dimerization occurs. 
Autophosphorylation of key tyrosine residues in the activation loops of their catalytic kinase domains 
then follows, resulting in subsequent stimulation of tyrosine-kinase activity.
[32]
 In the case of EGFR, the 
extracellular region is composed of four articulated domains that recognize the epidermal growth factor 
(EGF) ligand. On binding of the monomeric ligand to the receptor, the receptor opens up and binds to 
another copy of itself.
[33-34]
 As seen on the right of figure 7, two ligands (red) bind to an EGF-induced 
dimer (blue). When EGF is absent the receptor folds back onto itself (left of figure 7).
[33]
 EGFR 
dimerization is mediated entirely by receptor-receptor interactions and is activated by one of its many 
ligands, such as EGF or transforming growth factor alpha. Dimerization can either be with another EGFR 
(homodimerization) or one of the other receptors from the HER family (heterodimerization). This leads to 
the activation of the catalytic system of the tyrosine kinase, bringing about stimulation of signaling 
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1.3.3 Kinase architecture 
Before addressing the topic of kinase inhibitors, some insight into the architecture of kinases and their 
functioning is required. Protein kinase catalytic domains range from 250-300 amino acid residues and 
consist of 12 conserved subdomains of alternating regions of high and low conservation.
[28]
 Hanks and 
Hunter proposed that the conserved subdomains are either directly involved in the catalytic function or 
indirectly by contributing to the formation of the active site. On the other hand, the non-conserved regions 
allow the conserved regions to come together, forming loop structures.
[27-28]
 With technical advances, 
Hanks and Hunter’s findings and proposals have been confirmed and a greater understanding of the 
internal composition of kinases has been obtained over the years.The structural core of eukaryotic protein 
kinases is organized in such a way that it contributes in a unique manner to their dynamic regulation and 
catalysis. This universal regulatory mechanism developed by protein kinases is associated with a large 
activation segment that can be folded or unfolded in the course of cell functioning. The complex 
regulatory machinery and their function as molecular switches, distinguish eukaryotic protein kinases 
from most metabolic enzymes.
[36-37]
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The catalytic domain contains most of the crucial machinery for catalysis and for scaffolding, to ensure 
controlled function of downstream signaling. Most protein kinases have a common bi-lobal fold made up 
of helical and beta subdomains.
[37]
  
The two lobes converge to form a narrow hydrophobic pocket known as the ATP binging site.
[38]
 The 
smaller N-terminal lobe (N-lobe) consists of five-stranded anti-parallel β-sheet coupled to a helical 
subdomain. These β-strands are essential for binding of ATP and contain a flexible glycine-rich loop (G-
loop/P-loop) which anchors and position the γ-phosphate for phosphate transfer. The larger C-terminal 
lobe (C-lobe) is highly helical, plus a β-sheet, and is fairly conformationally stable. The helical 
subdomain forms the core of the kinase and serves as a tethering surface for protein/peptide substrates. 
The β-sheet resting on the core forms the bottom surface of the active site and consists of four short β-
strands which contains much of the catalytic machinery. Between β-strands 6 and 7 lies the catalytic loop 
which direct the γ-phosphate of ATP to the protein substrate. Between β-strands 8 and 9 is the DFG 
motif, where a conserved aspartate (Asp) binds to a catalytic magnesium ion and engages in a salt bridge 
formation. The activation loop, containing threonine, serine or tyrosine residues, lies on the outer surface 
of the C-lobe and occupies part of the active site when the residues are not phosphorylated. When an 
upstream kinase activates phosphorylation the activation loop exposes the active site, allowing ATP to 
bind and transfer its γ-phosphate to a substrate. This substrate can often be a downstream kinase.
[36-38]
 
The flexible hinge region which connects the N-lobe and C-lobe usually has one hydrogen donor with two 
hydrogen acceptors on one or either side of the donor atom.
[38]
 The hinge region plays an integral role in 
the design of the kinase inhibitors, as hydrogen interactions to this region are considered vital for kinase 
recognition.
[39]
 Another residue that plays an important role in protein kinase activation is the gatekeeper 
(gk) residue.
[38]
 The size/volume of the gatekeeper side chain dictates access into the hydrophobic pocket. 
77% of human kinases have relatively large gatekeeper residues (Leu, Met, Phe) while 21% of them 
(mostly in TK) have smaller gatekeeper residues (Thr, Val). Mutagenesis resulting in a reduction in 
size/volume of the gatekeeper side chain provides a potential inhibitor selectivity of the ATP site. 
Conversely, mutations that result in the steric enhancement of gatekeeper side chains have been 
responsible for drug resistance in certain patients.
[36]
 T790M in EGFR is an example of such a mutation, 
where the gatekeeper residue threonine 790 is substituted with a much bulkier methionine side chain 
which interferes sterically with the inhibitor binding and increases ATP affinity.
[40]
 Figure 8 shows ATP 
bound in a kinase active site, depicting the N-,C-lobe, hinge region and gatekeeper.
[38]
 Although the 
internal architecture of kinases is similar, they exhibit a variety of conformational states. Since kinase 
inhibitors target either the active or inactive conformation of kinases, these two distinctive states will be 
briefly discussed. 
Stellenbosch University  https://scholar.sun.ac.za
















Diagram illustrating ATP bound in the active site between the N- and C-lobe. The hinge region and gatekeeper are 
depicted on the right. Image reproduced from following reference.
[38] 
Johnson and co-workers stated that, “All active kinases are alike, but an inactive kinase is inactive after 
its own fashion.”
[41]
 Kinases switch between active and inactive conformations, a process that is highly 
regulated and complex. Analysis of local spatial pattern (LSP) alignments of kinases has revealed an 
architecture that is fully assembled in the active conformation of the kinase, but that is broken in the most 
inactive kinases. The LSP studies further revealed the presence of conserved hydrophobic motifs which 
contribute to the overall kinase assembly and architecture. These hydrophobic motifs, termed spines, 
provide a firm, but flexible connection between the lobes and are anchored to the F-helix in the middle of 




The R-spine is assembled as a consequence of phosphorylation, and causes the DFG motif to flip so that 
the phenylalanine is repositioned. This completes the R-spine and reveals the hydrophobic pocket. The 
movement also leaves the Asp to interact with a magnesium ion. This completed R-spine is referred to as 
a “DFG-in” conformation. In the inactive kinase state, the R-spine is broken and is referred to as a 
“DGF-out” conformation. The 180° flip of the highly conserved DFG motif changes the activation loop 
structurally to an inactive (DFG-out) conformation, resulting in obstruction of ATP binding and exposure 
of adjacent allosteric sites.
[42]
 However, it is important to evaluate the overall spine configuration before 
classifying a kinase as active or inactive, since certain DFG-in conformations can be inactive if the R-
spine is disrupted in another way. The R-spine is therefore a fundamental feature of the “switch 
mechanism” and plays a key role in regulation of kinase activity.In a similar manner to the insertion of 
phenylalanine to complete the R-spine, the C-spine is completed by the adenine ring of ATP.
[36-38]
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Although the most crucial catalytic machinery is located in the core of the kinase, the presence of flanking 
regions or domains (linkers and tails) which are anchored to the core, play an essential role in assisting 
catalysis and regulation.
[37]
 Kinases employ a number of different regulatory mechanisms to tightly 
regulate their activity. These regulatory mechanisms have been discussed in literature.
[20, 43-44]
 
Furthermore, multiple specificity mechanisms including structural features, complex formation and 
interactions between kinases and substrates, have been evolved by kinases to recognize particular 






The two hydrophobic spines and F-helix, defining the internal architecture of the protein kinase molecule. The red 





C - lobe 
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1.4 Targeting kinases 
1.4.1 Types of kinase inhibitors 
Protein kinases have developed into one of the more important target class in cancer drug discovery.
[45]
 
The first protein-kinase inhibitors were developed by Hidaka in the early 1980s, following the discovery 
of the first oncogene, vSrc, and its identification as an enzyme with tyrosine kinase activity. Inhibitor 
development projects were initially met with skepticism but the discovery of staurosporine, with its potent 
kinase inhibitor activity, made the pharmaceutical industry take notice and initiate drug development 
efforts. A landmark event occurred in 2001 when Imatinib (Gleevec) was approved for clinical use and 
provided motivation for the pursuit of kinase inhibitor design. Since then, the pharmaceutical industry has 
applied a large portion of their resources to the search for small molecule kinase inhibitors as target 
therapeutic agents.
[38, 45-46]
 Over the past two decades, 23 ATP competitive kinase inhibitor drugs have 
been approved and a large number of compounds are currently in preclinical and clinical development.
[47]
 
Despite the recent successes in targeted therapy and kinase inhibitors, lack of efficacy, drug resistant 




Although protein kinases serve as an attractive candidate to target in oncology, their “drugability” is 
significantly challenging. Three principle ways in which protein kinases can be inhibited exist: ATP-
competitive binding, competitive binding to the protein substrate site, and non-competitive binding at a 
remote site which allosterically disrupts enzyme function.
[20]
 Understanding inhibitor binding modes is 
very useful for the rational design of drugs. For this reason, the manner in which protein kinases 
inhibitors bind will be discussed in more detail.
[38]
 
The most commonly observed binding mode involves the inhibitor binding in and around the region 
occupied by the adenine ring of ATP. These inhibitors are classified as type I inhibitors and bind with the 
activation loop consuming a conformation conductive to phosphate transfer (active conformation).
[47, 49]
 
Type I inhibitors may form zero to three hydrogen bonds to the kinase hinge segment which often mimic 
the binding interactions of the adenosine moiety.
[20, 47]
 The region of inhibition is further divided into 
subregions, namely: the hydrophobic region I and II, the adenine region, the ribose region and the 
phosphate binding region (figure 10). All type I inhibitors occupy the adenine region, but the ability to 
bind to other regions promote inhibitor selectivity.
[49]
 Classic kinase inhibitors such as staurosporine, 
dasatinib and gefitinib are examples of type I inhibitors shown in figure 11.
[42, 47]
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Mutations affecting type I inhibitors that commonly occur are located at the gatekeeper position in the 
hinge segment where an enhancement in size/volume of the gatekeeper residue occurs (classically Thr is 
exchanged for Ile or Met).
[42]
 
Serendipity, combined with structure-activity relationship analysis, particularly when Imatinib was co-
crystalized with Abl, led to the discovery of type II binding mode. Type II inhibitors can also bind to the 
hinge region, but take advantage of the DFG-out conformation where an additional hydrophobic pocket 
adjacent to the ATP pocket, referred to as an allosteric site, is available for binding (Figure 10).
[42, 49]
 
These interactions in the allosteric site are characteristic of type II inhibitors and a hydrogen-bond pair 
between the inhibitor and the residues in the allosteric site is conserved in all type II modes of binding. 
All type II inhibitors also have a hydrophobic moiety, which forms van der Waals interactions with the 
allosteric site.
[49]
 Three classic examples of type II inhibitors include Imatinib, Nilotinib and Sorafenib.
[50]
 
Another well categorized class of inhibitors, type III, comparing molecules which bind outside the ATP-
binding site at an allosteric site and allosterically modulates the kinase enzymatic activity. CI-1040 is an 
example of a type III inhibitor and inhibits MEK1 and MEK2 by occupying a pocket adjacent to the ATP 
binding site.
[50]
 Type IV inhibitors are also classified as allosteric inhibitors, but bind at remote sites on the 






Representation of the ATP binding site divided into subregions (left) and Imatinib binding to an additional allosteric 
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Examples of type II kinase inhibitors. 
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Examples of type III and type IV kinase inhibitors. 
The majority of small molecule kinase inhibitors bind in or around the ATP binding site, thereby 
preventing ATP from binding.
[47]
 As described before, the catalytic domain in the active conformation is 
highly conserved throughout the kinase family, and this has been regarded as a major challenge in 
designing inhibitors with target specificity. Furthermore, potency of inhibitors is crucial to compete with 
high intercellular ATP concentrations.
[20]
 In addition, improved specificity for the intended target and 




Although a few examples of highly selective ATP-competitive kinase inhibitors exist, the majority of 
cases are troubled by selectivity issues, especially in the case of type I inhibitors which target the highly 
conserved active conformation. Targeting alternative sites which become accessible when the kinase 
adopts the inactive conformation, can address the challenges of selectivity and drug target residence 
times.
[48]
 Type II inhibitors are indirectly ATP-competitive, but since the amino acids in the allosteric 
pocket are less conserved throughout the kinase family, it has been proposed that kinase selectivity may 
be more easily achieved.
[49]
 Furthermore, the lower affinity for ATP in the DFG-out conformation, 
compared to the active conformation, attribute to the potent cellular activity of type II inhibitors.
[49]
 Type 
III and IV inhibitors have purely allosteric modes of action and tend to exhibit the highest degree of 
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The majority of inhibitors developed thus far are ATP-competitive compounds since they target the ATP 
binding or surrounding sites. These compounds inhibit protein catalytic activity in a reversible manner by 
binding through weak interactions (hydrogen bonds, van der Waals forces and hydrophobic 
interactions).
[52]
 The challenges implicated with these ATP-competitive, reversible drug candidates 
attributed to the emerging strategy to develop kinase-targeted drugs that are irreversible.
[40]
 Over the past 
century there have been many examples of medicines that are covalent drugs and some covalent, 
irreversible inhibitors include the anti-inflammatory drug aspirin and antibiotics such as penicillin.
[53-54]
 
The different types of kinase inhibitor binding modes are illustrated in figure 14. The development of 










1.4.2 Irreversible kinase inhibitors 
An important factor for the therapeutic success of protein kinase inhibitors is the amount of time spent by 
the inhibitor in the kinase nucleotide binding site. This is particularly important since these inhibitors 
generally compete with high concentrations of intracellular ATP.
[56]
 In this regard, irreversible kinase 
inhibitors behave in a non-competitive manner to ATP, by binding covalently and shifting the 
physiological equilibrium between ATP and the target kinase. Hereby, the catalytic activity of the kinase 
is permanently inhibited by remaining bound to the kinase active site, even when the level of the drug 
administered is lowered.
[55]
 Since covalency inactivates the enzyme and biological effects persist even 
after the inhibitor has left the circulation, in principle there is no need to maintain high levels of drug 
concentration to achieve continuous target engagement.
[52-53]
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In addition, irreversible inhibitors have the potential to overcome resistance due to the fact that they are 
less affected by changes in the ATP binding affinity, which can occur with mutant forms of the kinase.
[52]
 
The aggressive relapse of 50% of non-small cell lung cancer (NSCLC) patients treated with the ATP-
competitive, reversible inhibitors erlotinib and gefitinib is a classic example of the emergence of a 
secondary drug-resistant mutation.
[55]
 This mutation at the gatekeeper residue (T790M in EGFR) is a 
common mechanism of acquired resistance to kinase inhibitors and was discussed earlier (see section 
1.3.3). Irreversible inhibitors have shown to overcome this drug resistance and a number of irreversible 
drug candidates have progressed to late stage clinical development.
[40, 57-58] 
Another major advantage of irreversible inhibitors is improved selectivity, since only the kinases involved 
in the covalent interaction with the inhibitor will be inactivated.
[52]
 Most covalent inhibitor strategies 
target a highly nucleophilic cysteine thiol present in the target protein. Structural analysis of different 
conformations of the protein kinases, have revealed a thorough landscape of cysteine positions that can be 
harnessed for irreversible inhibition. As mentioned before, the shape of the ATP binding pocket has been 
classified as three conformations (active, inactive C-helix-out and inactive DFG-out) and the number of 
cysteine positions shared between kinases have been grouped accordingly.
[56]
 Liu et al. performed an 
informatics study in which 442 kinases were superimposed and their ATP-binding sites were evaluated to 
construct a graphical image of the accessible cysteines in the kinome. Figure 15 shows the representative 






Depiction of staurosporine in the kinase domain, displaying the various accessible cysteine positions in the kinome, 
as constructed by Liu et al. Image reproduced from following reference.
[53] 
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Many protein kinases possess cysteine residues in and around the ATP-binding site, but only a very small 
fraction of these kinases (20 kinases) have been targeted by currently available irreversible inhibitors. To 
date, only six distinct cysteine positions have been targeted. Due to the fact that the main focus of this 
project is directed towards EGFR inhibition, the cysteine target (Cys797) for EGFR irreversible inhibitors 
is important. Cys797 is located at the lip of the ATP binding site (just after the hinge region) and is 
present in 11 kinases.
[52-53]
 Harnessing very particular cysteine positions shared between only a few 
kinases illustrates the opportunity to enhance selectivity for target kinases. The reactivity of the cysteine 
thiol varies according to the protein microenvironment (chemical and location), which allows for 
additional fine tuning (selectivity and specificity) of the inhibitor.
[56]
 Furthermore, the identification of 
more accessible cysteine residues in different kinase conformations, unlocks tremendous potential to 
develop new irreversible inhibitors.
[52, 56]
 
Covalent irreversible kinase inhibitors have typically been developed by incorporating an electrophilic 
moiety to a noncovalent inhibitor which already possesses submicromolar binding affinity for the kinase 
targeted.
[53]
 Irreversible TK inhibitors are generally characterized by a heterocyclic core structure known 
as a driving portion. This driving portion docks into the active site of the kinase domain and resembles 
features of reversible inhibitors. The core structure carries, at a particular position, an electrophilic 
functionality known as a “warhead”. It is this “warhead” which covalently interacts with a nucleophilic 
cysteine residue in or near the ATP-binding site.
[52]
 The irreversible covalent bond is mostly achieved 
through a Michael reaction (Scheme 2). Functional groups typically used as Michael acceptors (warheads) 
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Electrophilic “warheads” used in irreversible kinase inhibitors. The black spheres represent the driving portions or 
other pharmacophore structures. Image reproduced from following reference.
[53]
 
A drawback of covalent irreversible inhibitors is promiscuity and the risk of covalently binding to other 
solvent exposed thiol groups. This leads to non-selective reactions with off-target proteins and increased 
toxicity. 
[52, 55]
 An integral part of drug optimization is to design compounds with a suitable driving 
portion, having at a particular position a low intrinsic reactive electrophilic warhead. The covalent 
reaction between the cysteine residue and inhibitor can only occur once the driving portion reversibly 
docks into the active site, interacts with the hinge region, and presents the reactive counterparts at a 
favourable distance and orientation.
[40, 52]
 In order for the driving portion to present a suitable “platform” 
to incorporate the electrophilic “warhead” at the proper trajectory, the less flexibility there is between the 




Lung cancer is the most common cause of cancer related deaths worldwide. NSCLC accounts for almost 
85% of all lung cancers. EGFR is the focus of many new treatment strategies and has become a well-
established target for the treatment of patients with NSCLC.
[58-59]
 Oncogenic activating mutations of 
EGFR result in abnormal signaling for 10-30% of NSCLC patients. In 2000, two first generation 
inhibitors - gefitinib and erlotinib - moved from the bench to the clinic. These inhibitors act in a reversible 
manner and are ATP competitive. 
[35]
 NSCLC patients with the most common EGFR mutations respond 
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Structures of the first generation inhibitors gefitinib and erlotinib. 
The advantages associated with covalent irreversible inhibitors have sparked a growing interest in their 
development and number of effective second generation irreversible EGFR inhibitors have progressed to 
late stage clinical development (figure 18).
[52, 58, 61-62]
 Clinical evidence suggests that superior performance 
of these drugs relative to reversible inhibitors is evident, but the emergence of drug resistance is also 
limiting their activity. Mechanisms of drug resistance include reversible cysteine-inhibitor warhead 
interactions and specific cysteine oxidation, which are currently under investigation.
[58, 60]
 The ongoing 
war on cancer and pursuit to develop more efficient, potent and safe therapeutic agents is an essential part 
of oncology research, particularly when the enemy is of such a complex and deadly nature.  
 
Figure 18 
Irreversible EGFR inhibitors in clinical trials.
[52-53]
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1.5 Natural products 
1.5.1 The inspiration from natural products and chemical space 
Aristotle stated that “Nature creates nothing without purpose or uselessly”.
[63]
 Nature’s symphonic 
processes have inspired human creation in fields such as science, arts and architecture for millennia.
[64]
 
Throughout the ages people have relied on natural products for the treatment of a wide spectrum of 
diseases with some of the earliest records dating from around 2600 BC.
[65]
They form the basis of most 
early medicines and have played an essential role in drug discovery, particularly in the development of 
chemotherapy and oncology.
[66]
 The complex and diverse secondary metabolites (natural products) are 
formulated within an organism - through interactions with the environment - to enhance their survival and 
competitiveness.
[67]
 Natural products have evolved to interact with multiple proteins, displaying a variety 
of biological activities and being effective modulators of almost all basic cellular processes.
[68]
 The 
scaffolds of these compounds are thought of as evolutionary-chosen “privileged structures”, positioning 
them as pre-validated starting points for library design.
[69-70]
 Today, natural products remain a major 
source of inspiration in drug development and often serve as a structural ‘muse’ for the design of new 
biologically active small molecules.
[69]
 
In the 1980s and 1990s, with the emergence of combination therapy, the focus of drug discovery shifted 
from Nature to the laboratory bench. However, synthetic chemists soon realized that new libraries lacked 
the “complexity” associated with natural products and this led to a shortage of lead compounds 
progressing into clinical trials.
[66, 71]
 The decade of 2000s witnessed a recovery in natural product drug 
discovery. Between 2005 and 2010, a total of 19 natural product based drugs were approved for 
marketing worldwide.
[67]
 An analysis of sources of new drugs over a certain period (1981-2010) indicated 
that only 36% of the 1073 chemical new entities can be classified as truly synthetic – i.e. with no natural 
product conception. The various classes are represented in a pie chart (figure 19), illustrating the immense 
contribution of natural products.
[65]
 Furthermore, of the 115 small molecules approved as anticancer drugs 
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Classification of new drug sources. Keys: N (natural product unmodified); NB (natural product botanical); ND 
(natural product modified); S (purely synthetic); S/NM (synthetic compound showing competitive inhibition of 
natural product substrate); S* (synthetic compound with natural product pharmacophore); S*/NM (synthetic 




Chemical space is enormous with estimates of 10
63
 small molecules populating drug-like chemical space. 
It should thus be obvious that is impossible to investigate all these opportunities by means of synthetic 
efforts. Therefore, a key challenge in chemical biology research and drug discovery is to identify, map 
and navigate biologically relevant chemical space.
[69-70]
 Several different approaches, in particular ones 
employing evolutionary arguments (sequence homology), mechanistic considerations, and the generation 
of chemical diversity (diversity-orientated synthesis, DOS), have been developed in the quest to identify 
these biologically relevant areas in chemical space.
[73-75]
 Natural products can display a vast range of 
biological activities when their common shared scaffold differs only in substitution pattern. Of 
significance is that only a tiny fraction of chemical space based on natural product scaffolds has been 
exploited. In fact, both protein folds and natural product scaffolds are highly conserved in nature. For this 
reason, only a limited number of small-molecule binding sites inspire rational approaches to inhibitor and 
ligand development.
[73, 75]
 As mentioned earlier, natural products have been regarded as biologically pre-
validated since they were chosen by evolution to interact with their biological targets. This fact, together 
with their particular molecular properties which encode architecture for substance recognition by enzymes 
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BIOS employ chem- and bio-informatics methods for mapping biologically relevant chemical space and 
protein space to generate hypotheses for compound collection design and synthesis.
[73]
 This strategy 
therefore builds on the inspiration given by nature through natural products, exploiting their structural 
conservatism and diversity.
[75-76]
 BIOS makes use of a hierarchical organization concept named “structural 
classification of natural products” (SCONP). This concept is based on a set of defined rules derived from 
organic and medicinal chemistry, to step-wise deconstruct the larger natural product scaffolds (child 
scaffolds) into smaller parent structures. This approach led to the SCONP scaffold tree where each 
chemical entity is a substructure of the original natural product, providing a way to reduce molecular 
complexity while retaining bioactivity. An illustration of the SCONP scaffold tree is depicted in figure 
21.
[70, 73, 75]
 Another concept used in BIOS is the protein structure similarity cluster (PSSC), which 
identifies ligand binding sites with high subfold similarity and attempts to link them to new potential 
biological targets of small molecules.
[73]
 The merging of SCONP and PSSC led to the BIOS approach 
which serves to identify new starting points in chemical space for the design and synthesis of small-
molecule libraries, in order to find new ligands for particular protein domains (figure 21). 
[73, 75]
 Small 
molecules synthesized according to BIOS are enriched in bioactivity and the synthesis of natural products 
has inspired compound collections with high scaffold, substituent and stereochemical diversity.
[73, 75]
 
However, it is often necessary to improve selectivity and potency of these protein ligands in subsequent 


















SCONP scaffold tree of natural products. Image reproduced from following reference.
[69]
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Plants have been used for the treatment of cancer throughout history and have formed the basis of 
sophisticated traditional medicine systems.
[65, 77]
 Almost all of the current drugs derived from natural 
products are of terrestrial origin.
[78]
 Natural products from marine organisms do not have a significant 
history in traditional medicines and their investigation was limited before the mid-1960s. The 
development of scuba diving, improved technology for deep-sea collections and large-scale aquaculture 
production opened the world’s oceans as an enormous resource for the discovery of potential 
chemotherapeutic agents.
[65, 78]
 The diversity of marine habitats and unique environmental conditions of 
the sea, offers mostly untapped sources of potential drugs with superior chemical novelty compared to 
terrestrial natural products. More than 20000 natural products have been isolated from marine life-forms. 
The review by Bharate and co-workers discusses and analyzes various marine-derived kinase inhibitors 
that are currently in various stages of clinical development.
[78]
 
Microorganisms of both terrestrial (plants and soil) and aquatic origin have provided some of the key 
drugs for cancer chemotherapy.
[77]
 They are either used directly for cancer treatment or modified to 
modulate activities against tumor cell growth. The bacteria from the order, Actinomycetales have 
produced some of the most impressive compounds directly from nature or semi-synthetic modifications. 
These bacteria have been the leading producers of medically useful drugs and introduce the natural 
product of interest for this project, called staurosporine.
[79]
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The discovery of staurosporine was made in 1977, when it was isolated from the bacterium Streptomyces 
staurosporeus, while screening for microbial alkaloids in a culture of soil. 
[80]
 Over the past few decades, 
staurosporine and related natural indolocarbazole compounds (more than 50) have been isolated from 
various Actinomycetes, slime molds, cyanobacteria and marine invertebrates.
[78, 81]
 The structure of 
staurosporine is shown in figure 22. A decade after the isolation of staurosporine, its potent kinase activity 
was identified.
[82]
 This discovery offered tremendous promise for drug development and stimulated a 
variety of medicinal programs aimed at synthesizing staurosporine analogues based on this compound. 
Numerous pharmaceutical companies pursued the search for selective kinase inhibitors by screening 















The natural product staurosporine. 
Initially, staurosporine was shown to be a nanomolar inhibitor of protein kinase C (PKC), but further 
investigation showed that staurosporine inhibited a “cocktail” of kinases.
[83]
 In fact, staurosporine inhibits 
the majority of human protein kinases and it is as a result of this promiscuity that staurosporine itself is 
not a viable option as an effective anticancer agent. The lack of selectivity demonstrated by staurosporine 
has been shown to lead to toxic, off-target activities.
[84]
 However, this natural product has been widely 
used in research as a universal kinase inhibitor and serves as a “structural muse” to design protein kinase 
inhibitors with improved specificity and selectivity.
[78, 84-85]
 
Staurosporine possesses all the elements that define an ATP-competitive inhibitor and numerous co-
crystal structures with various kinases reveal a common binding mode. The structure consists of a 
hydrogen bond donor/acceptor pair, a large rigid planar structure, and an aromatic ring system to 
complement the ATP binding pocket.  
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All of these structural features ensure that staurosporine mimics the natural binding interactions that 
provide the recognition and orientation of ATP in protein kinases. This explains why staurosporine 
interacts with such a wide range of serine/threonine and tyrosine kinases. Staurosporine docks into the 
ATP binding pocket with the planar indolocarbozole sandwiched between the N-lobe and C-lobe, oriented 
by hydrogen bonds to the hinge region. This mimics the adenine base of ATP. In addition, the 
indolocarbozole and sugar ring form a boat-shaped conformation within the kinase active site. Another 
hydrogen bond is formed between the methyl amino group on the sugar ring and a largely hydrophilic 
residue which normally stabilizes the ATP ribose hydroxyl moiety. These electrostatic interactions are 
illustrated as dashed lines in figure 23. Staurosporine is further stabilized by van der Waals interactions 
between the aromatic plane of staurosporine and the side chains of amino acids lining the ATP pocket. 
Many CH-π interactions between the conjugated indolocarbazole and CH moieties of these side chains 
have also been identified.
[20, 78]
 Molecular modelling of staurosporine within the EGFR kinase domain is 
illustrated in figure 24. The hinge region interactions between staurosporine amide and residues Met793 
and Gln791in the EGRF domain are highlighted on the right. 
 
Figure 23 
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Illustration of staurosporine in the EGFR kinase domain. The important hydrogen interactions between the amide of 
staurosporine and residues Met793and Gln791 in the EGFR protein are highlighted in the image on the right. 
As mentioned previously, natural products were among the first protein kinase inhibitors discovered and 
several natural product derived kinase inhibitors have entered clinical trials over the past decade.
[68]
 
Staurosporine is an intriguing natural product and many of its analogues have been evaluated against 
various human cancer cell lines, some showing promising therapeutic activity.
[78-79, 83, 85]
A major focus in 
the design and synthesis of these staurosporine derivatives has been to develop agents with improved 
selectivity, while retaining the potency associated with staurosporine.
[84]
 A few staurosporine inspired 
drug candidates, which demonstrate protein kinase inhibitory activity, and that are currently in active 
development, are show in figure 25. In addition, bisaryl maleimide derivatives (such as enzastaurin), 
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Staurosporine analogues as promising kinase inhibitors.
[78]
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CHAPTER 2 – CLICK CHEMISTRY AND KINASE INHIBITORS 
2.1 The impact of click chemistry on kinase inhibitors 
2.1.1 An introduction to click chemistry 
The chemist, George S. Hammond, stated that: “The most fundamental and lasting objective of synthesis 
is not production of new compounds, but production of properties.”
[87]
 In the case of the pharmaceutical 
industry, these useful properties are represented by aiming to synthesize more effective therapeutic drugs. 
The manner in which the organic synthesis is done has extensive impact on the entire process of drug 
discovery, development, and manufacture.
[87]
 In other words, a major objective is the development of an 
efficient synthetic strategy. In recent years, combinational chemistry has been introduced in the hope to 
improve the amount and rate of lead compound discovery and optimization. Unfortunately, combinational 
chemistry proved to be more dependable on individual reactions to generate the new network of chemical 
bonds compared to the ‘traditional’ synthetic chemistry, leading to a shortage of new lead compounds 
entering clinical trials.
[66, 88]
 Natural products have had an immense impact on drug discovery, but the 
intricate architecture of these secondary metabolites often result in slow and complex syntheses.
[87-88]
 
Furthermore, as mentioned earlier, the enormous available chemical space has staggering implications on 
drug discovery and a vast majority of molecules with useful properties remain to be discovered.
[70, 88]
 The 
way Nature performs her own type of combinational chemistry, achieving astonishing diversity and 
modularity from less than 40 monomers to make the macromolecules which are central to life processes, 
has inspired synthetic organic chemists.
[87]
 An investigation of the bioactivity of molecules created by 
nature, has revealed an overall preference for carbon-heteroatom bonds over carbon-carbon bonds.
[89]
 For 
example, all proteins arise from 20 building blocks that are joined via reversible heteroatom links 
(amides).
[87]
 Following Nature’s inspiration, and limiting the search for new structures to those that can 
easily be synthesized through joining small units through heteroatom links, led to the powerful strategy 
defined by Sharpless and co-workers as “Click Chemistry”.
[89]
 
A set of stringent criteria has been defined that a process must meet to earn the click chemistry status. For 
the criteria to be met, the reaction must be “modular, wide in scope, high yielding, create only inoffensive 
by-products (that can be removed without chromatography), be stereospecific, simple to perform, and 
require benign or easily removed solvent, readily available starting materials and reagents, and require 
simple product isolation.”  
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In this regard, the readily available, high energy olefins and acetylenes are useful reactive building blocks, 
ideal for the fast, irreversible assembly of diverse molecules with drug-like structural features. Several 
processes have been identified which meet the requirements to match the Click Chemistry criteria (figure 
26). These reactions are exothermic and thought of as being “spring loaded” for a single trajectory. This 
approach thus provides rapid synthesis from a set of powerful, highly reliable and selective reactions, to 









Of these reactions, the premier example of a click reaction is the copper (I) catalyzed variant of the 
Huisgen 1,3-dipolar cycloaddition of alkynes and azides to yield 1,2,3-triazoles.
[88, 90]
 In 2001, Meldal and 
co-workers reported the discovery of a novel regiospecific copper(I) catalyzed 1,3-dipolar cycloaddition 
of terminal alkynes to azides.
[91]
 Sharpless and Meldal laboratories independently realized that the 
introduction of the copper(I) catalysis lead to a dramatic rate acceleration of the coupling reaction.
[90, 92]
 
This finding, together with the discovery of the beneficial effects of water, placed the Cu(I) catalyzed 
Huisgen reaction at the center stage of click chemistry.
[88-89]
 This particular copper-catalyzed azide-alkyne 
cycloaddition (CuAAC) is a ‘near perfect’ reaction according to the criteria defined by Sharpless and is 
often referred to as “The” click reaction.
[89]
 Azide and alkyne functionalities are easy to install, and 
although they are amongst the most energetic species known, they are kinetically stable. These two 
attractive complementary coupling partners are inert to most biological and organic conditions, including 
molecular oxygen, water and the majority of reaction conditions in organic synthesis, and functional 
groups.
[89-90]
 Uncatalyzed Huisgen cycloadditions are slow, require elevated temperatures and often result 
in a mixture of products (1:1 1,4- and 1,5-regioisomer).  
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Besides the fact that the reaction rate increases up to 10
7
 times under Cu(I) catalyzed conditions, the 
regioselectivity is dramatically improved, affording the 1,4-regioisomer exclusively (figure 27).
[90, 93]
 In 
2005, Sharpless and co-workers, reported that ruthenium-catalyzed azides-alkynes cycloaddition 
(RuAAC) gave the 1,5-regioisomer product exclusively. Another advantage of RuAAC is that both 
terminal and internal alkynes can be utilized.
[94]
 However, for the purpose of this project, particular 





The CuAAC results in exclusive formation of the 1,4-disubstituted-1,2,3-triazole, while the thermally induced 
Huisgen cycloaddition results in the formation of a 1:1 mixture of 1,4-disubstituted-1,2,3-triazole and 1,5-
disubstituted-1,2,3-triazole.
[89] 
Since the discovery of the CuAAC approach, various sources of copper and reaction conditions (solvents, 
temperatures and pH range) have been tested.
[93]
 The robustness of the reaction is supported by the high 
yield of triazole formation under a variety of conditions.
[90]
 Meldal and co-workers initially described the 
use of Cu(I) salts in the solid phase, while Sharpless and co-workers reported solution-phase in-situ 
reduction of Cu(II) salts or comproportionation of Cu(0) and Cu(II).
[90-91, 93]
 It should be noted that the 
role of copper in this catalysis has been subject to many disputes and revisions.
[92]
 The mechanism has 
remained difficult to establish as a result of the multiple equilibria between several reactive intermediates 
involved during the reaction. Examination of the mechanism, although daunting, has been a pursuit of 
organic chemists to have a better understanding of the fundamental reactivity and to be able to optimize 
the reaction parameters.
[95]
 With this aim, the analysis of catalytic systems relies on one or a combination 
of methods. Some of these methods include the application of computational studies, initial rate studies, 
the study of isotope crossover and kinetic isotope effect, reintroduction of an intermediate in a reaction 
mixture to prove its involvement in the catalytic cycle, and analysis of stereoelectronic effects. 
Throughout the years, several possible mechanisms have been proposed, but despite the number of 
studies, the elucidation of the exact mechanism remains complex.
[92, 95-96]
 Fokin and co-workers have 
reported the latest plausible mechanism, which is supported by various theoretical studies.  
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The experiments were carried out by real-time monitoring of a cycloaddition reaction via heat-flow 
reaction calorimetry and crossover experiments with isotopically enriched exogenous copper source.
[95]
 


















CuAAC mechanism as proposed by Fokin and co-workers. Image reproduced from following reference.
[95]
 
Click chemistry uses the most practical and reliable chemical transformations, and its applications in 
chemistry, biology, and material sciences are extensive. In drug discovery, the applications range from 
lead finding through combinational chemistry and target template in situ chemistry, to proteomics and 
DNA research using bio-conjugation reactions.
[88, 96]
 CuAAC has been referred to as the gold standard of 
click chemistry, exhibiting remarkably broad scope and exquisite selectivity.
[96-97]
 The triazole products 
are more than just linkers, they associate with biological targets through hydrogen bonds and dipole 
interactions, acting as a pharmacophore in the field of medicinal chemistry. Besides being attractive 
connecting units and pharmacophores, the 1,2,3-triazole moieties are stable to metabolic degradation, and 
are capable of forming hydrogen bonds which can improve solubility and bind biomolecular targets.
[97]
 
Click chemistry, and in particular CuAAC, accelerates lead discovery and optimization, due above all to 
its broad scope, modular design, and its reliance on short sequences of near-perfect reactions.
[88]
 
2.1.2 The application of click chemistry in kinase inhibitor development 
A particular focus of this project was to develop kinase inhibitors via click chemistry. For this reason, an 
outline will be given on the topic of various kinase inhibitors synthesized by the click approach.  
The 1,2,3-triazole scaffold has been associated with several advantages in the development of kinase 
inhibitors, namely: (i) the 1,2,3-triazole ring can act as a mimic of the ATP purine that targets the ATP-
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binding site; (ii) the triazole ring can also function as a bioisostere of flat heteroaromatic rings (purine, 
pyrazole and imidazole) which are frequently present in kinase inhibitor structures; (iii) the 1,2,3-triazole 
can be easily assembled by click chemistry; (iv) a diverse group of structures can easily be generated by 
attaching commercially available alkynes and to a much lesser extent, azides. 
[98]
 Therefore, various 
examples in literature employing click chemistry to design kinase inhibitors are described in this section. 
The design of kinase inhibitors that exploit less conserved substrate-binding/allosteric pockets, is an 
attractive approach to enhance inhibitor selectivity. The fact that the majority of kinase inhibitors bind to 
the ATP-binding site is problematic, since the binding pocket is highly conserved throughout the kinase 
superfamily.
[48, 99]
 Drug development strategies to produce selective kinase inhibitors remain an active 
area of research. One such strategy is the rational design of bisubstrate inhibitors. This type of inhibitor 
consists of two conjoined inhibitor scaffolds, one binding to the ATP-binding site, while the other targets 
the allosteric/substrate-binding site. In these structures, the ATP-binding part affords affinity and the 
allosteric/substrate-binding part affords selectivity. Therefore, bisubstrate kinase inhibitors can be 
designed to impart improved selectivity and potency. A number of successful examples based on this 
approach have been demonstrated, showing improved selectivity and affinity for kinase inhibitors.
[99-100]
 
For example, Kalesh et al. developed an efficient method for the construction of small-molecule based 
bisubstrate inhibitors of Abl kinase using click chemistry.
[99]
 In their approach, two clickable warheads 
were designed to effectively bind to the ATP-binding site. The two scaffolds were based on the Imatinib 
core structure by replacing the piperazine-linked benzene ring with an alkyne group (figure 29). A small 
library of short chain azides was then subjected to click reactions with the two Imatinib-based warheads. 
In this manner, the warheads were able to project the diversity element (the azide chain) into the 
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Warheads based on Imatinib for the construction of the bisubstrate inhibitors. The red box indicates the part of the 






An example of the click chemistry approach used to generate the bisubstrate kinase inhibitor 1.
[99] 
This method led to the synthesis of 90 inhibitors, with the majority displaying better inhibition against 
Abl over Src kinase. Quantitative inhibition assays were carried out for 11 of these inhibitors to obtain 
their IC50 values against Abl kinase. A few moderately potent inhibitors were identified, some of which 
are comparable to the potency of Imatinib. The two most potent inhibitors of the various warheads (W1 
and W2) are represented below in figure 31. Although these compounds showed only a marginal 
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Imatinib based bisubstrate inhibitors of Abl kinase.
[99]
 
Similarly, the bisubstrate strategy was employed by Poot et al. to develop kinase inhibitors against PKC 
isozymes.
[100]
 In this approach, novel bisubstrate structures were generated by linking peptide-binding site 
inhibitors to ATP-binding site scaffolds through click chemistry. Initially, peptide microarrays were used 
to identify peptide substrates with large affinity differences within a given set of kinases. Three PKC 
isozymes, each from one of the subfamilies PKCα, PKCθ and PKCζ, were selected for substrate profiling. 
The peptide selected for this study was the peptide EILSRRPSYRKIL, derived from the cAMP-
responsive element binding protein. Peptide EILSRRPSYRKIL was then transformed into two 
pseudosubstrates and linked to the ATP-binding site inhibitor. A functionalized bisindolyl maleimide was 
next selected as the ATP-binding site scaffold. Through click chemistry, two novel bisubstrate-based 
inhibitors (3 and 4) were synthesized and their structures are shown in figure 32. They displayed 
improved potency and selectivity compared to their constituent parts. Compound (3) showed similar 
inhibition of PKCα compared to its respective bisindolyl maleimide constituent part, but its inhibition of 
PKCθ-mediated phosphorylation was significantly better. In addition, a fourfold reduction of its IC50 was 
observed (0.6-0.9 μM). Compound (4) did not inhibit PKCα, but showed excellent isozyme selectivity for 
PKCθ amongst the three isozymes evaluated. Its inhibition for PKCθ (IC50 = 0.4 - 0.8 μM) was similar to 
that of compound (3). 
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Bisubstrate inhibitors constructed from pseudosubstrates (transformed from peptide EILSRRPSYRKIL) and 
functionalized bisindolyl maleimide.
[100] 
Over the past decade, advances in the development of active compounds have been made to selectively 
inhibit Bcr-Abl kinase activity. Imatinib, the most well-known of these inhibitors, currently represents the 
first line treatment of CML. Resistance to Imatinib has led to a growing interest in developing second-
generation small-molecule inhibitors that are able overcome Imatinib-resistant CML.
[46]
 Arioli et al. 
attempted this by developing potential inhibitors of Bcr-Abl through the design of N-[2-methyl-5-(triazol-
1-yl)phenyl]pyrimidin-2-amine derivatives.
[101]
 The strategy was based on substituting the amide bond in 
the Imatinib structure with a 1,2,3-triazole ring, utilizing the bioisosterism between an amide group and a 
1,2,3-triazole ring. Six novel compounds were synthesized and their potency was assessed by evaluating 
their effects on enzymatic activity, cell proliferation, phosphorylation, cdc25A expression, and pro-
apoptotic activity. One particular compound (5) showed potent anti-enzymatic activity against 
recombinant Abl kinase (figure 33).Its efficacy was demonstrated by its antiproliferative activity in the 
low micromolar range with an IC50 value of 0.9 ± 0.1 μM against the K-562 cell line. Unfortunately, 5 
showed decreased activity against the Imatinib-resistant mutant Abl T3151. Furthermore, 5 had the ability 
to decrease the phosphorylation of Bcr-Abl, c-Abl, STAT-5, Scr, and was an active inhibitor of cdc25A in 
two different cell lines.  
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Aurora kinases are members of serine/threonine kinases. Many Aurora-selective small-molecule 
inhibitors have been developed, but none have been approved by the FDA. Song et al. developed a series 
of 1,2,3-triazolylsalicylamide derivatives via (CuAAC) click chemistry and evaluated their inhibitory 
activity against Aurora kinases.
[102]
 Their strategy was inspired by a previously identified antiproliferative 
agent 6, which exhibited very good selectivity for the Aurora A kinase. The antiproliferative agent was 
modified as illustrated in figure 34. A variety of substituents were readily installed through CuAAC, 
thereby generating a number of different compounds which were tested against Aurora A and Aurora B.  
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Design of 1,2,3-triazolylsalicylamide derivatives for the inhibition of Aurora kinases.
[102]
 
Most of the compounds showed some selectivity towards Aurora A and 5-50 times more strongly 
inhibited Aurora A over Aurora B. In addition, a few compounds inhibited Aurora A with IC50 values in 
the low micromolar to nanomolar range. Compound 7 (figure 35), the best among the series, showed 
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Another protein kinase which has been implicated in the development of a variety of cancers, and the 
subject of major interest in recent years, is the non-receptor tyrosine kinase Src. Src kinase is a key 
modulator of cancer cell invasion and metastasis, and several structural motifs have been reported to 
target this kinase.
[103-106]
 Dasatinib and Bosutinib have been approved to use in patients with CML, after 
Imatinib treatment as it is a dual Src/Abl inhibitor.
[104, 107-108]
 Kumar, A and Kumar, D et al. have 
independently reported two studies in which they attempt to synthesize inhibitors which target the Src 
kinase by using click chemistry.
[106, 109]
 Previous studies have shown that 3-phenylpyrazolopyrimidines 
bind to the ATP-binding pocket in such a manner that the hydrophobic interaction between the phenyl 
group and hydrophobic pocket is crucial. Furthermore, the pyrazolopyrimidine resembles the purine core 
of ATP and binds in a similar manner as the adenine base of ATP. A cavity which is usually occupied by 
the carbohydrate moiety and the triphosphate group of ATP, is left unfilled in the case of 3-




General structure of 3-phenylpyrazolopyrimidines.
[106, 109] 
In the first study, Kumar and co-workers synthesized and evaluated 1,4-disubstituted 1,2,3-triazoles as a 
novel template for Src kinase inhibition. They hypothesized that substitution at N1 and position 4 of the 
triazole with hydrophobic residues would display similar binding compared to 3-
phenylpyrazolopyrimidine and enhance the potency against Src kinase.
[109]
 To this end, two classes of 
compounds were synthesized by means of a one-pot click reaction . The first class of compounds included 
R1 as phenyl, substituted phenyl, coumarinyl, 2-thienyl, or other nonaromatic substituents on the 1,2,3-
triazole. Class 2 compounds included cyclopentanone-2-yl, cyclohexanone-2-yl, or cycloheptanone-2-yl 
as R1, which are represented as a circle in figure 37. For both classes, position 4 (R2) was phenyl, 
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General structure of the class 1 and class 2 1,4-disubstituted 1,2,3-triazoles.
[109]
 
The 1,4-disubstituted 1,2,3-triazole compounds were tested against Src kinase and a number of 
observations were made regarding the nature of substituent R1 and R2 on the inhibitory activity of the 
compounds. In general, the compounds exhibited weak Src kinase activity, but five of the compounds 
displayed modest inhibitory activity with the IC50s ranging from 32 - 43 μM. Of interest was compound 8, 
which demonstrated selectivity towards Src kinase when compared to other kinases (figure 38). The study 






Structure of compound 8 exhibiting modest inhibitory activity and selectivity against Src kinase.
[109]
 
In continuation of their efforts to develop Src kinase inhibitors, Kumar, A. et al. investigated whether the 
empty cavity formed, when 3-phenylpyrazolopyrimidines binds to the Src kinase, can be occupied when 
1,2,3-triazoles containing hydrophobic residues are substituted at the N1 position - thereby enhancing 
inhibitor potency.
[105-106]
 In this study, two classes of 3–phenylpyrazolopyrimidines (PhPP)-1,2,3-triazole 
conjugates were synthesized via click chemistry.
[106]
 The general structures obtained are illustrated in 
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In total, 20 final compounds were synthesized and tested against Src kinase. The compounds from class 1 
showed less inhibitory activity than PP2, although a number of compounds exhibited modest inhibitory 
activity in the IC50 range 5.6 – 29.6 μM. The data further revealed that the cavity cannot accommodate 
bulky groups attached to the triazole with an ethylene linker to PhPP. The class 2 compounds showed 
more diverse inhibitory activity, with some compounds exhibiting modest inhibition (IC50 = 9.1 – 23.1 
μM). Overall, the data suggested that incorporating a bulky group at position N1 was not tolerated very 
well. Compound 9 from class 1 and 10 from class 2 showed the best inhibitory activity amongst the group 





Compound 8 and 9 exhibiting modest inhibitory activity against Src kinase.
[106]
 
The Met kinase belongs to the receptor tyrosine kinase (RTK) family and plays a central role in signaling 
pathways. The progression of a malignant tumor involves cell scattering, which is induced by hepatocyte 
growth factor (HGF)/scatter factor (SF).  
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The Met kinase binds the HGF ligand and triggers signaling. HFG/Met alterations lead to deregulated 
downstream signaling contributing to tumorigenesis and cancer progression. Oncogenic Met is also 
responsible for oncogene addition and drug resistance. 
[111-112]
 Furlan et al. recently synthesized a 
compound, triflorcas, which successfully targets cancer cells dependent on oncogenic Met. 
[113]
 The amide 
present in triflorcas, and its bioisosterism to 1,2,3-triazole, inspired Colombo and co-workers to 
synthesize a triazole-based analogue of triflorcas.
[114]
 As can be seen in figure 41, a 1,2,3-triazole ring 
(red) was incorporated into triflorcas in place of the amide (blue) functionality by way of CuAAC click 
chemistry. The triazole-based analogue (11) was evaluated and maintained good inhibitory activity 
compared to the lead compound, triflorcas. 11 efficiently inhibited Met-triggered biological activities, 
including cell scattering and tumorigenicity.
[114]
 Their study further demonstrates how click chemistry can 
be utilized to exploit the bioisosterism between amides and 1,2,3-triazole rings to develop new analogues 
from inhibitors containing amide groups.  
 
Figure 41 
Lead compound triflorcas and its triazole-based analogue 11.
[114]
 
Casein kinase II (CK2), a serine/threonine protein kinase, has been afforded the status “master 
regulator”.
[115]
 This is ascribed to its global role in activities related to cell growth, cell death, and cell 
survival.CK2 is a potent suppressor of apoptosis, making it an attractive target to avoid tumor cells 
escaping death through an alternative pathway. Various cancers have demonstrated elevated levels of 
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Swider and co-workers synthesized and evaluated 4,5,6,7-tetrabromobenzotriazole (TBB)-based 
derivatives, capable of acting as multisite-directed inhibitors toward protein kinase CK2. These 
compounds were designed to occupy the ATP-binding site, and to interact with the protein substrate 
binding residues, as well as the Mg
2+
- chelating residues. The synthesis involved CuAAC of three 
alkylated TBB compounds with a series of azides to generate a small library of 14 compounds. These 
compounds were then tested against CK2, and compound (12) exhibited the best inhibitory activity with 
an IC50 of 44.5 μM. The structure of this compound is represented in figure 42. Molecular modeling 






The TBB-based CK2 inhibitor (12) exhibiting the best inhibitory activity, amongst the family synthesized.
[116]
 
Members of the transforming growth factor-β (TGF-β) superfamily, signal through a combination of 
transmembrane serine/threonine kinases (type II and type I receptors), and play a crucial role in 
development and disease.
[98]
 TGF-β is a member of the TGF-β superfamily, along with bone morphogenic 
proteins (BMPs), growth and differentiation factors (GDFs), activins, inhibins, nodal and anti-Müllerian 
hormone. In humans, three isoforms of TGF-β have been described. Active TGF-β binds selectively to the 
membrane-spanning serine/threonine kinase receptorII (TβRII), which then activatesTGF-β receptor type 
I (TβRI) - also known as activin receptor-like kinase 5 (ALK5). The activated TβRI/ALK5 interacts and 
phosphorylates downstream Smad effectors, which eventually lead to complexation with a Smad mediator 
and translocation to the nucleus. TGF-β overproduction is commonly observed in a number of solid 
tumors when the TGF-β suppressive effects are lost. Inhibition of the protein kinase ALK5 could 
therefore effectively disrupt the mechanism of action, and prevent tumor growth.
[98, 117-118]
 
Attempts to block the TGF-β effect have been investigated, with particular focus on targeting the ALK5 
kinase. A number of potent imidazole and pyrazole inhibitors have been developed, which display 
anticancer activities.  
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In continuation with their efforts to develop 1,2,3-triazole anticancer agents, and studying the current 
ALK5 inhibitors - with particular interest in the binding interaction of compound IN-1166 - Li and co-
workers designed and synthesized 1-(6-methylpyridin-2-yl)-5-(quinoxalin-6-yl)-1,2,3-triazoles as novel 





Design of 1-(6-methylpyridin-2-yl)-5-(quinoxalin-6-yl)-1,2,3-triazoles based on the AKL5 inhibitor IN-1166.
[98]
 
The synthetic strategy, shown in scheme 3, was straightforward and applied click chemistry (CuAAC) for 
the combination of 2-azido-6-methylpyridine and various alkynes (R). The resulting compounds of 1-(6-
methylpyridin-2-yl)-1,2,3-triazoles was subsequently coupled with 6-bromoquinoxaline to afford the final 
compounds. The inhibitory activity of these compounds was then evaluated against AKL5 and p38α MAP 
kinase (to produce a selectivity profile). The synthesized 1-(6-methylpyridin-2-yl)-5-(quinoxalin-6-yl)-
1,2,3-triazoles exhibited modest to significant AKL5 inhibitory activity and displayed good selectivity 
differences versus p38α MAP. Overall, compound 13 shown in figure 44, demonstrated the best 
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3-Phosphoinositide-dependant protein kinase 1 (PDK1) is a serine/threonine kinase that belongs to the 
AGC family. PDK1 is responsible for regulating the activity of at least 23 other AGC kinases by 
phosphorylating a specific threonine or serine residue within the activation loop (T-loop). Downstream 
signaling of these kinases has often been implicated in cancer development.
[119-120]
 The work of Merkul et 
al. has led to the effective synthesis of 7-azaindole analogues, which display inhibitory activity against 
PDK1 kinases. Indoles and their aza analogues play an important role as scaffolds for biologically active 
molecules. The ability of 7-azaindoles to bind to the hinge region of the kinase domain, makes its 
structure of particular interest for kinase inhibitors. The simplified synthetic analogues of marine natural 
products variolin B, known as meriolins, are prominent examples of azaindoles having a heterocyclic 
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Upon investigating the binding features of previously synthesized 7-azaindole analogues, Merkul and co-
workers decided to continue their study by incorporating 1,2,3-triazoles into the structures. In their 
research, they reported a diversity-orientated synthetic approach to generate 3-triazolyl-substituted 
(aza)indole scaffolds. The strategy involved a one-pot synthetic procedure, including a Sonogashira 
coupling and CuAAC reaction, to generate several triazolyl NH-heterocycles. The kinase inhibitory 
activity of these synthesized compounds was then tested against a broad panel of kinases (95-121 
kinases).It was found that a few of these compounds, represented in figure 46, exhibited inhibition against 
PDK1 kinases with IC50 values in the low micro molar region (˂ 1μM). Furthermore, it was shown that 
the 1,2,3-triazole ring acts as more than just a linker but displays biological activity. This observation was 
made by the significantly reduced inhibitory activity exhibited by a compound, when the triazole ring was 
replaced with a pyrazolyl group. A crystal structure obtained for one of the compounds with PDK1, 
demonstrated the important binding interactions. This information obtained can be used to design more 




Triazolyl substituted NH heterocyclic inhibitors for PDK1 kinase.
[121]
 
The serine/threonine family of Pim (proviral integration site for Moloney murine leukemia virus) kinases 
is involved in the regulation of important proliferation and survival pathways in cancer cells. The Pim 
family consists of three members (Pim1-3) and forms part of a sub-family within the CAMK 
(calcium/calmoduli-dependant protein kinase) group. These enzymes have been found to be over-
regulated in solid tumors and hematological malignancies. Pim kinases are therefore relevant targets for 
the development of new anticancer drugs.
[122-123]
 Letribot and co-workers demonstrated that pyrrolo[2,3-
a]carbozole-3-carbaldehydes are potent Pim kinase inhibitors.
[124]
 By studying the binding interactions of 
pyrrolocarbozole-3-carbaldehyde (figure 47) in the ATP-binding site of the protein kinase Pim, they 
envisioned to synthesize new pyrrolocarbazoles substituted at the N-10 position via click chemistry.  
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Structure of the reference compound pyrrolocarbozole-3-carbaldehyde. 
This particular position was shown not to be directly involved in the interaction within the ATP-binding 
site, and could serve as a promising site to introduce a group to improve water solubility of the 
compound, or to introduce a fluorescent moiety to aid in detection.
[123]
 
The azide was introduced to the pyrrolocarbazole backbone over four steps, followed by CuAAC reaction 
with several alkynes bearing hydroxymethyl, choline (ammonium) and dansyl groups to obtain the final 
compounds 18, 19, and 20, represented in figure 48. The kinase inhibitory activity of these compounds 
was tested against Pim1-3, and the pyrrolocarbozole-3-carbaldehyde was used as a reference. The results 
indicated that the 1,2,3-triazole compounds (18-20) inhibited Pim-1 in the same concentration range as 
the reference compound, whereas they were less active towards Pim-3. Letribot and co-workers thus 
showed that the N-10 position can be substituted without losing Pim-1 and Pim-3 inhibitory activities. 
Furthermore, compounds 18 and 19 showed improved aqueous solubility compared to pyrrolocarbozole-
3-carbaldehydeand compound 20 demonstrated that fluorescent labels could be added without significant 
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Synthesized analogues substituted at position N-10 via CuAAC.
[123]
 
The fibroblast growth factor receptor (FGFR) family includes four homologous receptor members 
(FRGR1-4) that are involved in wound healing, development and inflammation. Eighteen FGF ligands 
have been identified that bind to these types of receptor tyrosine kinases (RTKs). Aberrant FGFR 
signaling results in the activation of mutations, leading to ligand-independent firing or overexpression of 
the receptor itself.FGFR3 has been identified as an oncogene in bladder cancers, multiple myeloma, 
cervical and prostate cancers.
[125]
 An inhibitor (PD173074), exhibiting high potency against FGFR1, 
VEGFR2 and FGFR3, sparked the interests of Le Corre et al. to develop a library of pyrido[2,3-
d]pyrimidines using click chemistry. Their efforts were based on the investigation of the binding 
interactions of the two FGFR-3 inhibitors, PD173074 and SU5402, co-crystallized with FGFR1. Their 
work involved the synthesis of PD173074 analogues bearing substituents at position 2. By using click 
chemistry, biologically active triazoles were introduced into the compounds and a small library of 
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Rationale for the synthesis of “click” pyrido[2,3-d]pyrimidines analogues.
[126]
 
The synthetic strategy employed generated three series of diverse structures. Upon biological evaluation 
of the compounds, a number of useful observations were made. Among the 27 analogues synthesized 
more than half exhibited 55-89% inhibition of in vitro FGFR3 kinase activity at 2 μM. Introduction of the 
1,2,3-triazole moiety at position 2 of the pyridopyrimidine scaffold had no significant negative effect on 
potency, but the triazole geometry was shown to be crucial for biological activity. For example, 






Compound 21 exhibited the most potent inhibitory activity for FGFR3 amongst the library of analogues.
[126]
 
Over the past decade, a useful approach for lead generation, known as fragment-based lead discovery, has 
emerged.
[127]
 In this strategy, small fragments are identified as starting points to be optimized, and 
generate lead compounds in subsequent synthetic steps. Efficient potency (affinity) of the initial fragment 
simplifies the optimization step to deliver potential novel lead compounds for kinase targets.  
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In the work of Irie and co-workers, it was demonstrated that a kinase focused evolved fragment (KFEF) 
library could be generated using click chemistry to identify an evolved fragment compound as lead 
candidate. The design concept of the KFEF library involves the combinatorial assembly of kinase 
privileged-alkyne fragments and a diverse group of azide fragments as shown in figure 51. The kinase 
privileged fragments were chosen from kinase inhibitors in the literature to incorporate the crucial hinge 
binding interactions into the KFEF library. Two different click reactions were then used to generate a 
diverse library of 1,2,3-triazole compounds. The Cu-catalyzed click reaction were used to synthesize the 









In this way a KFEF library of 76 compounds was successfully synthesized and screened against protein 
kinases FLT3 and GSK3β to identify promising lead compounds. Furthermore, the binding efficiencies, 
and binding modes of the most potent candidates were evaluated. The KFEF synthesis and screening 
approach successfully identified two hit compounds shown in figure 52: 22 which exhibited selective 
inhibitory activity (IC50 = 1.1 μM) for FLT3 with excellent binding efficiencies (BEI = 25.2), and 23 
which exhibited selective inhibited selective inhibitory activity (IC50 = 0.49 μM) for GSK3β, also 
displaying excellent binding efficiencies (BEI =26.7).  
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Two most promising selective lead compounds (22 and 23) selected from the KFEF library. Both compounds are 
based on the CuAAC approach to afford the regioselective 1,4-disubstituted 1,2,3-triazole structures.
[39]
 
Hereby, Irie and co-workers proved that the KFEF library showed great potential in fragment-based drug 




For the purpose of this project, specific focus is aimed towards cancer drug discovery and protein kinase 
inhibitors. However, abnormal protein kinases have been implicated in various diseases and are presented 
as attractive drug-targets in several fields of medicinal research. Malaria is a major threat to world health, 
and parasitic protein kinases are suitable targets for drug development. Many of these kinases display 
profound structural and functional divergence from the human host counterparts. Plasmodium falciparum 
protein kinase 7 (PfPK7) is an “orphan” kinase (non eukaryotic-like protein kinase) which offers 
promising P. falciparum specific drug targets. The organism P. falciparum is responsible for the most 
virulent form of malaria.
[128-129]
 
Purines are involved in many metabolic processes which play significant roles in cell signaling and other 
fundamental biological processes. This important heterocycle is also the core structure of adenine and 
guanine in nucleic acids. To design selective kinase inhibitors, the independent work of Shokat and Pan et 
al., showed that non-ATP binding pockets (less conserved) are targeted by 4-aminopyrazolo[3,4-
d]pyrimidine scaffolds with a “bent” geometry of the substituents in the 3-position of the pyrazole 
ring.
[130-131]
 Klein and co-workers were motivated by these findings, to develop new 4-aminopyrazolo[3,4-
d]pyrimidines, by using click chemistry to introduce a bent geometry triazole ring at position 3 of the 
pyrazole ring. Two efficient routes, involving a one-pot two-step reaction, were used to obtain 
compounds (24 and 25) with both 1- and 4-substituted triazole rings in the 3-position of the pyrazole ring 
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Upon investigation of X-ray studies of PfPK7 kinase with different known inhibitors, Klein et al. 
observed that the structures of the inhibitors were based on the same pyrazolopyrimidine scaffold as those 
synthesized in their work. Therefore, the 4-aminopyrazolo[3,4-d]pyrimidine analogues synthesized via 
the click chemistry approach were tested against recombinant PfPK7 kinase. These tests involved an 
inhibition assay that measured the efficacy of compounds at decreasing myelin basic protein (MBP) 
phosphorylation. A significant decrease in MBP phosphorylations was observed with compounds 26 and 
27 (IC50 = 20 μM and 10μM, respectively) as shown in figure 54. The binding mode of 26 in docking 
studies revealed that the compound binds in the ATP-binding site of the kinase and not in an allosteric 
site, as was desired. Although the compounds were able to decrease the activity, complete inhibition of 
the kinase was not successful. However, the study identified some of the very few inhibitors that target 
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Compounds 26 and 27 exhibiting inhibitory activity against PfPK7.
[132]
 
As previously stated, (See section 1.5.2) the natural product staurosporine has been an inspiration for the 
design of various therapeutic agents.
[83]
 In addition, the “open” form of the natural indolocarbazole 
scaffold has exhibited improved selectivity as demonstrated by the two PKC selective kinase inhibitors, 
Enzastaurin and Ruboxistaurin, currently under clinical trials.
[133-134]
 The enhanced selectivity of these 
structures, together with the fact that click chemistry has become a major tool in hit discovery, motivated 
Gu and co-workers to develop novel bisaryl maleimides through the CuAAC approach. A general 
structure of the click bisaryl maleimides is shown in figure 55. In this study, seven structurally diverse 
click bisaryl maleimides were generated and evaluated against four cancer cell lines. One compound (28), 
shown in figure 56, was selected as a representative to enter into kinase inhibitor assay, and proved to be 
a highly selective hit compound. In a panel of 124 kinases, the hit compound 28 only showed high 
potency against three kinases (GSK-3β, CLK2 and VEGFR2). From the kinase inhibitory activity data, 
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The design of bisaryl maleimides via click chemistry. These structures are based on the “open”, selective 
indolocarbazoles, Enzastaurin and Ruboxistaurin.
[86]
 
To understand the high selectivity demonstrated by compound 28, its structural features were 
investigated. An ATP-competitive experiment confirmed that 28 is an ATP competitive inhibitor and 
docking studies involving the GSK-3β crystal structure identified further interactions (figure 56). An 
interesting observation, to explain the mechanism of selectivity, was the distinct inward flip of Phe67 in 
the active site. In this way, Phe67 was presented at a suitable distance to the phenyl group of 28 to form 
π-π interactions. The inward flipping of Phe67 caused a conformational change of the P-loop and thereby 
a dramatic topological change of the ATP binding site. The authors proposed that the deformed P-loop 
may account for the high selectivity of 28 in the 124-kinase assay. In addition, the triazole ring, 
introduced by the click reaction, allowed for additional π-π stacking interactions within the binding 
pocket. The work of Gu et al. showed that the combination of click chemistry and rational design can be a 
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The selective bisaryl maleimide 28 and a representation of its docking within the ATP-binding site of GSK-3β 




Click chemistry has proven to be a powerful tool in biomedical research, and the importance of triazole 
compounds is undeniable.
[88, 97]
 The various examples given in this section illustrate the use of the click 
approach, particularly CuAAC, in the development of kinase inhibitors. The work undertaken by these 
research groups is also current (published between 2009 and 2014), demonstrating the potential of 
utilizing click chemistry as a promising approach to develop new effective kinase inhibitors. 
2.2 Aims 
In this project we envisaged to develop potential kinase inhibitors that would selectively target EGFR. 
Exploiting the attractive features demonstrated by the natural product staurosporine, the design was based 
on a staurosporine scaffold. The project was composed of two parts. The first part involved the synthesis 
of compounds having the closed pyrrolocarbazole core, while the second part focused on the synthesis of 
compounds resembling an “open” form of indolocarbazole derivatives (figure 57). 
Stellenbosch University  https://scholar.sun.ac.za





Staurosporine inspired pyrrolocarbazole and “open” indolocarbazole compounds. 
The pyrrolocarbazole scaffold could act as a driving portion that would present a suitable platform to 
incorporate various warheads (R) at a proper trajectory (figure 58). Displaying the warhead at a particular 




Pyrrolocarbazole driving portion with warhead. 
The second part of this project was mainly motivated by the success of the “open” indolocarbazole 
derivative, enzastaurin, which has demonstrated kinase inhibitory activity with enhanced selectivity. A 
major source of inspiration in the design of these “open” structures is based on click chemistry to generate 
bisaryl maleimide derivatives, as well as bisamino maleimides as seen in figure 59. Incorporating a 
warhead (R) is also crucial in this strategy to afford potential kinase inhibitors. It must be noted that the 
warhead (R) can be a functionality that either acts in a reversible, or irreversible manner. 
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The staurosporine muse enzastaurin (left structure), an inspiration for the design of the click- and bisamino products. 
In the following chapters, we discuss the research strategies undertaken to generate the desired 
compounds. A detailed description of the synthesis is given, including the challenges encountered and 
decisions taken to successfully obtain the final products.  
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CHAPTER 3 –PYRROLOCARBAZOLE ANALOGUES 
3.1 Towards the pyrrolocarbazole kinase inhibitors 
The initial focus of this project was towards the synthesis of staurosporine-inspired pyrrolocarbazole 
compounds as kinase inhibitors. Incorporating various groups onto the pyrrolocarbazole scaffold would 
allow for the prospect of developing both reversible and irreversible inhibitors. In the following section, 
the research strategies employed will be described, as well as the reactions used to design the 
staurosporine analogues as potential EGFR kinase inhibitors. 
3.1.1 Motivation from previous research 
The design of these compounds was motivated by previous research undertaken in our group. In this 
regard, compound 29 demonstrated encouraging results upon biochemical screening against the wild type 
(WT) and mutant strains of EGFR. A favorable selectivity profile towards the mutant strains was 
exhibited with very little inhibitory activity for the normal EGFR WT. Good inhibition for the single 
mutant EGFR was shown (IC50 = 1320 nM), while a better inhibitory activity (IC50 = 1190 nM) was 
demonstrated for the double mutant strain of EGFR (figure 60). Compared to the FDA approved EGFR 
inhibitor, Gefitinib (see section 1.4.2, figure 17), compound 29 exhibits an inhibitory activity 
approximately twice as potent against the double mutant strain, and 0.5 fold more potent against the 
single mutant strain. These promising results, together with the practicable synthetic procedures, inspired 
the development of various derivatives based on the pyrrolocarbazole scaffold.  
 
Figure 60 
 Compound 29 activity against single and double mutations and the general structure of the pyrrolocarbazole 
derivatives synthesized in this project. 
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3.2 Strategy pertaining to the synthesis of N–acryloyl target compound 30 
In order to build the pyrrocarbazole backbone, a proposed synthetic strategy was considered, as outlined 
in scheme 4. The linear synthesis involved a number of steps including protection, reduction, oxidation, 
Wittig reaction, Diels-Alder reaction, aromatization and finally the introduction of a possible warhead. A 
particular concern was the outcome of the exposed acidic indole amine proton during the Wittig reaction. 
In addition, the 2-vinyl-1H-indole could have posed a possible threat to instability and caused the product 
to undergo polymerization. For this reason, we proposed that the introduction of an electron withdrawing 
protecting group on the indole amine, prior to the Witting reaction, could circumvent these potential 
problems. Once the alkene product was generated, a Diels-Alder reaction, using maleimide as the 
dienophile, could be performed. Following aromatization, the pyrrolocarbazole scaffold would then be 
available for further modification.  
Scheme 4 
 Outline of strategy towards the pyrrolocarbazole backbone. 
The initial target compound [6-acryloylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione] (30), was devised to 
incorporate a Michael acceptor functionality, namely the acryl amide group, in the pyrrolocarbazole 
scaffold (figure 61). The acryl amide group has been involved in numerous investigations as an 
electrophilic warhead in the design of irreversible kinase inhibitors.
[40,54,135-136]
 By integrating this 
functionality into an appropriate driving portion, such as the pyrrolcarbazole scaffold, the potential to 
form a covalent interaction with an appropriate cysteine residue present in the kinase, was expected to be 
enhanced (see section 1.4.2).  
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Structure of N – acryloyl target compound as a potential irreversible kinase inhibitor. 
Molecular modeling analysis for this target compound was performed previously in the group and the 
docking studies revealed an appropriate orientation and distance (2.9 Å) of the potential inhibitor warhead 
(β carbon of the acryloyl group) to the nucleophilic thiol of cysteine 797 (Cys797) (figure 62). A major 
goal in the design of the target compound was to improve kinase selectivity (by introducing the 
irreversible warhead), while maintaining the potency of staurosporine. With this aim in mind, the 
synthesis of the pyrrolocarbazole scaffold (driving portion) was embarked. 
 
Figure 62 
Representation of the target compound 30 in the EGFR domain. The close proximity (2.9 Å) between the β carbon 
of the acryloyl group and Cys797 is demonstrated. 
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3.3 Towards N-acryloyl target compound 30 
3.3.1 Synthesis of 1-tert-butyl 2-ethyl 1H-indole-1,2-dicarboxylate (32) 
 
Scheme 5 
The first step of the synthesis involved conversion of 31 into 32. This was done to avoid possible 
polymerization of the impending vinyl indole. The electron-withdrawing ability of this carbamate group 
was envisioned to stabilize the Wittig product. Following a procedure in literature, the reaction proceeded 
smoothly as shown in scheme 5.
[138]
 Upon treating a solution of ethyl indole-2-carboxylate (31) in MeCN 
with Boc2O and DMAP, the product was obtained and purified by means of column chromatography. The 
pure compound (32) was afforded in a good yield of 85%. 
The 
1
H NMR spectrum of the product 32 corresponded well to that 
reported in literature.
[138]
 A clear indication that the Boc protection was 
carried out successfully was demonstrated by the absence of the broad 
signal for the –NH indole group, and the formation of a new singlet at 
1.64 ppm. The singlet integrated for nine and was assigned to Hl. The 
remainder of the proton signals corresponded to the starting material and 
could all be accounted for in the spectrum. 
3.3.2 The reduction and oxidation reactions 
A number of reducing and oxidizing agents are capable of generating the 1H-indole-2-carbaldehyde 
required for the Wittig reaction. One option was to use the reducing agent DIBAL, which is known to 
reduce esters into aldehydes in a single step, but risks the formation of a mixtures of products.
[139]
 It was 
decided to synthesize the indole aldehyde in two separate controlled steps. Firstly, the reactive hydride 
reducing agent, LiAlH4, would be used to form the alcohol, followed by oxidation using MnO2, to 
generate the desired aldehyde species. This approach was motivated by the high yields reported in 
literature and the accessibility of the reagents.
[140-145] 
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3.3.2.1 Reduction using LiAlH4 
LiAlH4 is a powerful reducing agent, which reduces a vast number of different functional groups. Its 
discovery was made in 1947 by Finholt, Bond and Schlesinger.
[146]
 The presence of a polar metal 
hydrogen bond makes LiAlH4 a strong reducing agent, serving as a source of hydride for reduction.
[147]
 
This reaction is one of the best ways of making alcohols from esters.
[148]
 The reactive LiAlH4 hydride 
attacks the carbonyl of the ester, forming an aldehyde. This aldehyde is even more reactive than the ester 
starting material, and readily undergoes a second attack from the LiAlH4 hydride, forming an alkoxide 
anion. Following hydrolysis by H2O, the primary alcohol product is generated. The general mechanism is 
illustrated in scheme 6.
[148]  
Scheme 6 
General mechanism for the reduction of an ester using LiAlH4.
[148]
 
3.3.2.2 Attempted synthesis of tert-butyl 2-(hydroxymethyl)-1H-indole-1-carboxylate (33) 
 
Scheme 7 
Direct LiAlH4 reduction of the Boc product 32, resulted in numerous products (as per TLC) and the 
reaction was attempted without the Boc-protecting group.  
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Subsequently, the reduction of commercially available ethyl indole-2-carboxylate (31), was carried out 
successfully by using the same procedure as described in section 3.3.2.2. and in literature.
[143]
 The 
reaction was completed within 30 minutes when stirred at room temperature. Upon completion the excess 
LiAlH4 was quenched with H2O and NaOH (1M) and stirred for a further 30 minutes. Following 
filtration, a workup was performed. The crude product was purified by column chromatography, affording 
the pure product (34) in an excellent yield of 93%. 
The 
1
H NMR spectrum of the product (34) corresponded well to that reported 
in literature.
[149]
 The reduction of the ester group to a primary alcohol 
functionality was clearly evident by the presence of a broad –OHk signal at 
1.99 ppm. Further evidence was obtained by the singlet of Hj at 4.80 ppm, 
integrating for two. The absence of the triplet and quartet signals, which belonged to the ester 
functionality, was another indication that the reduction was successful.  
3.3.2.4 Oxidation using MnO2 
MnO2 is one of the most attractive inorganic materials due to its extensive range of applications, its low 
cost, and environmentally benign nature. MnO2 is a widely used standard oxidant, employing very mild 
conditions and simple work-up procedures.
[150-151]
 The oxidative ability of MnO2 has been known since 
the 1870’s. 
[151]
 The first publication of active MnO2 as organic oxidant was reported in 1948 by Ball et 
al. for the oxidation of vitamin A to retinene.
[150,152]
 The oxidizing power of this reagent depends largely 
on its preparation and reaction temperature. MnO2 is able to oxidize a large number of functionalities and 
perform selective oxidation, provided that the reaction temperature is not too high. 
[147,151]
 Mechanistic 
studies involving the oxidation of alcohols with MnO2 have met a number of difficulties and uncertainties 
regarding the chemical nature of the real reagent in the excess of MnO2. 
The mechanism involves complexation of the alcohol on the surface of MnO2 particles, followed by 
oxidation and desorption of the carbonyl compound. The complexation may be aided by the presence of 
foreign particles in the large amount of MnO2. A number of mechanistic proposals have been made which 
correspond with experimental data.  
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Pratt and van de Castle suggested a radical mechanism as shown in scheme 9. In combination with the 
work of Hall and Story, a refined radical mechanism involving an intermediate manganese ester, was 
proposed by Goldman (Scheme 9). Kwart and George also proposed a mechanism whereby hydrogen 





Proposed mechanisms for MnO2 oxidation.
[151]
 




Another effective reaction in our synthetic route was the oxidation of the primary alcohol (34) to the 
aldehyde (35). This reaction proceeded smoothly without any difficulties. MnO2 was employed as 
oxidizing agent and led to the procedure being very simple. Prior activation of the MnO2 was achieved by 
placing a beaker of MnO2 in an oven at 120 ° C for 24 hours.  
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The activation step was a crucial preliminary measure taken to ensure the oxidation reaction succeeded. 
Upon completion of the reaction, the product (35) was afforded in a good yield of 76%. This allowed for 
subsequent Boc-protection compound 36.  
The 
1
H NMR spectrum of the product (35) compared well to that found in 
literature.
[139,149]
 The loss of the signal at 4.80 ppm, which belonged to the 
methylene group of the primary alcohol, and the formation of the distinctive 
Hk aldehyde singlet at 9.86 ppm, was an indication that the product formed 
was in fact the 1H-Indole-2-carbaldehyde. In addition, the remainder of the aromatic peaks and the amine 
–NHa were all accounted for.  




The Boc-protection of the 1H-Indole-2-carbaldehyde (35) followed a similar method to the protection 
reaction of the indole ester (31) utilized earlier (see section 3.3.1), shown in scheme 11, affording the pure 
compound (36) in a good yield of 88%. 
The 
1
H NMR spectrum of the product (36) compared well to that in 
literature.
[149]
 The absence of the indole –NHa broad signal and the presence 
of the new singlet (Hl) at 1.72 ppm, which integrated for nine, was proof that 
the Boc-protection had been successful.  
 
 
3.3.4 The Wittig reaction 
The impact of the Wittig reaction on synthetic organic chemistry has been monumental. This reaction 
between phosphorus ylids and aldehydes/ketones has been referred to as “the most important practical 
method for the construction of carbon-carbon double bonds.” 
[153,154]
 The first ylid was synthesized more 
than a century ago, but ylid chemistry did not flower until the Nobel-Prize-winning work of Wittig in 
1953.  
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The Wittig reaction was born in 1919-1921, when Staudinger and coworkers, prepared, isolated and 
recognized the first ylid. However, the significance of this discovery and its versatility as a synthetic tool 
for olefination of carbonyl compounds was only established by George Wittig a few decades later. 
[154-155]
 
One of the main virtues of the Wittig reaction is its complete structural specificity. The formation of Z or 
E alkenes can be controlled by the selection of the type of ylid, the type of carbonyl compound, or the 
reaction conditions – all of which have been the subject of intense study.
[154]
 The mechanism of the Wittig 
reaction has been investigated for more than 40 years and a total of eight mechanisms have been proposed 
since 1953.
[153]
 Detailed studies led to the currently accepted mechanisms which can be described 
separately according to the nature of the ylid.
[154]
 Stabilized ylids characteristically have conjugating or 
anion-stabilizing substituents adjacent to the negative charge, whereas non-stabilized ylids do not possess 
these functionalities. The general rule states that stabilized ylids are selective for the formation of (E)-
alkenes, while non-stabilized ylids favour the formation of (Z)-alkenes.
[148]
 Although no single 
mechanism exists, a “general mechanism” - as represented in scheme 12 - does encompass the behaviour 
of the different ylids. Two major aspects of the ylids, which account for the stereochemical outcome, 






 General mechanism of the Wittig reaction involving oxaphosphatanes and different rate-determining steps.
[153]
 
For the purpose of this project, the Wittig reaction product required to build the pyrrolocarbazole 
backbone may demonstrate instability and risk polymerizing as shown in figure 63. To circumvent this 
potential problem, the introduction of an electron withdrawing protecting group could offer stabilization 
to the vinyl indole and avoid polymerization.  
 
Figure 63 
 Possible polymerization of the vinyl indole. 
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3.3.4.1 Attempted synthesis of tert-butyl 2-vinyl-1H-indole-1-carboxylate (37) 
 
Scheme 13 
Having the Boc-protected 1H-indole-2-carbaldehyde (36) in hand, the Wittig reaction was performed as 
shown in scheme 13, with the aim of synthesizing the stabilized vinyl indole (37). Unfortunately, this 
reaction was unsuccessful. The procedure initially involved the generation of the ylid, by treating 
MePPh3Br with nBuLi in dry THF. The yellow/orange colour change of the reaction was a good 
indication of ylid formation. The ylid was then reacted with the Boc-protected 1H-Indole-2-carbaldehyde 
(36), but resulted in most of the starting material remaining unreacted. Upon increasing the temperature 
and the concentration of the ylid, multiple spots were observed (as per TLC), and it was suspected that the 
Boc-protecting group was not stable enough to withstand these reaction conditions. 
3.3.5 Use of an alternative protecting group 
The problems associated with the Wittig reaction led to the belief that the Boc-carbamate was not the 
correct choice of protecting group for the strategized synthesis. Sulfonamides are amongst the most stable 
of the nitrogen protecting groups.
[156]
 For this reason, it was decided to devise an alternative route using a 
benzenesulfonyl protecting group. Not only would it serve as a good protecting group, but additionally, it 
would facilitate a directed ortho-lithiation reaction to incorporate the desired aldehyde functionality.The 
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3.3.5.1 Synthesis of tert-butyl 2-formyl-1H-indole-1-carboxylate (39) 
 
Scheme 15 
The synthetic route was embarked by firstly introducing the benzenesulfonyl group to the indole (38). 
This was accomplished by treating indole, dissolved in dry DMF, with NaH, followed by the drop-wise 
addition of benzenesulfonyl chloride. The reaction mixture was stirred at room temperature overnight. 
Upon completion, a workup was performed, and no further purification was required. In this manner, the 
crude product (39) was obtained in a yield of 55%.  
The 
1
H NMR spectrum of the product (39) was compared to that in literature and 
corresponded well.
[157]
 The absence of the broad signal of the indole –NHa and 
the clear increase of aromatic signals (Hk, Hl, Hm), was indicative of the 





3.3.5.2 Synthesis of 1-(phenylsulfonyl)-1H-indole-2-carbaldehyde (40) 
 
Scheme 16 
Having synthesized the benzensulfonyl indole (39), the next reaction involved a directed ortholithiation 
using a large bulky base (TMP), n-BuLi and DMF as shown in scheme 16. A proposed mechanism of the 
reaction is shown in scheme 17. The manner in which the reaction was carried out is briefly explained. 
Formation of the non-nucleophilic base LiTMP was performed in situ by treating a solution of TMP, in 
dry THF, with n-BuLi at -78 °C. The reaction flask was transferred to an ice bath and stirred at 0 °C, for 
30 minutes. The indole was then added to the LiTMP solution and stirred for an hour at -78 °C, following 
an extra 20 minutes of stirring at 0 °C. At this stage we had hoped to form the aryllithium species.  
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The presence of the sulfonyl functionality was critical for this step, since the sulfonyl oxygen guides the 
LiTMP to attack the adjacent proton, by forming a complex with the Lewis-acidic lithium atom.
[148]
 
The next step of the reaction was to introduce the aldehyde functionality by using DMF. This was 
achieved by adding DMF to the reaction mixture at -78 ° C, and allowing the reaction temperature to 
increase to room temperature. The progress of the reaction was monitored by TLC, and it was observed 
that some of the benzenesulfonyl indole (39) remained unreacted. For this reason, the reaction was left to 
stir overnight. Unfortunately, the reaction did not progress to completion. The mixture was then quenched 
with saturated NH4Cl and a workup was performed. The product (40) was purified by means of column 
chromatography and was obtained in a rather low yield of 36%. The low yield can be ascribed to the 
reaction not proceeding to completion. This may be as a result of the aryllithium species formation not 
being completely successful.  
The 
1
H NMR spectrum of the product (40) was compared to that found in 
literature and corresponded well.
[158]
 The formation of a new singlet at 10.53 
ppm which integrated for one, was indicative of the characteristic aldehyde 
signal of Ho. The rest of the aromatic signals were all accounted for in the 







 Proposed ortholithiation mechanism to generate the benzensulfonyl indole aldehyde.
[148]
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3.3.6 Use of the unprotected indole system 
In addition to the anticipated problems regarding vinyl indole polymerization (see figure 63), another 
reason for incorporating a protecting group was not only to obtain the desired products, but also to 
synthesize these compounds in high yield. Previous studies have shown that the pyrrolocarbazole 
demonstrates poor solubility – a factor which becomes rather problematic, especially when performing 
subsequent reactions.
[159]
 This establishes another motive for introducing a protecting group - to provide 
the pyrrolocarbazole with a more organic character and enhance solubility. Unfortunately, both the Boc-
protecting group and benzenesulfonyl group did not meet the requirements to a satisfactory level - the 
Boc-carbamate resulted in multiple products during the Wittig reaction, while the route incorporating the 
benzenesulfonyl group rendered low yields. A concurrent synthetic strategy was undertaken, involving a 
procedure in which a protecting group was omitted, as demonstrated by Tao et al.
[160]
 The previous 
premonition of 2-vinyl-1H-indole instability was reconsidered, and the unprotected route was attempted. 
Furthermore, we envisioned that the pyrrolocarbazole would be soluble in DMF, which is a suitable 
solvent to carry out the final step (an alkylation reaction), to introduce the acryloyl moiety. 
3.3.6.1 Synthesis of 2-vinyl-1H-indole (41) 
 
Scheme 18 
This reaction was performed in the same manner as the initial Wittig reaction (see section 3.3.4.1) as 
shown in scheme 18. The ylid generation was carried out exactly the same, but with a higher 
concentration relative to the indole aldehyde (35). A number of optimization reactions were carried out in 
which the equivalents of ylid used was varied. Once the ylid was formed, a solution of compound 35 was 
added in a drop-wise manner at 0 °C, and stirred for 6 hours at room temperature. To our delight, TLC 
monitoring indicated full consumption of the starting material and conversion to the product. Upon 
completion, a workup was performed and the compound was purified by column chromatography. The 
pure product (41) was afforded in a satisfactory yield of 74%, and was stored in a dark environment, and 
under an inert atmosphere to prevent potential polymerization. 
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H NMR spectrum of the product (41) was compared to that reported in 
literature and corresponded well.
[139]
 The vinyl protons, Hk and Hk’, were 
present as two doublets at 5.55 ppm and 5.27 ppm, respectively. In addition, 
the doublet of doublets integrating for one at 6.75 ppm was assigned to Hj. 
The rest of the aromatic signals and indole –NHa were all accounted for and matched the expected 
integration. 
3.3.7 The Diels-Alder reaction 
In 1928, Professor Otto Diels and his research student, Kurt Alder, identified the products arising from 
the reaction of cyclopentadiene with quinone (Scheme 19).
[161]
 This historic event in the field of chemistry 
led to the birth of the Diels-Alder reaction, rewarding the namesakes with the Nobel Prize in 1950.
[162]
 
The true power and effectiveness of this pericyclic reaction began to be realized in the 1950s and 1960s 
when it was applied to the total synthesis of many complex natural compounds. An example includes the 
work of Woodward and co-workers, who adopted the Diels-Alder reaction as a key step in the synthesis 
of cortisone, cholesterol and reserpine.
[161]
 To date, the Diels-Alder reaction remains one of the most 




 Reaction products of cyclopentadiene with quinone, as identified by Diels and Alder.
[161]
 
The Diels-Alder reaction is the most famous example of the pericyclic reactions.
[148]
 This particular 
pericyclic reaction forms part of the class known as cycloadditions and is a special case which involves 
the combination of conjugated dienes with an alkene (4 + 2). A six-membered ring is created by the 
formation of two new σ-bonds at the expense of two π-bonds.
[163]
 In order for the reaction to be successful 
and avoid dimerization, the alkene must possess a conjugated electron-withdrawing group, or some sort of 
extra conjugation. This group is known as the dienophile.
[148]
 Dienes on the other hand can have different 
kinds of substituents, and can be open-chain or cyclic. Many dienes can occur in two conformations (s-
trans/s-cis) since they are capable of rotating about the single bond, between the conjugated double 
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The Diels-Alder reaction has a regioselective and stereospecific nature and the stereochemistry of the 
product depends on that of the diene and dienophile. An important feature of Diels-Alder reaction, 
recognized in 1934 by Alder and Stein, is that the product predominantly or exclusively leads to the 
formation of the endo cycloadduct and not the exo diastereoisomer. This observation is illustrated in the 
most famous Diels-Alder reaction of all time – that between cyclopentadiene and maleic anhydride 
(Scheme 20).
[148]
 The preference for the more sterically crowded and less thermodynamically stable 
transition state, was explained by Hoffmann and Woodward and ascribed to secondary orbital 
interactions.
[161, 164]
 In the example below, these secondary orbital interactions are formed between the 
carbonyl groups of the dienophile and the developing π-bond at the back of the diene.
[148]
 Many 
experimental and theoretical arguments have been proposed to explain the formation of the endo product. 
Besides the secondary orbital theory, other explanations include stabilization of the endo orientation by 
inductive, charge-transfer, or CH-π interactions. However, the exact factors controlling the endo [4 +2] 




The reaction between cyclopentadiene and maleic anhydride forming the less stable endo cycloadduct.
[148]
 
For the purpose of this project, the conjugated diene required for the Diels-Alder reaction is obtained 
following the Wittig reaction. The choice of the dienophile is based on the crucial hydrogen bond 
interactions between the amide functionality of staurosporine and the hinge region of the EGFR kinase 
domain. Furthermore, investigating the structures of the staurosporine-derived analogues as promising 
kinase inhibitors (see section 1.5.2), it was noted that almost all the compounds possess an unsubstituted 
−NH amide/imide group. We proposed that the –NH is essential for the formation of hydrogen bond 
interactions in the hinge region, and was thus included in the design strategy of our compounds. For this 
reason, maleimide was chosen as the dienophile. The Diels alder reaction between the indole alkene and 
maleimide is represented below in scheme 21. It must be noted that the newly formed π-bond rearranges 
to reconstruct the conjugated system of the compound. 
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Diels-Alder reaction between indole alkene (diene) and maleimide (dienophile). 
3.3.7.1 Synthesis of 4,5,6,10c-tetrahydropyrrolo[3,4-c]carbazole-1,3(2H,3aH)-dione (42) 
 
Scheme 22 
The Diels-Alder reaction is a key tool in organic chemistry to increase the molecular complexity 
(molecular size, stereochemistry, functionality) in a single step, and has been widely utilized in the 
synthesis of complex natural products. 
[162,164]
 As stated in section 3.3.7, the choice of our dienophile was 
maleimide. The reaction was performed as shown in scheme 22. The reagents were heated together, upon 
which they melted, fused and solidified. The crude product formed was highly insoluble, which led to 
challenges and complications in purification by crystallization or column chromatography. For this 




H NMR spectrum of the crude product (42), although a bit unclean, 
did reveal indicative signals. Unfortunately, only one broad peak of –NHa 
was found. We suspect that the maleimide –NHn may have been 
shadowed by an impurity. The four multiplets for the diastereotopic 
protons of Hk and Hj were found upfield and integrated for one each. Hp 
and Hl were located at 4.17 ppm and 3.17 ppm respectively, and each 
integrated for one proton. The aromatic peaks could all be accounted for. 
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3.3.8 The aromatization of the pyrrolocarbazole scaffold 
MnO2 has been widely used for dehydrogenation and aromatization reactions. 
[147]
 In addition to the vital 
role of this reagent for the synthesis of the indole aldehyde in this project, MnO2 is also used for the 
aromatization step required to generate the conjugated pyrrolocarbazole system.  
Another powerful oxidant employed in the design strategy is DDQ. DDQ is a versatile quinone reagent, 
combining high oxidation ability with relative stability.
[147]
 In this project DDQ was used as an alternative 
reagent for the aromatization step. The reagent has proven useful for a wide range of reactions, including 
dehydrogenation, oxidation and selective deprotection.
[151]
 DDQ’s mechanism of dehydrogenation is 
believed to involve an initial rate-determining transfer of a hydride ion from the hydrocarbon to the 
quinone oxygen atom - forming a phenolate anion and a carbocation as shown in scheme 23. The 
following step is rapid, and involves the carbocation of the product losing a proton (forming a double 
bond in the process) and generating hydroquinone. The degree of stabilization of the carbocation is 
essential for dehydrogenation to occur. The presence of functionalities (alkene or aromatic moieties) 
capable of stabilizing the transition state is therefore necessary to initiate hydrogen transfer. 
[147,165]
 An 
example of the mechanism is shown in scheme 23. 
 
Scheme 23 
 Mechanism of dehydrogenation by DDQ.
[165]
 
3.3.8.1 Synthesis of pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione (43) 
 
Scheme 24 
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Following the Diels-Alder reaction, the final step to build the pyrrolocarbazole backbone (43) required 
the aromatization of the compound (scheme 24). This reaction was carried out by dissolving the solid 
Diels-Alder product (42) in DMSO and treating the solution with DDQ. The reaction mixture was stirred 
for 2 hours at 50 °C. Cold H2O was then added drop-wise to the reaction mixture, which led to formation 
of a precipitate. The precipitate was collected and no further purification was required. The product (43) 







H NMR spectrum of the product (43) was evaluated and all six 
aromatic protons (He, Hf, Hg, Hh, Hj, Hk) were identified. The two 
distinctive broad signals of the indole amine –NHa and the imide –NHn, 
were also present in the spectrum. Evaluation of the 
13
C NMR spectrum 
revealed all the carbon signals as expected. For example, the two carbonyl 
signals (Co and Cm) were clearly evident at 170.4 ppm and 170.3 ppm. 
Finally, the IR spectrum showed the presence of the 2° amine stretch at 3186 cm
-1
 and the imide stretch at 
3057 cm
-1
, as well as the carbonyl stretch at 1697 cm
-1
. 




Numerous attempts were made towards the final step of the synthesis. Despite the various efforts, the 
reactions performed to incorporate the acryloyl moiety were unsuccessful. Firstly, the reaction was 
carried out without the use of a base. The acryloyl chloride (diluted in DMF) was added drop-wise to a 
solution of compound 43 in DMF at 0 °C. The reaction mixture was then stirred at 80 °C, under N2 gas, 
for 2 days. While monitoring the progress of the reaction by TLC, it was observed that compound 43 
remained unreacted. The same reaction was then performed, after initial treatment of compound 43 with 
NaH (scheme 25).  
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The colour of the reaction mixture changed from yellow to purple once the NaH was added. Upon 
addition of the diluted acryloyl chloride, a colour change back to yellow was observed. The reaction was 
again monitored by TLC, but unfortunately showed no product formation over a period of 4 days. Fearing 
that the maleimide –NH might be the reason for the problems, an alternative approach to introduce the 
acryloyl group, which utilizes a protected maleimide was attempted (scheme 26). In this manner possible 
regioselectivity problems between the nucleophilic indole amine and acidic maleimide imide present in 
(43), could be avoided.  
Scheme 26 
Outline of strategy using Boc-protected maleimide as an alternative approach to introduce the acrolyl moiety. 









The reaction to protect maleimide (44) was carried out smoothly, following a procedure in literature to 





H NMR spectrum of the product (45) was evaluated and showed the presence of 
two signals. The singlet at 6.78 ppm, integrating for two, was assigned to Ha. The Boc 
group (Hb) integrated for nine, and was located at 1.57 ppm. The absence of the broad 
signal of –NH was another indication that the Boc-protection reaction was a success. 
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The Diels-Alder reaction was performed, as shown in scheme 28, by adding the Boc-protected maleimide 
(45) and 2-vinyl-1H-indole (41) neat to a reaction flask. The reaction temperature was kept at 70 °C, since 
higher temperatures resulted in protecting group cleavage. Unfortunately, complete consumption of 41 
was not observed, even when increasing the equivalents of protected maleimide (45). This result could be 
ascribed to improper mixing of the starting materials in the melt. After the reaction, the crude product was 
purified by column chromatography to afford the pure compound 46 in a yield of 59%.  
In the 
1
H NMR spectrum of the product (46), the singlet (Hp) from the Boc 
group was evident at 1.45 ppm. The diastereotopic protons of Hj and Hk 
were present as four distinct signals in the range between 2.80 – 1.86 ppm, 
each integrating for one. A single broad signal for –NHa was identified at 
11.07 ppm. The 
13
C NMR spectrum showed the carbonyl signals (Cq and 
Cm) at 175.7 ppm and 173.4 ppm, while that of the Boc group (Cn) was 
located at 147.1 ppm. Finally, the results of the mass spectral analysis of 
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The Boc-protected Diels-Alder product (46) was dissolved in DMF in a reaction flask and treated with 
DIPEA. The mixture was cooled to - 5 °C and a solution of acryloyl chloride in DMF was added drop-
wise. The reaction temperature was then increased to 60 °C and stirred for 2 days. Unfortunately, the Boc 
group was cleaved with the reaction conditions and the product was not formed. Another reaction 
involving aromatization of compound 46 was also attempted prior to the acryloyl introduction. 
Unfortunately, both DDQ and MnO2 oxidants did not succeed in the aromatization of the Boc-protected 
Diels-Alder product (46), since the heat required during these reactions led to the Boc group being 
cleaved. The inability to install the acryloyl functionality onto the indole amine therefore required a 
modification of the project targets. 
3.4 New target compounds 
The challenges experienced thus far led the synthesis of target compound 30 being discontinued. The 
focus was directed towards the design of different target compounds shown in figure 64. It must be noted 
that particular interest was directed towards the activity of the unaromatized compounds compared to 
their aromatized partners. The pyrrolocarbazole has a rigid scaffold relative to the unaromatized Diels-
Alder product which displays a more flexible nature. The envisaged strategy of these new target 
compounds are discussed in detail in the following sections. The aim was to synthesize potential kinase 
inhibitors by utilizing the pyrrolocarbazole (aromatized and unaromatized) scaffold and introducing the 
various warheads (hydroxyl, propargyl and nitrile) onto the structure. As discussed earlier (see section 
1.4.2, figure 16), the propargyl and nitrile moieties have the ability to form covalent interaction and could 
demonstrate irreversible inhibition. 
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Illustration of the new target compounds. 
3.5 Synthesis of N–tether hydroxyl target compounds 48 and 49 
The promising results demonstrated by compound 29 (see page 63), encouraged the synthesis of a similar 
compound, having one less carbon in the chain linking the hydroxyl functionality. The envisaged strategy 
required the introduction of a silyl-protected 2-bromoethoxy group to the commercially available indole 
ester (31). The various reactions highlighted earlier (reduction, oxidation, Wittig, Diels-Alder, 
aromatization) were once again included in the strategy as shown in scheme 30. Together with a silyl-
deprotection reaction, these procedures were utilized to generate target compounds 48 and 49.  
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Outline of strategy towards target compounds 48 and 49. 




The first step in the synthetic route was to generate the silyl-protected 2-bromoethoxy group (55). The 
reaction was carried out successfully by treating a solution of imidazole and MeCN with 2-bromoethanol 
(54) and TBDMSCl at 0 °C (scheme 31). The product (55) was afforded as an oily liquid in a satisfactory 




H NMR spectrum of the product (55) was compared to that reported in literature 
and corresponded well.
[167]
 The singlet located at 0.90 ppm integrated for nine, and was 
identified as He. In addition, the upfield singlet at 0.09 ppm was assigned to the protons 
(Hc) of the Si-C bond and integrated accurately for six protons. Finally, the signals of Ha 
and Hb were also clearly evident at 3.39 ppm and 3.89 ppm, respectively.  
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3.5.2 Synthesis of ethyl 1-{2-(tert-butyldimethylsilyloxy)ethyl}-1H-indole-2-carboxylate (56) 
 
Scheme 32 
Having synthesized compound 55, it could be introduced to the commercially available ethyl indole-2-
carboxylate (31) in the reaction shown in scheme 32. This reaction was carried out by treating a solution 
of 31 in DMF with NaH, followed by 2-bromoethoxy silyl (55). Upon completion of the reaction, the 
product was purified by column chromatography to obtain compound 56 an acceptable yield of 73%.  
The 
1
H NMR spectrum of the product (56) was evaluated and all the 
expected signals could be identified. The absence of the broad indole –
NHa signal, together with the location of all the peaks identified earlier 
for the 2-bromoethoxy silyl protecting group, confirmed the formation 
of the desired product. Finally, the results of the mass spectral analysis 





3.5.3 Synthesis of [1-{2-(tert-butyldimethylsilyloxy)ethyl}-1H-indol-2-yl]methanol (57) 
 
Scheme 33 
The reduction reaction using LiAlH4 was performed similarly to that in section 3.3.2.2. The only slight, 
but crucial difference, was that the reaction temperature was kept at 0 
o
C, once the solution of the 
compound 56 was added to the LiAlH4.  
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It should be noted that removal of the ice bath during this step led to the loss of the ethoxy silyl group 
from the indole alcohol product. After the reaction, the product (57) was purified by column 




H NMR spectrum of the product (57) was similar to that of the starting 
material, except for the absence of the ester signals. The loss of the quartet 
and triplet of the ethyl ester group was replaced by a broad singlet at 3.23 
ppm for Hp, and a singlet belonging to the methylene Ho integrated for two at 
4.78 ppm. The loss of two carbon signals in the 
13
C NMR spectrum of the 
product (57) was also indicative for the successful formation of the indole 
alcohol from the indole ester. IR analysis showed the hydroxyl stretch at 
3258 cm
-1
. The results of the mass spectral analysis of 306.1889 amu 
correlated with the expected mass of 306.1889 amu. 
3.5.4 Synthesis of 1-{2-(tert-butyldimethylsilyloxy)ethyl}-1H-indole-2-carbaldehyde (58) 
 
Scheme 34 
The oxidation reaction was performed exactly according to the procedure in section 3.3.2.5, but required a 
longer reaction time. Once completed, the product (58) required no further purification, and was afforded 
in a very good yield of 83%.  
The 
1
H NMR spectrum of the product (58) revealed the distinctive aldehyde Hp 
singlet located downfield at 9.88 ppm, which integrated for one. Furthermore, 
the carbonyl Co signal in the 
13
C NMR spectrum was identified at 182.7 ppm. 
The rest of the aromatic and ethoxy silyl group were all present in the spectra 
and integration corresponded accurately. Lastly, the results of the mass spectral 
analysis of 304.1730 amu correlated with the expected mass of 304.1733 amu. 
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3.5.5 Synthesis of 1-{2-(tert-butyldimethylsilyloxy)ethyl}-2-vinyl-1H-indole (59) 
 
Scheme 35 
The Wittig reaction was carried out with the same conditions as the procedure used in section 3.2.4.6, 
with the difference allowing for a longer reaction time (scheme 35). The crude product was purified by 
means of column chromatography, which afforded the pure product (59) in a satisfactory yield of 79%. 
The vinyl protons Hp and Hp’ were clearly present in the 
1
H NMR spectrum of 
the product 59. They were identified as doublet of doublets at 5.26 ppm and 5.76 
ppm respectively, and each integrated for one. Ho was located at 6.77 ppm as a 
doublet of doublets, with coupling constants corresponding to the respective 
vinyl protons. An extra carbon signal for Cp, was shown in the 
13
C NMR 
spectrum of the product (59). The remaining signals in the spectra were all 
accounted for, and matched the expected integration for the 
1
H NMR spectrum. 
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The Diels –Alder reaction, shown in scheme 36, was carried out neat with compound 59 and maleimide – 
similarly to that performed in section 3.3.7.1. However, TLC monitoring revealed that some of the 
starting material 59 remained unreacted – a result observed even when the equivalence of the maleimide 
was increased. The incomplete reaction of compound 59 could be ascribed to the way in which the 
starting reagents mixed in the melt, not being in complete contact throughout the mixture. The crude 
product appeared as a combination of a highly insoluble solid and an oily solid. The insoluble solid was 
used in the following synthetic step without further purification, while the oily solid could be purified by 
column chromatography. Taking into account the recovered starting material (59), the yield of the product 
(60) was calculated as 78%.  
The 
1
H NMR spectrum of the product (60) was evaluated and showed the 
presence of a new broad signal for the maleimide –NHt. A number of new 
multiplets were also observed. The signals of Ho and Hp were identified as 
four multiplets for the diastereotopic protons, integrating for one each. These 
signals were located upfield between 2.92 – 1.69 ppm. The multiplets of Hr 
and Hq were also present, close to the methylene (Hj/Hk) protons. Four new 
carbon signals were identified in the 
13
C NMR spectrum of the product, 
including the 2 distinctive carbonyl signals (Cs/Cu) at 180.3 ppm and 178.6 
ppm. The results of the mass spectral analysis of 399.2109 amu correlated 
with the expected mass of 399.2104 amu. 
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The next step in the proposed synthetic route was to remove the silyl-protecting group to expose the 
hydroxyl functionality, thus generating target compound 48. The deprotection reaction was performed by 
treating compound 60 with TBAF·3H2O, as shown in scheme 37. The reaction proceeded smoothly 
within 30 minutes at room temperature. Upon completion, a workup was performed and the compound 




H NMR spectrum (figure 65) of the product (48), it was 
clearly visible that the deprotection reaction was successful. The intense 
proton signals of the tert-butyl and dimethyl groups of the silyl protecting 
group disappeared, while a broad peak for the newly formed hydroxyl group 
–OHl was present at 4.84 ppm. The 
13
C NMR spectrum also revealed the 
absence of the three carbon signals belonging to the silyl-protecting group. 
IR analysis showed the hydroxyl stretch at 3421 cm
-1
. Finally, the results of 
the mass spectral analysis peak at 285.1246 amu correlated with the expected 





H NMR of target compound 48. 
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3.5.8 Synthesis of 6-(2-Hydroxyethyl)pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione (49) 
 
Scheme 38 
The final step in the route towards target compound 49 was to perform an aromatization reaction as seen 
in scheme 38. The previous aromatization reaction (section 3.3.8.1) made use of the quinone DDQ. 
However, as a result of the availability of MnO2, it was decided to use this oxidant instead. Compound 48 
was dissolved in dioxane in a reaction flask and treated with an excess of MnO2. As for the previous 
oxidation reactions, the MnO2 was activated beforehand. The compound was finally purified by column 




H NMR spectrum of the final aromatized product 49 (figure 66) was 
evaluated and displayed six signals in the aromatic region. The newly 
formed doublets of Hm and Hn, integrated for one each. The – OHl signal is 
no longer just a singlet – a result ascribed to long range coupling to Hk.The 
13
C NMR spectrum also revealed a shift of some of the carbon signals to 
the aromatic region. Finally, the results of the mass spectral analysis of 
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H NMR of target compound 49. 
3.6 Synthesis of N–propargyl target compounds 51 and 52 
The design strategy of compounds 51 and 52 was based on the fact that the propargyl group could be 
introduced to the indole alkene, as shown by the reaction performed by Perez-Serrano and co-workers.
[168]
 
The 2-vinyl-1H-indole adds to the propargyl bromide by means of a nucleophilic substitution reaction.  
A Diels-Alder cycloaddition and aromatization reaction would then be able to afford the respective target 
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3.6.1 Synthesis of 1-(2-propynyl)-2-vinyl-1H-indole (61) 
 
Scheme 40 
The propargyl group was introduced to the previously synthesized 2-vinyl-1H-indole (41) by a 
nucleophilic substitution reaction. A literature procedure was followed and the reaction proceeded 
smoothly.
[168]
 Compound 41, dissolved in dry DMF, was treated with Cs2CO3 and propargyl bromide as 
shown in scheme 40. After a work-up, the compound was purified by means of column chromatography, 
affording the product (61) in a yield of 45%. The low yield could probably be ascribed to polymerization 
side reactions.  
The 
1
H NMR spectrum of the product (61) was compared to that reported in 
literature and corresponded well.
[168]
 The absence of the broad singlet of –NHa, 
together with the formation of the new doublet (Hj) and the triplet (Hl), confirm 
the successful synthesis of the product. The signal assigned to Hj integrated for 
two, while Hl had an integration of one. The splitting pattern of Hj and Hl was 
ascribed to long range coupling. The rest of the proton signals were all accounted for and corresponded 
well with the expected integration. 




In order to obtain target compound 51, the Diels-Alder reaction was performed in the same manner as that 
in section 3.3.7.1, with the only difference being a lower reaction temperature (160 °C) as shown in 
scheme 41. Similarly, starting material (61) did not react to completion.  
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The crude product was purified by column chromatography. The yield of the pure product (51) was 
calculated to be in a range of 35-58%, taking into account the recovered starting material (61).  
The 
1
H NMR spectrum of the product (51) (figure 67) was evaluated and 
showed the formation of a number of new signals. The broad peak of –NHr 
was located at 11.03 and integrated for one. Four signals were identified 
for the diastereotopic methylene protons (Hm/Hn) between the range 2.93 – 
1.85, each integrating for one. The signals of Hp and Ho were also clearly 
evident at approximately 3.48 ppm and 4.21 ppm. The 
13
C NMR spectrum 
of the product (51) showed the formation of four new carbon signals, 
including the distinctive carbonyl (Cq/Cs) peaks at 180.7 ppm and 1789.0 ppm. Lastly, the results of the 
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3.6.3 Synthesis of 6-(2-propynyl)pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione (52) 
 
Scheme 42 
The final step to synthesize target compound 52 was an aromatization reaction. This reaction was 
performed, as shown in scheme 42, using an excess of MnO2, and heating compound 51 to reflux in 
dioxane for a minimum of 8 hours. Upon completion, the crude product was obtained as a highly 
insoluble compound and could not be purified by column chromatography. Triturating the crude product 




H NMR spectrum of the product (52) (figure 68) showed six signals 
located in the aromatic region – each integrating for one. The newly 
aromatized protons, Hm and Hn, were identified as doublets at 8.08 ppm 
and 7.90 ppm. The carbon signals of the carbazole were all accounted for 
in the 
13
C NMR spectrum of the product (52), and were located in the 
region between 143.6 ppm and 110.3 ppm. Analysis of the IR spectrum 
showed the presence of the alkyne stretch at 657 cm
-1
. Finally, the results 
of the mass spectral analysis of 275.0316 amu correlated with the 
expected mass of 275.0821 amu. 
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H NMR of target compound 52. 
3.7 Towards N–tether nitrile target compounds 50 and 53 
Studies by Smaill et al. suggested that the introduction of side chains on the amine of the carbazole 
structure, were best implemented on the 2-vinyl-1H-indole prior to the construction of the 
pyrrolocarbazole backbone (43). 
[169]
 In this manner, regioselectivity problems are prevented, since the 
imide of the maleimide is frequently the preferred site of alkylation. Their work served as a motivation for 
our envisioned strategy outlined in scheme 43. This route involved a Michael addition to incorporate the 
cyanoethyl group, followed by a Diels-Alder cycloaddition (50), and finally an aromatization reaction to 
afford the compound 53. 
 
Scheme 43 
Outline of strategy towards target compounds 50 and 53. 
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3.7.1 Synthesis of 3-(2-vinyl-1H-indol-1-yl)propanenitrile (62) 
 
Scheme 44 
To introduce the nitrile group to the compound, a Michael addition between the 2-vinyl-1H-indole (41) 
and acrylonitrile was performed (scheme 44). Compound 41 was dissolved in MeCN, and treated with 
acrylonitrile and DBU. Acrylonitrile is a conjugated nitrile and a good Michael acceptor. In this reaction, 
the Michael addition using acrylonitrile introduced a β-cyanoethyl group to the structure, a process known 
as cyanoethylation.
[148,170]
 A proposed mechanism of the reaction is given in scheme 45. DBU has been 
used as a powerful catalyst in Michael additions, and allowed the use of mild conditions.
[171]
 For this 
reason we decided to employ DBU and avoid the side-reactions associated with strongly basic conditions 
of classic base catalysis. The indole amine attacked the alkene (conjugate addition) to yield a stable 
delocalized anion. Protonation at the carbon restored the cyanide functional group and afforded the 
product. The base catalyst DBU was able to facilitate this process. 
 
Scheme 45 
Proposed Michael addition mechanism to introduce the cyanoethyl group. DBU acts as the catalytic base during the 
reaction. 
The reaction proceeded smoothly at room temperature within 8 hours. Unfortunately, the reaction did not 
reach completion, even with increased equivalents of reagents. In addition, the reaction temperature was 
kept at room temperature to prevent possible polymerization of acrylonitrile and 2-vinyl-1H-indole (41). 
After the reaction, the crude product was purified by means of column chromatography. Taking into 
account the recovered 2-vinyl-1H-indole starting material (41), the yield was calculated to be 84%.  
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H NMR spectrum of the product (62) showed the loss of the broad 
indole -NHa signal, which was replaced by new signals of the cyanoethyl 
group. The diastereotopic protons of Hj and Hk were located at 4.47 ppm and 
2.73 ppm, respectively. They appeared as two separate doublet of doublets, 
each integrating for two. Analysis of the
 13
C NMR spectrum of the product 
(62) revealed the presence of three new carbon signals. The IR spectrum 
showed a clear nitrile stretch at 2247 cm
-1
. Lastly, the results of the mass 
spectral analysis of 197.1072 amu correlated with the expected mass of 197.1079 amu. 




The addition of a Lewis acid to a Diels-Alder reaction can catalyze the process by interaction of this 
Lewis acid with the dienophile. Numerous Lewis acid catalysts have been identified, and the manner in 
which they enhance regioselectivity in Diels-Alder reactions has been a subject of interest for many 
years.
[161-162]
 In this case, SnCl2 was used as a Lewis acid and was able to complex to the carbonyl of 
maleimide, thereby increasing the electron withdrawing ability of the dienophile and promoting the 
reaction. In this reaction, compound 62, maleimide and the Lewis acid SnCl2, were added to a reaction 
flask and heated to reflux in toluene (scheme 46). The reaction mixture was then stirred for 16 hours. As 
witnessed in the previous Diels-Alder reactions, this reaction did not reach completion, even when left for 
longer reaction times or increasing the equivalents of starting material added. The crude product was 
purified by column chromatography to obtain the pure target compound 50. The yield for the reaction was 
calculated to be 71%, taking into account the recovered starting material.  
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H NMR spectrum of the product (50) (figure 69) was evaluated and a 
number of new signals supported the success of the reaction. The 
diastereotopic methylene protons Hm and Hn appeared as four individual 
multiplets, each integrating for one, located in the region between 2.88 – 1.75 
ppm. The presence of a broad maleimide –NHr was identified at 11.02 ppm. 
Four new carbon signals were located in the 
13
C NMR spectrum, including 
the distinctive carbonyl peaks at 180.3 ppm and 178.5 ppm. IR analysis 
showed the presence of the nitrile stretch at 2246 cm
-1
. The results of the 
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The final aromatization step to synthesize the target compound 53 was performed in exactly the same 
manner as that in section 3.3.2.3. As a result of the insolubility of the crude product, column 
chromatography was not employed as a purification technique. Recrystallization from DMF was thus 
used to obtain the product as a pure compound (53) in a yield of 30%. It is suspected that the yield is not a 




H NMR spectrum of the product (53) (figure 70), six signals in the 
aromatic region were identified. Each of these signals integrated for one 
and was assigned to the aromatic protons He, Hf, Hg, Hh, Hm and Hn. The 
number of carbon signals in the 
13
C NMR spectrum of the product (53) 
corresponded with the expected amount. The nitrile stretch was evident at 
2251 cm
-1
 in the IR spectrum. Finally, the results of the mass spectral 
analysis of 290.0928 amu correlated well with the expected mass of 
290.0930 amu. 
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H NMR of target compound 53. 
3.7.4 Alternative approach attempted towards target compound 54 
While the envisioned strategy towards target compounds 50 and 53, following the route depicted in 
scheme 43 was under way, another strategy to generate target compound 53 was being applied. The route 
of this alternative strategy is outlined in scheme 48. The design of this synthesis involved introducing the 
cyanoethyl group to the already built pyrrolocarbazole scaffold. To avoid the challenges associated with 
the unprotected pyrrolocarbazole experienced in section 3.3.9, it was decided to protect the maleimide 
with a group that could withstand the reaction conditions. The protecting group would then finally be 
removed to expose the crucial imide –NH group. Furthermore, this route would allow for a more 
divergent synthesis, since the ability to introduce other functionalities, by N-alkylation of the protected 
pyrrolocarbazole structure, would permit the generation of several pyrrolocarbazole analogues. For this 
route we decided to use benzylamine as a protecting group. The approach described was motivated by the 
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Outline of alternative strategy towards target compound 53. 
3.7.4.1 Synthesis of 1-benzyl-1H-pyrrole-2,5-dione (64) 
 
Scheme 49 
This strategized route began with the synthesis of benzyl maleimide (64) as shown in scheme 49. The 
reaction was carried out smoothly, following a procedure described in literature.
[173]
 Maleic anhydride 
(63) and benzylamine were added to a reaction flask and dissolved in AcOH. The reaction mixture was 
heated to reflux for 2 hours. Upon completion, the product was purified by column chromatography to 
afford the pure compound (64) in a yield of 62%. 
The 
1
H NMR spectrum of the product (64) was compared to that in literature and 
corresponded well.
[173]
 The compound contains symmetry and three signals were 
identified in the spectrum. The aromatic protons (Hc, Hd and He) were found as a 
multiplet integrating for five at 7.24 ppm. The Hb signal was located as a singlet at 
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4.61 ppm and integrated for two.The chemically equivalent Ha protons were also identified as a singlet, 
integrating for two at 6.64 ppm. 
3.7.4.2 Synthesis of 2-benzylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione (65) 
 
Scheme 50 
The synthesis of the benzyl-protected pyrrolocarbazole scaffold (65) involved a one pot procedure of the 
Diels-Alder cycloaddition and MnO2 aromatization reactions. Having the 2-vinyl-1H-indole (41) in hand, 
the Diels-Alder reaction could easily be performed in a melt at 140 °C with the previously synthesized 
benzyl maleimide (64). After 40 min, the crude product was dissolved in dioxane and treated with an 
excess MnO2. The reaction mixture was then heated to reflux for 5 hours. Following filtration through 
Celite, the product was purified by column chromatography to afford the pure compound (65) in a 
satisfactory yield of 84% over the two steps. 
The 
1
H NMR spectrum of the product (65) was evaluated and a number 
of multiplet signals in the aromatic region were identified – these signals 
were assigned to the carbazole protons (He, Hf, Hg, Hh, Hj, Hk) and the 
phenyl ring protons (Hp, Hq, Hr). The integration of the aromatic 
multiplets summed to 11. Furthermore, a broad signal for –NHa was 
identified at 12.10 ppm, and the methylene Hn integrated for 2 at 4.82 
ppm. The 
13
C NMR of the product showed the distinctive carbonyl 
signals (Cs, Cm) at 169.4 ppm and 169.3 ppm. Lastly, the results of the 
mass spectral analysis of 327.1131 amu correlated with the expected 
mass of 327.1134 amu. 
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The cyanoethyl group was next incorporated into the pyrrolocarbazole scaffold (65), as shown in scheme 
51, in a similar manner as the procedure described by Caballero et al.
[172]
 For this reaction, 3-
bromopropionitrile was used as the alkylating agent. A suspension of compound 65 in benzene was 
treated with NaOH (50%) and TBAHS. The TBAHS acted as a phase transfer agent to catalyze the 
nucleophilic substitution reaction. 3-bromopropionitrile was then added to the reaction mixture and it was 
stirred at room temperature for 14 hours. The product was purified by means of column chromatography 




H NMR spectrum of the product (66) revealed the absence of 
the broad -NHa signal and newly formed multiplet peaks belonging 
to the cyanoethyl group. Hv showed a doublet of doublets at 3.08 
ppm and integrated for two. The signals of Hu and Hn overlapped 
and formed a multiplet at 4.76 ppm, integrating for four. Three extra 
carbon signals were evident in the 
13
C NMR spectrum of the product 
(66). IR analysis showed the nitrile stretch at 2251 cm
-1
. The results 
of the mass spectral analysis of 380.1401 amu correlated with the 
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A method for removing a benzyl protecting group from an amide is to perform a hydrogenation reaction 
using Pd/C as catalyst, in AcOH.
[174]
 We attempted using a similar approach to deprotect the benzyl group 
from the pyrrolocarbazole scaffold (scheme 52). In our case, the debenzylation was not successful and the 
starting material remained unreacted (66). Transfer hydrogenation is a more promising approach to 
remove a benzyl from an imide, and is an alternative approach that could be employed.
[175]
 Unfortunately, 
the limited availability of compound 66, together with the time constraints, resulted in the approach being 
aborted. Fortunately, the success from the approach utilized in section 3.7.3. was able to generate target 
compound 53. 
3.8 The six final compounds 
In summary, the six target compounds represented in figure 63 were successfully synthesized using the 
various envisaged design strategies. Three respective warheads (hydroxyl, propargyl and nitrile 
functionalities) were incorporated into the unaromatized and aromatized pyrrolocarbazole scaffold. These 
final compounds were subsequently sent to Germany to test their inhibitory activity against EGFR 
kinases. The biochemical assay results are discussed in detail in Chapter 5.  
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CHAPTER 4 – STAUROSPORINE INSPIRED ‘OPEN’ ANALOGUES 
4.1 Towards novel bisaryl maleimide kinase inhibitors 
The second part of this project focused on the synthesis of bisaryl maleimide derivatives as potential 
kinase inhibitors of EGFR. As mentioned previously (see section 2.2), the staurosporine inspired “open” 
form of the natural indolocarbazole scaffold, has demonstrated better selectivity in terms of kinase 
inhibition. Enzastaurin and Ruboxistaurin, are two examples of bisindole maleimide as selective kinase 
inhibitors undergoing clinical trials (figure 71). 
 
Figure 71 
Bisaryl maleimides as PKC selective kinase inhibitors 
4.1.1 Motivation from literature 
The rationale behind the design strategy was based on the independent work of the researchers Souffrin 
and Gu. Souffrin and co-workers applied the Sonogashira cross-coupling reaction to synthesize 
disubstituted maleimides. Their main interest was to couple various terminal alkynes to the maleimide 
scaffold.
[176]
 The research of Gu et al. implemented Cu(I) click chemistry to generate bisaryl maleimides 
as kinase inhibitors.
[86]
 This work was discussed in more detail in section 2.1.2. The general structures of 
the ‘click’ bisaryl maleimide and dialkynylated maleimide, of Gu and Souffrins work respectively, are 
illustrated in figure 72.  
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Structures of ‘click’ bisaryl maleimide and Sonogashira coupled dialkynylated maleimide. 
Together, this research motivated and inspired the design of disubstituted maleimide structures 
resembling the ‘open’ form of staurosporine. This chapter constitutes 3 main sections. The first section 
pertains to the synthesis of bisaryl maleimides by employing a ‘double click’ approach. Thereafter, the 
following section involves indolylmaleimde click products, and finally, the last section aims to synthesize 
bisaminated maleimide derivatives. Having described the objective for the second part of the project, we 
now endeavor to synthesize the various compounds. A discussion of the different envisaged research 
strategies, reactions and problems encountered is given in the remainder of this chapter.  
4.2 The bisaryl maleimide double click compounds 
The initial focus of this chapter was towards the synthesis of bisaryl maleimide scaffolds by attempting a 
‘double click’ approach. Incorporating a ‘warhead’ (R), such as an acryloyl group, into the structure 
would permit the compound to behave as a potential irreversible kinase inhibitor. The Cu(I) click 
reactions can be performed by utilizing either the disubstituted azide or disubstituted alkyne maleimide 




Structures of the ‘double click’ products following the addition of a warhead (R). 
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4.2.1 Strategy pertaining to the bisaryl maleimide ‘double click’ compounds 
The design strategy started with the chlorination of the commercially available maleic anhydride, 
followed by the subsequent transformation to the maleimide. The significance of the –NH imide has been 
discussed in section 3.7.4. Thereafter, a substitution reaction of the chloro atoms with sodium azide 
prepared both the mono- and diazido maleimide compounds. An outline of the strategy, to determine the 
effectiveness of a simple ‘double click’ reaction, is shown in scheme 53. Once the ‘double click’ reaction 
proof of concept could be established, a scope of opportunities would be available to perform click 
reactions simultaneously with aryl groups, having a pre-installed warhead (acryloyl group), as shown in 
Figure 74.  
 
Scheme 53 
Outline of strategy towards the bisaryl maleimide compound. 
 
Figure 74 
‘Double click’ approach to introduce ‘warhead’ (acryloyl group) pre-installed in an aryl group. 
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4.2.2 Synthesis of bisaryl maleimide ‘double click’ compounds 
4.2.2.1 Synthesis of 3,4-dichlorofuran-2,5-dione (69) 
 
Scheme 54 
The first reaction pertaining to the strategy involved the chlorination of maleic anhydride (68), as shown 
in scheme 54. The synthesis was carried out smoothly, following a procedure described in literature 
which utilized a thionyl chloride-pyridine method.
[177]
 The manner in which the reaction progressed did 
not follow a simple replacement of hydrogen by chlorine, and the mechanism was investigated and 
described in detail by Relles.
[177]
 The reaction was performed by treating a solution of maleic anhydride 
(68) and SOCl2 with pyridine, afforded compound 69 in a yield of 70% in sufficient purity. 
The 
1
H NMR spectrum showed no proton signals present for the product (69). Two 
carbon signals were identified in the 
13
C NMR spectrum owing to the symmetrical 
structure of the product. The carbonyl carbon (Cb) was located at 162.0 ppm, while 
Ca was found at 130.4 ppm.  
4.2.2.2 Synthesis of 3,4-dichloro-1H-pyrrole-2,5-dione (70) 
 
Scheme 55 
The important imide functionality was introduced by following a simple procedure described in the 
literature.
[178]
 In the reaction the solids dichloro-maleic anhydride, urea and NaCl were ground together 
and reacted at 120 °C for 20 minutes (Scheme 55). The reaction mixture was then recrystallized from 
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In order to perform the click reactions, we decided to synthesize both the mono- and diazido maleimide 
compounds. The substitution reactions were carried out smoothly, generating the respective products 
depending on the equivalents of azide added (Scheme 56). A solution of NaN3 dissolved in H2O was then 
prepared and added to the reaction flask. The addition of 1 equivalent of NaN3 formed the 3-azido-4-
chloro-1H-pyrrolo -2,5-dione product (71), while 3 equivalents gave the 3,4-diazido-1H-pyrrolo -2,5-
dione product (72). It must be noted that the diazido compound (72) could also be prepared from the 
mono-azido compound (71). The reaction mixture was stirred overnight at room temperature. Upon 
completion, a workup was carried out and the products were purified by column chromatography. The 
monoazido product (71) was afforded as a light yellow solid in a yield of 79%. When 3 equivalents of 
NaN3 was used the diazido product (72) was afforded as a bright yellow solid in a yield of 66%.  
The 
1
H NMR spectrum of the product (71) showed the presence of the broad –NHc 
signal at 11.46 ppm. Four carbon signals were identified in the 
13
C NMR spectrum of 
the product. The carbonyl signals (Cb and Cd) were located at 165.05 ppm and 164.89 
ppm. The signal of Ca was found most upfield at 111.0 ppm, while Ce was found at 
136.7 ppm. Importantly, the IR spectrum revealed a clear azide stretch at 2149 cm
-1
. 
The results of the mass spectral analysis of 172.9700 amu correlated with the expected mass of 172.9866 
amu. 
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A distinctive feature of the diazido product (72), is that it is symmetrical, while the 
monoazido compound clearly is not. For this reason, the 
13
C NMR of the product 
revealed only two carbon signals – Cb located at 166.4 ppm and Ca at 112.0 ppm. The 
1
H NMR of the product showed the presence of the broad –NHc signal at 11.28 ppm. 
Furthermore, a strong azide stretch at 2088 cm
-1 
could be identified in the IR 
spectrum. The MS technique utilized did not result in detection of the molecular ion of compound 72. 




As mentioned before, a simple ‘double click’ reaction was initially carried out to investigate and 
determine the most optimal reaction conditions (scheme 57). Since phenyl acetylene was readily 
available, it was chosen as the alkyne counterpart for this click reaction.The ‘double click’ reaction 
proved to be very challenging. Various reaction conditions were attempted as shown in table 1. Different 
sources of copper, solvent, temperature, reaction time and equivalents of phenyl acetylene were tested, 
without any success. The reactions were monitored by TLC, and the starting material remained unreacted, 
with no new spot formation being observed. A trace amount of what seemed to be the product was 
obtained from the reaction conditions highlighted in table 1. This particular reaction was performed by 
treating compound 72 in MeOH with a mixture of CuSO4•5H2O and sodium ascorbate dissolved in H2O. 
The reaction mixture was then left to stir at 40 °C for 4 days. After this time, it seemed as if the reaction 
had reached its completion, with some starting material (72) remaining unreacted. Following a workup 
and purification by column chromatography, only a trace amount of the product (73) was obtained. 
Unfortunately, due to the small amount of product available - and DMSO required as NMR solvent - the 
product was not recovered and full characterization was not possible. 
 
Stellenbosch University  https://scholar.sun.ac.za





H NMR spectrum of the product (73) showed a 
broad signal for -NHc at 11.28 ppm. Structural symmetry 
allowed for several protons to be chemically equivalent, 
which corresponded with the expected integration. The 
indicative proton signal of the triazole ring (Hd) was 
located at 8.75 ppm and integrated for two. The Hg 
signal appeared as a doublet at 7.93, integrating for four. 
The rest of the phenyl proton signals (Hh and Hi) 




Reaction conditions for the ‘double click’ reaction 
 
 
4.2.3 Tackling the first possible obstacle 
The challenges associated with the ‘double click’ reaction, led us to question the viability of this 
approach, and to target the possible problems which may attribute to its limited success. The initial 
rationalization was that the close proximity of the azide groups altered the electronics in such a manner 
that the ‘double click’ was prohibited. To verify this point, a click reaction was carried out using the 
mono-azido maleimide (3-azido-4-chloro-1H-pyrrolo-2,5-dione) (71) as shown in scheme 58. This 
reaction was performed in a similar manner as that described in the previous click reaction (subsection 
4.2.2.4). Similarly, TLC monitoring revealed that the starting material (71) remained unreacted with no 
new spot formation. Hence, the electronic nature of the diazido maleimide (72) was excluded as a 
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4.2.4 Tackling the second possible obstacle 
Another plausible explanation for the ‘double click’ reaction being unsuccessful was that the imide –NH 
group may be troublesome - possibly acting as a good ligand for complexation to the copper ion. For this 
reason we attempted a strategy in which a methyl group was incorporated into the maleimide structure. 
An outline of the strategy is illustrated in scheme 59.  
 
Scheme 59 
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4.2.4.1 Synthesis of 3,4-dichloro-1-methyl-1H-pyrrole-2,5-dione (75) 
 
Scheme 60 
The methyl group was introduced onto the dichloromaleic anhydride (69) by following a procedure 
described in literature.
[179]
 The reaction was carried out smoothly by adding compound 69 and AcOH to a 
reaction flask, and treating the solution with CH3NH2·HCl and NaOMe at 0 °C. The reaction mixture was 
then heated to reflux for 4 hours. It has been shown that this reaction does not proceed in the absence of a 
base, even at high temperatures. The required base must be stronger than methylamine, such as 
methoxide. The NaOMe acts by liberating the nucleophilic CH3NH2 gas in situ. Upon completion, a 
workup was carried out, and the product was purified by means of column chromatography, affording the 
pure product (75) in a yield of 62%. 
The 
1
H NMR spectrum of the product (75) was compared to that in literature and 
corresponded well.
[180]
 The signal of the methyl group protons (Hc) was located at 
2.95 ppm.  
 









The substitution reaction to introduce the azide/s to compound 75, was performed in exactly the same 
manner as the reactions in subsection 4.2.2.3. Both the mono-and diazido product were synthesized as 
shown in scheme 61.  
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As mentioned previously, the various products could be generated from compound 75 depending on the 
equivalents of NaN3 added. Column chromatography was used to purify the products synthesized by each 
reaction. 3-azido-4-chloro-1-methyl-1H-pyrrole-2,5-dione (76) was afforded as an off-white solid in an 
excellent yield of 98% and the pure product of 3,4-diazido-1-methyl-1H-pyrrole-2,5-dione (77) was 
obtained in a yield of 68%. 
The 
1
H NMR spectrum of the product (76) showed the –NMe (Hc) signal at 3.07 ppm. 
Five carbon signals were identified in the 
13
C NMR of the product. The two carbonyl 
signals (Cd and Cb) were found at 164.21 ppm and 164.12 ppm. The signal of Ce was 
identified at 135.79 ppm, while that of Ca was found more upfield at 113.14 ppm. The 
IR spectrum revealed the distinctive azide stretch at 2115 cm
-1
. The MS technique 
utilized did not result in detection of the molecular ion of compound 76. 
The 
1
H NMR spectrum of the product (77) showed the –NMe (Hc) signal at 3.02 ppm. 
The structure contains symmetry and revealed three carbon signals in the 
13
C NMR. 
The carbonyl Cb was identified at 164.8 ppm, and Ca at 119.8 ppm. The results of the 
mass spectral analysis (-2N2) of 138.0315 amu correlated with the expected mass of 
138.0304 amu. 









The ‘double click’ reaction, as shown in scheme 62, was performed in a similar manner as that in 
subsection 4.2.2.4. Unfortunately, the reaction did not proceed as hoped. TLC monitoring indicated that 
most of compound 77 remained unreacted, with only a faint product spot being identified on the TLC 
plate. No further product formation was observed at a longer reaction time.  
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The product was purified by column chromatography, affording a trace amount of the pure compound 




H NMR spectrum of the product (78) revealed 
the indicative triazole singlet (Hd) at 8.75 ppm, 
integrating for two (structural symmetry). 
Furthermore, all the signals of the phenyl ring could 
be accounted for. Hg and Hh were located at 7.94 ppm 
and 7.47 ppm, respectively. The signal of Hg appeared 
as a doublet, and Hh as a multiplet, both integrating 
for four. Hi integrated for two and was located at 7.37 
ppm as a multiplet. The -NMe (Hc) was identified 
most upfield at 2.94 ppm and integrated for three. 
4.2.5 Tackling the third possible obstacle 
The unsatisfactory outcome of the ‘double click’ reactions thus far, challenged us to attempt a different 
strategy whereby the alkyne/azide counterparts are switched for the click reaction – i.e. a click reaction 
was to be performed between a dialkynylated maleimide and the azide fragments. An outline of this 
strategy is shown in scheme 63. The rationalization behind this approach was in continuation to the idea 
that the electronics of the azide-maleimide system were perhaps not suitable for effective triazole ring 
formation. The inspiration for this strategy was acquired from the work of Souffrin et al. in which they 






Outline of strategy whereby a click reaction is performed with a dialkynylated maleimide. 
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4.2.5.1 Sonogashira cross-coupling reaction 
Metal-catalyzed cross-coupling reactions have grown into a powerful strategy and are considered 
cornerstones in the field of organic chemistry.
[181]
 These reactions have found application in a vast scope 
of synthetic procedures, including the total synthesis of natural products, pharmaceuticals, and molecular 
organic materials. Methodologies based on metal catalysis, particularly palladium, have been a major 
source of stimulation in maleic anhydride/imide chemistry.
[181-182]
 
The Sonogashira reaction is the most popular palladium-catalyzed cross-coupling reaction for the 
alkynylation of aryl or alkenyl halides.
[181]
 The C-C bond formation involves a terminal sp hybridized 
carbon from an alkyne with a sp
2
 carbon of an aryl or vinyl halide (or triflate).
[183]
 The reaction was 
discovered in 1975 by Sonogashira, Tohda, and Hagihara, and was an extension of the independent work 
of Heck and Cassar.
[184]
 The mild conditions of the Sonogashira reaction made it an attractive synthetic 
procedure compared to the high temperatures required by the palladium-catalyzed Heck and Cassar 
reactions. The successful alkynylation at room temperature, achieved by the Sonogashira reaction, was 
ascribed to the already known Stephans-Castro coupling between copper acetylides and phenyl or vinyl 
halides.
[185]
 Combining the copper-mediated transmetalation of alkynes with a powerful and versatile 
catalyst such as palladium, greatly increased the reactivity of the system.
[184]
 
Sonogashira’s insight of using a co-catalytic amount of CuI together with a Pd(0) catalyst has afforded 
remarkable success in diverse areas of chemistry.
[181,183]
 An excess amount of amine is required for the 
Sonogashira reaction and may even be used as the solvent. A stable and soluble Pd(II) derivative, such as 
Pd(PPh3)4 or PdCl2(PPh3)2, is often employed and reduced in situ to the catalytically active Pd(0) 
species.
[148]
 A general procedure of the Sonogashira reaction is illustrated in scheme 64. A drawback of 
using a copper co-catalyst is that undesirable alkyne homocoupling (Glaser coupling), can occur upon 
exposure to air or oxidative agents.
[181]
 For this reason, researchers now pursue the development of 
coupling procedures that are copper-free, which are still considered as Sonogashira reactions, regardless 
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Uncertainties pertaining to the exact mechanism of the Sonogashira reaction continue.
[183]
 However, a 
proposed mechanism for the Pd(0)/Cu(I) catalyzed reaction involves the interaction between two 
independent catalytic cycles as shown in figure 75. Cycle A, known as the palladium-cycle, is a classical 
form of C-C coupling and includes oxidative addition, transmetalation and reductive elimination, to 
afford the coupled product and regenerating the Pd(0) catalyst. Cycle B, is known as the copper-cycle, 
which generates the alkynyl copper used for the transmetalation step. It is suggested that the base plays an 






Proposed mechanism for the Sonogashira cross-coupling reaction using Cu(I) as co-catalyst. L represents 
phosphane, base, solvent or alkyne. Image reproduced from following reference.
[183]
 







Regarding the Sonogashira reaction, the bromide sp
2
 species is generally more reactive than the chlorine 
version.
[181]
 For this reason, it was decided to incorporate the dibromo atoms onto the maleimide group. 
The first step in this strategy involved the bromination of maleic anhydride (68) as shown in scheme 65. 
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The reaction proceeded smoothly, following a procedure described in literature.
[186]
 The procedure 
involved heating a mixture of compound 68 with Br2 and a catalytic amount of AlCl3 and the product (79) 
was afforded in a good yield of 72%.  
The 
1
H NMR spectrum of the product (79) showed the absence of the proton signal 
present in the maleic anhydride starting material (68). Two chemically equivalent 
carbon signals were identified in the 
13
C NMR spectrum of the product (79). The 
carbonyl Cb was located at 167.6 ppm and Ca at 163.2 ppm.  
4.2.5.3 Synthesis of 1-benzyl-3,4-dibromo-1H-pyrrole-2,5-dione (80) 
 
Scheme 66 
Following the strategy used by Souffrin et al, we decided to synthesize the benzyl-protected dibromo 
maleimide (80). The reaction was carried out according to a procedure described in literature, in which a 
solution of compound 79 in AcOH, was treated with benzylamine.
[187]
 The product (80) was purified by 
column chromatography, and obtained in a yield of 55%.  
The 
1
H NMR spectrum of the product (80) showed two signals assigned to the 
benzyl group and corresponded to that reported in literature.
[187]
 The aromatic 
protons (Ce, Cf, Cg) were located as a multiplet at 7.4-7.3 ppm, and integrated for 
five. The methylene signal of Cc was located as a singlet at 4.8 ppm, integrating for 
two. Furthermore, the IR spectrum of the product revealed the presence of the 
carbonyl stretch at 1707 cm
-1
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4.2.5.4 Synthesis of 1-benzyl-3,4-bis{(trimethylsilyl)ethynyl}-1H-pyrrole-2,5-dione (81) 
 
Scheme 67 
The Sonogashira reaction was performed as described by Souffrin and co-workers and the synthesis of the 
dialkynylated maleimide product (81) was carried out successfully as shown in scheme 67.
[176]
 The 
procedure utilized the Pd(0)/Cu(I) catalytic system, with DIPEA as amine base. Since the Cu(I) click 
reaction requires a terminal alkyne, we envisaged using TMSA for the double Sonogashira reaction. 
Standard freeze-pump-thaw techniques were employed to ensure an inert, O2-free environment, and to 
prevent undesirable alkyne homocoupling. Upon completion and following a workup, the product (81) 
was purified by means of column chromatography and obtained in a yield of 68%.  
The 
1
H NMR spectrum of the product (81) was compared to that in 
literature and corresponded well.
[176]
 The successful coupling of the 
TMSA group was supported by the presence of the new signal of Cj, 
located at 0.3 ppm, integrating for eighteen. The rest of the benzyl proton 
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4.2.5.5 Attempted synthesis of 1-benzyl-3,4-diethynyl-1H-pyrrole-2,5-dione (82) 
 
Scheme 68 
Removal of the TMS group proved to be problematic and the procedure shown in scheme 68 was not 
successful. Compound 81 was dissolved in a mixture of THF and saturated NH4Cl, and treated with 
TBAF·3H2O. The NH4Cl was included in the hope of quenching the anion formed upon deprotection. It 
must be noted that maleimide-based enediynes have been reported as good systems for 
cycloaromatization at low temperatures. The carbonyl groups of maleimide are able to lower the energy 
barrier of Bergman cyclization, allowing the reaction to proceed at moderate temperatures.
[188]
 For this 
reason, the reaction was performed in the dark at room temperature. This precaution was taken to avoid 
any possibility of cycloaddition occurring in the reactive system. The progress of the reaction was 
monitored by TLC, and it was detected that all the starting material was consumed within the first hour. 
Two new spots were formed, including one on the baseline. Unfortunately, the product formed was 
unstable and complete degradation took place upon purification by column chromatography. TLC 
indicated that the new spot disappeared, and was replaced by one spot on the baseline. Since the product 
was lost upon purification, we decided to follow a similar strategy, circumventing the degradation 
problem by attempting a one pot deprotection/ ‘double click’ reaction. Having 3,4-dichloro-1-methyl-1H-
pyrrole-2,5-dione (75) in hand, we utilized this starting material in the strategy.  
4.2.5.6 Synthesis of 1-methyl-3,4-bis{(trimethylsilyl)ethynyl}-1H-pyrrole-2,5-dione (83) 
 
Scheme 69 
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The Sonogashira reaction was performed in exactly the same manner as that described in subsection 
4.2.5.4, with the only difference being the amine base used (TEA), as shown in scheme 69. The product 
(83) was purified by column chromatography and obtained in a rather low yield of 43%.  
The 
1
H NMR spectrum of the product (83) showed a clear signal for the 
TMSA group coupled to the starting material. The singlet assigned to Hf 
integrated for eighteen, and was located at 0.26 ppm. Three additional 
carbon signals were found in the 
13
C NMR spectrum of the product (83), 
compared to that of the starting material (75). Cf was located at -0.6 ppm, 
while Ce and Cd were located at 117.1 ppm and 94.4 ppm respectively.  
 




The one pot reaction was carried out by first performing a deprotection reaction, followed by a ‘double 
click’ reaction. The reaction conditions were similar to those utilized by Gu et al.
[86]
 Compound 83 was 
dissolved in a mixture of THF and MeOH, and then treated with TBAF (1M in THF).  
The reaction was monitored by TLC and showed the formation of two new spots (product and baseline 
spot). Benzyl azide, CuSO4·5H2O and sodium ascorbate were then added the reaction mixture and it was 
stirred overnight at room temperature in the dark. TLC indicated the formation of a faint new spot, 
together with an intense spot on the baseline. Following the workup, the product was purified by column 
chromatography, affording the pure compound (84) in a very low yield of 5%. The low yield was ascribed 
to the degradation of the product following the deprotection step – as indicated by an intense spot on the 
baseline. It is therefore difficult to determine the effectiveness of the double click reaction in this 
situation. Unfortunately, as a result of the low yield and the fact that the NMR spectrum samples were 
performed in DMSO, the product could not be recovered and full characterization was not possible.  
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The product 84 could only be tentatively characterized by the 
1
H NMR spectrum, due to the small amount 
obtained. 
The structure of the product has symmetry and a number of 
proton atoms were therefore chemically equivalent. The 
1
H 
NMR spectrum of the product (84) revealed the indicative 
triazole proton He at 8.62 ppm, integrating for two. The proton 
signals of the benzyl group were all accounted for. Hf was 
located at 5.64 ppm and integrated for four. The aromatic 
proton Hi was found as a doublet at 7.84 ppm (integrated four), 
while the rest of the aromatic signals (Hh, Hi, Hj) were 
identified in the range 7.46 – 7.29 ppm as a multiplet and 
integrated for six. The methyl protons Hc, could not be seen in 
the spectrum and we suspect the singlet is masked by the H2O present in the DMSO solvent. The number 
of carbon signals in the 
13
C NMR spectrum of the product (84) corresponded with the expected number of 
carbon atoms (ten) in the structure, taking symmetry into account.  
4.2.6 Remarks about the ‘double click’ strategy 
In summary, the overall results obtained for the ‘double click’ reactions were disappointing. Although the 
yields were very low and in some cases only trace amounts were obtained, the fact that the products did 
form was a hopeful indication for possible optimization. In particular, the dialkynylated maleimide 
appears to be a more suitable and promising system for the ‘double click’ reaction. Provided the 
degradation of the deprotected TMSA maleimide moiety can be avoided or overcome, it is suspected the 
double click reaction could afford the desired products in higher yields. Unfortunately, due to time 
constraints, it was decided to abandon this route and focus the attention to the synthesis of bisaryl 
maleimide derivatives, employing click chemistry.  
4.3 Bisaryl maleimide click products 
In the next section, the synthesis of the bisaryl maleimide click products as demonstrated by Gu et al. was 
endeavored.
[86]
 The reader is reminded that several bisindolylmaleimide analogues have shown promising 
activity as kinase inhibitors.
[189-190]
 The purpose of this area of work in the project was to determine the 
effectiveness of the simple click reaction on an indolylmaleimide system. The strategy is outlined in 
scheme 71 and includes a condensation, Sonogashira and click reaction.  
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Upon accomplishing the click reaction with a simplified moiety, such as benzyl azide, the next attempt 
would be to perform a click reaction with a pre-installed warhead functionality (for example an acryloyl 
group).  
It must be noted that the focus of this section of research was towards investigative purposes, and 
unfortunately the low yields afforded by the click reactions did not generate enough material for full 
characterization. Furthermore, DMSO was used as NMR spectrum solvent and the products were 













Outline of strategy towards bisaryl maleimide click products, where R is a methyl or benzyl group. 
4.3.1 Indole Grignard Reagents 
The first reaction performed in this strategy involves a condensation reaction between N-substituted 
dichloromaleimide and indolyl-MgBr. Grignard reagents have been the most widely used organometallic 
reagents over the past century.
[191]
 Since their discovery in 1900, these organomagnesium reagents display 
a broad range of applications in both organic and organometallic synthesis. Their contribution to synthetic 
chemistry earned Victor Grignard the Nobel Prize in Chemistry in 1912.
[191-192]
 A decade after the 
discovery of alkylmagnesium halides, Oddo reported that indole reacted in diethyl ether with the Grignard 
reagent, ethylmagnesium iodide, producing the indole Grignard reagent (indolylmagnesium iodide) with 
the evolution of ethane.  
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To date, the procedure described by Oddo is still commonly employed for the preparation of indole 
Grignard reagents.
[193-194]
 The general structure of the indole Grignard reagent is represented in figure 76.  
 
Figure 76 
Indole Grignard reagent, where X is usually iodide or bromide. 
The indole Grignard reagent has been widely utilized as an intermediate in synthetic work and undergoes 
many reactions characteristic of simple alkylmagnesium halides. Their widespread use is ascribed to the 
selective substitution predominately at the 3-position of the indole ring.
[193]
 When dealing with Grignard 
reagents, care should be taken to avoid exposure to air or water, which may destroy the reagent by 
protonolysis or oxidation. The choice of solvent is another important factor which affects the yield, 
stereo-, and regiochemistry of reactions with Grignard reagents. In this regard, ethereal solvents such as 
diethyl ether and THF are the most commonly used solvents.
[192,194]
 
A variety of approaches have been reported for the synthesis of indolylmaleimides, but one of the more 
common approaches for preparing mono- and bisindolylmaleimides involves the condensation of an 
indole Grignard reagent with a dihalomaleimide.
[195,198]
 In our case, a similar strategy was employed to 
couple the indole to the N-substituted-dichloromaleimide. The initial step of the reaction involved the 
generation of the indole Grignard reagent (indolylmagensium bromide) in situ. The work by Brenner et 
al. demonstrated that the solvent used strongly affects the outcome of the reaction. When using toluene, 
the bisindolyl product forms, whereas the monosubstituted product is obtained when THF is the chosen 
solvent.
[198]
 For this reason, it was deemed crucial that the reaction was performed in a THF solution to 
prevent a disubstitution reaction from occurring. A proposed mechanism for the synthesis of this 
compound is illustrated in scheme 72. 
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Proposed mechanism for the synthesis of monoindolyl maleimide compound. 
Here follows the synthesis of the various compounds illustrated in the outline, represented in scheme 71. 
For comparative reasons, both the methyl and benzyl moieties were incorporated into the 
indolylmaleimide system. Since the procedures employed were the same for both protecting groups, the 
reaction schemes of only the N-Me-indolylmaleimide compound are shown, followed by the individual 
characterization for the methyl and benzyl indolyl maleimide products. 
4.3.2 Synthesis of 1-benzyl-3,4-dichloro-1H-pyrrole-2,5-dione (85) 
 
Scheme 73 
The route incorporating a benzyl-protected maleimide was carried out, and its effectiveness was 
compared to the route involving the methyl-protected maleimide as utilized by Gu and coworkers.
[176]
 The 
first step was to generate the benzyl-protected dichloromaleimide species (85).  
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The reaction was carried out smoothly as shown in scheme 73, by simply heating compound 69 and 
benzylamine in AcOH to reflux. Upon completion, a workup was carried out, and the crude product was 
purified by column chromatography. The pure compound (85) was afforded in a good yield of 76%.  
The 
1
H NMR spectrum of the product (85) was compared to that in literature 
and corresponded well.
[199]
 The benzyl methylene protons Hc were located at 
4.73 ppm, as a singlet and integrated for two. The aromatic protons (He, Hf, 
Hg) integrated for five, and were found as a multiplet in the range 7.40-7.23 
ppm. 
 




The indole Grignard was prepared in situ by treating indole with EtMgBr. The THF used was freshly 
distilled and degassed to prevent the reaction of H2O and O2 with the Grignard reagent.The reaction flask 
containing the indole solution was then transferred to an ice bath and EtMgBr was added drop-wise. The 
temperature was increased to 60 °C and stirred for 1 hour. Thereafter, a solution of the respective 
protected dichloromaleimide (75 or 85) in THF was added to the indole Grignard reagent and the reaction 
was heated to reflux for a further 2 hours. Upon completion, a workup was carried out and the product 
was purified by column chromatography. The pure product of 86 was afforded in a yield of 57%. The 
synthesis of 87 was performed according to the exact same procedure, and obtained in a yield of 43%. 
The 
1
H NMR spectrum of the product (86) was compared to that in literature 
and corresponded well.
[176]
 Upon inspection, the spectrum revealed the presence 
of both the N-Me-maleimide and indole signals, proving the success of the 
coupling reaction. 
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The broad signal of the –NHm peak was located at 12.14 ppm, while Hn was found as a singlet at 8.08 
ppm. The aromatic protons Hh and Hk, were identified as doublets at 7.93 ppm and 7.52 ppm. Hi and Hj 
were found at 7.23 ppm and 7.16 ppm, both as multiplets. All the aromatic signals integrated for one 
each. The methyl group protons (Hc) were located at 3.00 ppm, as a singlet, and integrated for three.  
The 
1
H NMR spectrum of the product (87) showed the presence of the indole- 
and benzyl aromatic proton signals, confirming that the coupling was a 
success. The broad –NHq signals was located at 12.18 ppm, and the singlet of 
the methylene benzyl protons Hc were found at 4.73 ppm, integrating for two. 
The benzyl aromatic protons (He, Hf, Hg) were identified in the range 7.38-
7.27 ppm as a multiplet and integrated for 5. Hl and Ho were located at 7.95 
ppm and 7.52 ppm as doublet of doublets, both integrating for one. Two 
multiplets were found at 7.25-7.21 ppm and 7.20-7.13 ppm, which were 
assigned to Hm and Hn. The two carbonyl carbon signals (Cb, Ch) were located 
at 168.4 ppm and 165.9 ppm in the 
13
C NMR spectrum of the product. Furthermore, all the carbon signals 
of the indole group and benzyl moiety were accounted for. The IR spectrum revealed the amine (-NH) 
stretch at 3279 cm
-1
, the carbonyl (C=O) stretch at 1696 cm
-1
,and the C-Cl stretch at 696 cm
-1
. 
4.3.4 Synthesis of 3-(1H-indol-3-yl)-1-methyl-4-{(trimethylsilyl)ethynyl}-1H-pyrrole-2,5-




The next reaction in the strategy was a Sonogashira reaction, performed in a similar manner to that in 
section 4.2.5.4.In this manner, the pure product of 88 was obtained in an excellent yield of 87%. The 
synthesis of 89 was performed according to the exact same procedure, and the desired product was 
obtained in a good yield of 83 %. 
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H NMR spectrum of the product (88) was compared to that in 
literature and corresponded well.
[176]
 The presence of the TMSA moiety 
was confirmed by the presence of the trimethylsilyl protons Hq, which 





H NMR spectrum of the product (89) revealed the presence of 
the methyl silyl protons Hu at 0.09 ppm as a singlet, integrating for 
nine. The 
13
C NMR of the product (89) also showed three additional 
carbon signals, which were not present in the starting compound 
carbon spectrum. The results of the mass spectral analysis of 
399.1528 amu correlated with the expected mass of 399.1529 amu. 
 
 
4.3.5 Synthesis of 3-(1-benzyl-1H-1,2,3-triazol-4-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-
2,5-dione (90) and 1-benzyl-3-(1-benzyl-1H-1,2,3-triazol-4-yl)-4-(1H-indol-3-yl)-1H-pyrrole-
2,5-dione (91) 
Scheme 76 
To confirm the effectiveness of the click reaction on the indolylmaleimide system, it was initially carried 
out using the simple benzyl azide, which was available. The procedure followed by Gu et al., involved a 
silyl deprotection and click reaction in one pot, as shown in scheme 76. The deprotection step showed a 
clear transformation to one new product spot, and no additional degradation spots were observed on the 
baseline of the TLC. The click reaction TLC showed that there was incomplete consumption of the alkyne 
compound (88 or 89), and multiple new spots were observed.  
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Following a workup, the crude product was purified by column chromatography, which afforded the 
product 90 in a low yield of 19%. The synthesis of 91 was performed according to the exact same 
procedure, and the product 91 was obtained in a yield of 20 %. 
The 
1
H NMR spectrum of the product (90) revealed the 
indicative triazole Hp signal at 8.20 ppm (or masked by the 
protons in the aromatic region). The benzyl group was also 
clearly present in the spectrum, as the number of multiplet 
signals in the aromatic region increased. The methylene Hq 
was located at 5.70 ppm and integrated for two. The 
remainder of the indole and N-Me-maleimide proton signals 
could all be accounted for. The 
13
C NMR spectrum of the product (90) showed the carbonyl signals 
(Cd/Cb) at 170.9 ppm and 170.8 ppm. The symmetrical aromatic carbons Cs and Ct were found at 128.8 
ppm and 127.7 ppm. Furthermore, Cq and Cc could be identified at 52.8 ppm and 24.1 ppm respectively. 
The rest of the carbon signals proved to be difficult to assign, but were present in the spectrum.  
The 
1
H NMR spectrum of the product (91) revealed the 
indicative triazole proton signal Ht and indole Hr at 8.58 
ppm and 8.23 ppm. Both singlets integrated for one and 
their assignment could not be distinguished. The methylene 
protons (Hu and Hc) of the benzyl moieties were located at 
5.69 ppm and 4.75 ppm. Both appeared as singlets, 
integrating for two. The broad –NHq was identified at 11.97 
ppm. The remainder of the aromatic signals could all be 
located as multiplets. 
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Due to the fact that the one pot deprotection/click reaction made it difficult to distinguish the cause of the 
low yield, and the effectiveness of the actual click reaction, it was decided to perform these two reactions 
individually (scheme 77). The TMSA deprotection reaction was initially performed in a similar manner to 
the previous deprotection in THF/MeOH, using TBAF·3H2O instead of TBAF. The TLC revealed the 
formation of a new spot (product), as well as a spot on the baseline within 1 hour. Again, upon 
purification, the product (92) was obtained in a very poor yield of 14%. It was then decided to use a 
different solvent mixture (THF and saturated NH4Cl), and stir the reaction overnight in the dark. The TLC 
showed that the reaction lacked complete consumption of the starting material. In addition to the product 
spot, a spot on the baseline was observed. This time column chromatography afforded the pure product 
(92) in an increased yield of 44%. The synthesis of 93 was performed according to the exact same 
procedure, and obtained in an improved yield of 59 %. 
The 
1
H NMR spectrum of the product (92) confirmed the TMSA 
deprotection. The trimethylsilyl signal was replaced by a singlet for Hp, 
integrating for one, and located at 5.10 ppm. The number of carbon signals 
in the 
13
C NMR spectrum corresponded to the number of carbon atoms of 
the product. The terminal alkyne carbon peak could not be clearly identified 
in the 
13
C NMR spectrum.  
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H NMR spectrum of the product (93) revealed all the proton signals 
of the starting material, together with the loss of the methyl silyl singlet. 





4.3.7 Synthesis of N-(4-[4-{4-(1H-indol-3-yl)-1-methyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-
yl}-1H-1,2,3-triazol-1-yl]phenyl)acrylamide (94) 
Scheme 78 
A small scale click reaction was performed with the deprotected TMSA product and an azide acryloyl 
moiety previously synthesized in our group. The reaction was performed as a test reaction to verify 
whether the click reaction, incorporating a warhead such as the acryloyl group, would afford the desired 
product. The click reaction was carried out as shown in scheme 78. The product was purified (94) by 
column chromatography and obtained in a low yield of 26%. The same reaction was performed using the 
benzyl-protected indolylmaleimide starting material, but purification of the product by means of column 




Stellenbosch University  https://scholar.sun.ac.za





H NMR spectrum (figure 77) of the product 
(94) clearly showed the presence of two broad –
NH signals at 11.92 ppm and 9.92 ppm. The 
indicative triazole Hp was located at 8.18 ppm as 
a singlet, and was a verification that the click 
reaction did work. Furthermore, the distinctive 
vinyl protons Hx/Hx’and Hw were located at 6.27 
ppm (Hy’), 5.78 ppm (Hy), and 6.53-6.43 ppm 
(Hx), respectively. The methylene Hq was found 
at 5.68 ppm and integrated for two. The remainder of the aromatic proton signals and N-Me-maleimide 
could all be accounted for in the spectrum. The 
13
C NMR spectrum of the product (94) revealed all the 
carbon signals corresponding to the number of carbon atoms of the product. Only a few of the signals 
could be assigned. The carbonyl carbon signals Cb/d were located at 171.0 ppm and 170.8 ppm, while the 
acryloyl carbonyl Cw was found at 163.8 ppm. The methylene Cq was located upfield at 49.6 ppm, and the 




H NMR spectrum of compound 94. 
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4.3.8 Attempted synthesis of 3-Azido-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione (95) 
 
Scheme 79 
In order to test whether the click reaction could be performed on the indole maleimide azide version, we 
attempted the synthesis of compound 95 as shown in scheme 79. The procedure utilized by Teller et al. 
was followed, with the only difference being that the researchers utilized a bromo halogen.
[200]
 
Unfortunately, the reaction was not successful. A different attempt was made in which the condensation 
reaction between the indole Grignard reagent and previously synthesized 3-azido-4-chloro-1-methyl-1H-
pyrrole-2,5-dione (76) was carried out. To our dismay, IR revealed no azide stretch and we concluded that 
the desired product had not been formed. These two reactions were also attempted utilizing the benzyl-
protected starting material, with no success.  
4.3.9 Remarks about the indolylmaleimide click strategy 
In summary, we could conclude that by employing the strategy in scheme 71, we were able to obtain the 
methyl indolylmaleimide click product (94). However, the product (94) shown in scheme 78, was not a 
viable compound to send for biochemical assay testing, since the presence of the N-Me group is 
undesirable, and prevents the formation of crucial hydrogen bonds in the kinase hinge region. Thus 
deprotection was required. The fact that the click products were synthesized in very low yields (19%-
26%), made the imide deprotection reactions found in literature trivial. It must be noted that both the 
methyl and benzyl deprotection involves the generation of the anhydride, followed by treatment with 
ammonium acetate or urea.
[176,198,201]
 In addition, another reason for not pursuing the imide deprotection 
reaction was that molecular modeling analysis revealed the structure of the compound was too large to fit 
into the targeted EGFR kinase domain. Furthermore, we anticipated that the reactive acryloyl moiety may 
not withstand the deprotection conditions. 
The low yield of the click reaction was partly ascribed to the TMSA deprotection step. Although the 
deprotection reaction performed in section 4.3.6 was optimized, the yield remained unsatisfactory. No 
distinct trend could be observed between the methyl-and benzyl protecting group’s effectiveness. 
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Improved yields were obtained for both the methyl-and benzyl indolylmaleimide, depending on the 
particular reaction carried out. 
4.4 Towards bisamino maleimide derivatives 
Awauh and Capretta recently published an article which involved the synthesis of bisaryl-maleimides, 
anilinoaryl-maleimides, and bisanilino-maleimides (Figure 78).
[202]
 Their efforts focused towards the 
development of a procedure that allowed the necessary control to permit symmetrical or nonsymmetrical 
derivatives. In addition, their research investigated effective N-protecting groups, which would alter the 
electronics of the maleimide system and facilitate the second amination reaction. Another criterion for a 
suitable protecting group was that its deprotection had to proceed effortlessly.  
 
Figure 78 
General representation of bisaryl-maleimides, anilinoaryl-maleimides, and bisanilino-maleimides, as proposed by 
Awauh and Capretta.
[202] 
An important observation was made in which the introduction of an amino group, by a conjugate 
addition/elimination reaction, altered the electronic nature on the neighboring site in such a manner that 
more forceful conditions (heating) were required to install the second amino group. This result was 
ascribed to the subtle interplay between the electron-donating ability of the first amine and the 
nucleophilicity of the second amine. The electrophilicity of the carbon bearing the Br is significantly 
reduced in the monoaminated system, since it becomes the end of an enamine system as well as an α,β-
unsaturated amide.  
For this reason, the second amino group introduced requires a more nucleophilic nature than the first 
(figure 79). These findings were very helpful in the understanding of our maleimide system and choice of 
protecting group. 
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Crucial order of addition of the amino vectors. 
Finally the synthesis towards bisamino maleimide irreversible kinase inhibitors was undertaken, by 
incorporating a ‘warhead’ (acryloyl/propargyl moiety) into the substituted maleimide system as shown in 
scheme 80. p-Nitroaniline was chosen as a suitable protecting group (PG), since its removal evolves a 
simple step, discussed in more detail in section 4.4.9. An important factor to note, was that the order of 
the amine addition was essential – the bisamination would only be successful if the less nucleophilic 
amine (aniline) was added first, followed by the more nucleophilic amine (N-Boc-piperazine). The 
following subsections involve the synthesis of the various compounds illustrated in scheme 80. Molecular 
modelling demonstrated the possibility of a potential hydrogen bond interaction forming between the 
dynamic target compound acryloyl carbonyl functionality and the amine of Cys797 residue within the 
EGFR kinase domain, which could promote the potential of a covalent bond forming between the 
β-carbon of the acryloyl group and the nucleophilic thiol of cysteine 797 (figure 80). All molecular 
modeling calculations, docking studies and image generations were carried out using Accelerys 
Discovery Studio software.  
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Molecular modelling illustrating the possible hydrogen bond formation between the acryloyl carbonyl functionality 
and the amine of the Cys797 residue within the EGFR domain - promoting the formation of a potential covalent 
bond. 
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4.4.2 Synthesis of 3,4-dibromo-1-(4-nitrophenyl)-1H-pyrrole-2,5-dione (96) 
 
Scheme 81 
The nitroaniline protected maleimide product (96) was successfully synthesized according to a literature 
procedure as shown in scheme 81.
[203]
 The reaction was performed by heating a solution of previously 
synthesized dibromomaleic anhydride in AcOH, with p-nitroaniline at reflux. The product was purified by 
column chromatography, and obtained in a yield of 69%.  
The 
1
H NMR spectrum of the product (96) was compared to that in literature and 
corresponded well.
[203]
 Two doublets were identified at 8.39 ppm and 7.69 ppm, and 
were assigned to the symmetrical He and Hd protons, respectively. Both of these 
signals integrated for two. Six carbon signals were identified in the 
13
C NMR spectrum 
of the product, corresponding to the number of chemically equivalent carbon atoms in 
the structure.  
 
4.4.3 Synthesis of 3-bromo-1-(4-nitrophenyl)-4-(phenylamino)-1H-pyrrolo-2,5-dione (97) 
 
Scheme 82 
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The monoaminated maleimide product (97) was synthesized by a conjugate addition/elimination reaction 
as shown in scheme 82. The reaction involved the addition of a mixture of aniline and TEA in dry THF, 
to a solution of compound 96 in THF, at 0 °C. The reaction mixture was then left to stir at room 
temperature, overnight. Upon completion, a workup was carried out and the product was purified by 
column chromatography. The pure compound (97) was afforded in a very good yield of 79%. 
The 
1
H NMR spectrum of the product (97) showed the presence of the 
additional proton signals of the aniline group. The broad –NHi signal 
was located at 10.11 ppm, while the aniline aromatic signals (Hl, Hk, Hm) 
were found in the range 7.44-7.36 ppm and 7.29-7.20 ppm, altogether 
integrating for five.The remainder of the proton signals (He and Hd) were 
also accounted for. The number of carbon signals in the 
13
C NMR 
spectrum of the product (97) corresponded with the number of 
chemically equivalent carbon atoms in the structure. The results of the 
mass spectral analysis of 387.9938 amu correlated with the expected mass of 387.9933 amu. 
4.4.4 Synthesis of N-Boc-piperazine (99) 
 
Scheme 83 
In order to incorporate the secondary aliphatic system (98), onto the monoanilated maleimide product, a 
Boc-protection reaction was performed. The procedure utilized by Jo et al. was followed and the reaction 
proceeded smoothly by treating a concentrated solution of piperazine (98) in MeOH, with a diluted 
Boc2O/MeOH solution.
[203]
 The Boc2O solution was added drop-wise to the piperizine (98) solution at 0 
°C, and stirred at room temperature for 2 days. An acid/base workup was then carried out to separate the 
disubstituted product from the desired product (99). No further purification was required. The pure 
product (99) was afforded in a yield of 59%.  
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H NMR spectrum of the product (99) was compared to that reported in literature and 
corresponded well.
[203]
 The broad –NHa was located at 2.22 ppm, as a singlet. The 
chemically equivalent protons of Hc and Hd were identified as multiplets at 3.45-3.28 ppm 
and 2.86-2.72 ppm, respectively. Both signals integrated for four each. The Hg was found 
at 1.43 ppm as a singlet and integrated for nine. 




The next reaction involved the introduction of the Boc-protected piperazine (99) to the monoaminated 
maleimide (97) as shown in scheme 84. The second amination reaction was performed in the same 
manner as that in subsection 4.4.3. However, the second conjugate addition/elimination reaction required 
an increased reaction temperature of 55 °C. The reaction did not proceed to completion, and some of the 
starting material (97) remained unreacted. Following a workup, the product was purified by column 
chromatography. The pure product (100) was obtained in a yield of 80%, when taking the recovered 
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H NMR spectrum of the product (100) showed all the proton 
signals of the starting material. In addition, all the proton signals of 
the N-Boc piperazine group were identified, proving that the second 
amination reaction had worked. The two sets of chemically 
equivalent Hn and Ho protons were located in the range 3.30-3.25 
ppm and 3.18-3.10 ppm. Both signals appeared as multiplets and 
integrated for four each. The Boc singlet Hr was found at 1.36 ppm 
and integrated for nine. The 
13
C NMR spectrum of the product 
(100) revealed five new carbon signals. The carbonyl of the Boc 
group (Cp) was located at 153.7 ppm, and the Cq an Cr signals were 
found at 79.1 ppm and 28.0 ppm, respectively. Cn and Co were both 
identified at 47.1 ppm. The results of the mass spectral analysis of 494.2043 amu correlated with the 
expected mass of 494.2043 amu. 




The Boc-deprotection was carried out smoothly as shown in scheme 85. The reaction was performed by 
treating a solution of compound 100 in CH2Cl2 with diluted TFA (in CH2Cl2). Following the TFA 
addition at 0 °C, the reaction temperature was increased to 35 °C and stirred overnight. The reaction 
mixture was then basified and a workup was carried out. Column chromatography then afforded the pure 
product (101) in an excellent yield of 98%.  
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H NMR spectrum of the product (101) showed the absence of the 
Boc proton signal, proving that the deprotection was a success. The -NHp 
signal and chemically equivalent Hn protons were identified as a multiplet 
in the range 3.62-3.18 ppm, integrating for five. The Ho protons were also 
shown as a multiplet at 2.69-2.57 ppm and integrated for four. The rest of 
the proton signals could all be identified. The 
13
C NMR spectrum of the 
product (101) was similar to the starting material, but with the absence of 
the three carbon signals belonging to the Boc group. The results of the 
mass spectral analysis of 394.1510 amu correlated with the expected mass 
of 394.1515 amu. 




The acryloyl ‘warhead’ could then be added to the bisamino maleimide scaffold as shown in scheme 86. 
The reaction proceeded smoothly within 2 hours at room temperature. The procedure involved the drop-
wise addition of diluted acryloyl chloride (in THF), to a mixture of compound 101 and TEA dissolved in 
dry THF/DMF, at 0 °C. Following a workup, the crude product was purified by column chromatography 
to afford the pure compound (102) in a yield of 61%.  
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H NMR spectrum of the product (102) showed the presence of the 
indicative protons of the acryloyl moiety, and the absence of the –NHp 
signal. The vinyl protons Hs and Hs’ were identified at 5.68 ppm and 6.26 
ppm, respectively, both integrating for one. Their coupling pattern 
corresponded to the proton Hr, which was located at 6.47 ppm as a 
doublet of doublets and also integrated for one. The 
13
C NMR spectrum 
of the product (102) revealed three additional carbon signals as expected. 
The carbonyl signal (Cq) was found at 165.5 ppm, while Cr and Cs/s’ were 
located between the aromatic carbon signals. The results of the mass 
spectral analysis of 448.1612 amu correlated with the expected mass of 
448,1621amu 




The propargyl ‘warhead’ could also be incorporated into the bisamino maleimide scaffold as shown in 
scheme 87. The reaction was performed by treating a solution of compound 101 in DMF, with propargyl 
bromide. The reaction was carried out smoothly within 2 hours at 50 °C. A workup was then performed, 
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H NMR spectrum of the product (103) showed the absence of the –
NHp signal, previously present in the starting material. This signal was 
replaced by two additional proton signals – Hq and Hs. Hq was located as a 
doublet at 3.24 ppm and integrated for two, while Hs was identified at 2.25 
ppm as a multiplet, integrating for one. Furthermore, the 
13
C NMR 
spectrum of the product (103) revealed three additional carbon signals. 
The methylene Cq was found most upfield at 47.0 ppm. Cr and Cs were 
located at 78.4 ppm and 73.6 ppm, respectively. The results of the mass 
spectral analysis of 432.1666 amu correlated with the expected mass of 
432.1667 amu. 
 
4.4.9 Synthesis of 3-(4-acryloylpiperazin-1-yl)-4-(phenylamino)-1H-pyrrole-2,5-dione (104) 
and 3-(phenylamino)-4-(4-(prop-2-yn-1-yl)piperazin-1-yl)-1H-pyrrole-2,5-dione (105) 
 
Scheme 88 
The deprotection of the nitroaniline-protected diamino maleimide derivatives was easily carried out by an 
aminolysis reaction as shown in scheme 88. The procedure involved the treatment with methanolic 
ammonia at room temperature, as employed by Awuah and co-workers.
[202]
 The reaction was carried out 
by dissolving compound 102 (or 103) in CH2Cl2/MeOH, and bubbling NH3 gas through the reaction 
mixture. A crucial initial step in the procedure was the evacuation under high vacuum and filling the 
reaction flask with Ar. Without this precaution the reaction did not proceed. Once the solution was 
saturated with NH3, the reaction mixture was stirred at room temperature for 8 hours. The product was 
purified (104) by column chromatography and afforded in a very good yield of 86%.  
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The synthesis of (105) was performed in the exact same manner, and obtained the pure product (105) in 
an excellent yield of 91%. 
The 
1
H NMR spectrum (figure 81) of the product (104) showed the 
presence of the new -NHc signal at 8.16 ppm. Hk and Hl appeared as a 
multiplet at 3.53 – 3.21 ppm, integrating for eight. Furthermore, the 
aromatic signals of the nitroaniline group were lost – confirming the 
success of the deprotection. The 
13
C NMR spectrum of the product (104) 
also revealed the absence of the carbon signals belonging to the protecting 
group. The remainder of the proton and carbon signals could all be 
identified. The results of the mass spectral analysis of 327.1447 amu 
correlated with the expected mass of 327.1457 amu. The IR spectrum 
showed two –NH stretches at 3317 cm
-1





H NMR (figure 82) and 
13
C NMR spectra of the product 
(105) also revealed the absence of the nitroaniline protecting group proton 
and carbon signals. The new –NHc signals was identified at 7.79 ppm in the 
1
H NMR. The remainder of the proton and carbon signals could all be 
located in the spectra. The results of the mass spectral analysis of 311.1497 
amu correlated with the expected mass of 311.1508 amu. The IR spectrum 
showed two –NH stretches at 3277 cm
-1
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H NMR spectrum of compound 105. 
4.4.10 Remarks about the bisamino maleimide strategy 
The strategy pertaining to the synthesis of the bisamino maleimide derivatives was carried out smoothly, 
generating the two final target compounds. Employing this design strategy enabled the synthesis of 
derivatives resembling the “open” form of the natural product staurosporine. In addition, by incorporating 
warhead moieties, such as acryloyl and propargyl, the compounds can potentially demonstrate irreversible 
kinase inhibitory activity. Overall, the structures illustrated in scheme 80, were obtained in moderate to 
high yields. Utilizing p-nitroaniline as protecting group proved to be a suitable choice, and could 
effectively be applied to other strategies involving maleimide scaffolds.  
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As part of future work, these satisfying results inspire the synthesis of a broad scope of possible bisamino 
maleimide kinase inhibitor derivatives. 
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CHAPTER 5 - BIOLOGICAL EVALUATION OF THE TARGET 
COMPOUNDS AND CONCLUSION 
5.1 Synthesized target compounds 
In total, eight target compounds were synthesized and evaluated for inhibitory activity against EGFR 
(figure 83). Of these compounds, six were generated in the first part of this project, and were based on the 
pyrrolocarbazole scaffold. The two remaining compounds, 104 and 105, resembled the “open” form of 
staurosporine, and were synthesized in the second part of the project.  
Figure 83 
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5.2 EGFR mutations 
As previously mentioned, EGFR has a multidimensional role in the progression of cancer, and has 
become an attractive, well-established target for anti-cancer therapy – particularly for the treatment of 
NSCLC.
[204]
 Currently, three EGFR inhibitors (Erlotinib, Gefitinib and Lapatinib) have received FDA 
approval. Furthermore, several second- and third-generation TKIs (afatanib, neratinib and WZ4002) are 
in preclinical or late stage clinical development (figure 84).
[205]
 Despite the clear clinical benefits of these 
inhibitors, EGFR TKI treatment is not curative in patients.
[206]
 The decreased efficacy of these therapeutic 
agents is primarily ascribed to the development of acquired resistance (AR). Several mechanisms of AR 





EGFR inhibitors that are currently in clinical development or that have received FDA approval. 
One of the most important factors to cause drug resistance and sensitivity to the inhibitors is the presence 
of somatic mutations in the EGRF domain. The functional core of the EGFR protein (TK domain) 
stretches from exon 18 to exon 24, and approximately 90% of its somatic mutations are found in exon 18-
21.
[208]
 In order to develop new effective anti-cancer agents to target drug-resistant mutants, it is essential 
to understand the mechanism and drug response to the mutations – a pursuit of many researchers. In the 
work of Ai et al., the complete profile of several representative EGFR inhibitors in response to various 
EGFR mutations was investigated.
[206]
  
Stellenbosch University  https://scholar.sun.ac.za
Chapter 5 – Biological evaluation of the target compounds and conclusion  
150 
 
In addition, several potential mutations that might cause drug resistance in EGFR were identified. During 
this study, it was shown that most observed mutations in the EGFR domain were far away from the ATP-
binding site, and had limited effect on inhibitor binding. However, the few mutations located around the 
ATP-binding site (figure 85), were shown to substantially impact the inhibitor binding, by either directly 
preventing the reversible interaction to EGFR, or by indirectly affecting the inhibitor binding through 













EGFR architecture illustrating important mutations located around ATP-binding site. Image reproduced from 
reference.
[206] 
The most common type of AR mutation – notorious for its AR to gefitinib - is known as the “gatekeeper 
mutation”.
[204]
 This threonine-to-methionine mutation in codon 790 (T790M) has been identified in 
approximately 50-60% of cases with AR to EGFR TKI treatment, as a second-site mutation in the EGFR 
domain that coexist with the EGFR activating mutation.
[207]
 The drug resistance of the T790M mutation is 




Another mutation that can directly reshape the geometric and physiochemical properties of the binding 
site is the inhibitor-sensitizing EGFR mutation Leu858Arg (L858R). In the specific case of gefitinib, the 
inhibitor binds 20-fold more tightly to the EGFR L858R mutant than to the wild-type EGFR.
[206]
 For the 
purpose of this project, our synthesized target compounds were screened against the EGFR wild-type 
(WT) as well as the two medicinally relevant mutant deviants – L858R and the double mutant 
L858R_T790M. 
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Interestingly, staurosporine has been shown to exhibit selective inhibitory activity on the T790M and 
L858R_T790M mutants.
[206]
 The IC50 values of staurosporine against the EGFR WT, T790M and 
L858R_T790M mutants were measured to be 937, 12 and 3 nM, respectively. Staurosporine inhibitory 
efficacy was therefore 80-fold higher on the T790M mutant over the WT. A possible explanation for this 
result was obtained from investigating the complex structure model of staurosporine with the T790M 
mutant. It was found that the mutated M790 residue could form hydrophobic interactions and S···π 
interactions with the aromatic ring and amide moiety of staurosporine, as shown in figure 86. These 
interactions contributed stabilization energy to the complex system and eliminated some unfavourable 
polar interactions associated with the WT system.
[206]
 Although staurosporine was found to have a low 
sensitivity to the L858R mutant, the dual L858R_T790M mutation, which is very common in AR of 
NSCLC, showed a significantly enhanced selectivity. Comparing the staurosporine IC50 value of 3 nM for 
the L858R_T790M double mutant, to that of gefitinib and elotinib (which is more than 5 μM), 
demonstrates the potency of this natural product.
[210]
 Staurosporine could therefore be considered as a 
promising lead compound to develop new inhibitors that could combat AR, particularly associated with 
the T790M mutation. 
 
Figure 86 
Hydrophobic force and S···π interactions formed between staurosporine and M790 residue in T790M mutant EGFR. 
Image reproduced from reference.
[206]
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5.3 Biochemical screening methodology 
Numerous detection methodologies have been applied to evaluate and measure kinase activity.
[211]
 Cisbio 
developed a simple and robust assay platform, namely HTRF, to screen compounds for their tyrosine and 
serine/threonine kinase inhibitory activity.
[212]
 Homogeneous time-resolved fluorescence (HTFR) is 
frequently used in drug discovery, and eliminates some of the difficulties experienced by other 
conventional screening assay methodologies.
[211,213]
 The technique combines standard fluorescence 
resonance energy transfer (FRET) technology with time-resolved measurements of fluorescence. All 
HTRF kinase assays follow the same general format, and are based on the method that uses FRET 
between two fluorophores – a donor fluorophore (Europium cryptate) and an acceptor fluorophore 
(XL665). In this manner, the interactions between biomolecules can be evaluated by coupling each 




, is an extension of the HTRF technology (developed in partnership with Upstate), 
that utilizes antibody-based detection to assess kinase activity.
[212]
 The kinase assay consists of two main 
steps – kinase reaction and detection of the phosphorylated product by HTRF reagents. The method 
involves a unique biotinylated peptide substrate containing a single phosphorylation site. Upon 
phosphorylation, the substrate is recognized by a monoclonal antibody labeled with the donor fluorophore 
(Eu
3+
cryptate). The addition of streptavidin labeled with the acceptor fluorophore (XL665), completes the 
detection step. These substrate and detection reagents have been validated on many kinases, and the 
success of the HTRF® KinEASE
TM 
homogenous assay has been demonstrated for protein kinase 
selectivity studies as well as high-throughput screening campaigns.
[212]
 A more detailed description of the 
exact procedure used, for the evaluation of the compounds synthesized in this project, follows. 
Following the synthesis and purification of the eight target compounds, they were all sent for biochemical 
assay testing. IC50 values of our compounds were determined by utilizing the HTRF KinEASE-TK assay. 
The particular biochemical screening of our compounds involved the use of the EGFR wild type, and 
mutants (L858R and L858R_T790M). The procedure started with a control experiment in which a 
biotinylated poly Glu-Tyr substrate peptide was phosphorylated by EGFR. Completion of the reaction 
was followed by the introduction of the antiphosphotyrosine antibody labeled with Eu
3+
 cryptate and 
streptavidin XL665. The phosphorylation of the peptide substrate could then be quantified by measuring 
the FRET between the donor and acceptor fluorophores (Eu
3+
 and XL665).  
Following the control experiment, the ATP concentrations were set at their respective Km values (30 μM 
for the EGFR-WT, 60 μM for EGFR-L858R, and 30 μM for EGFR-L858R_T790M) and 50 nM of 
substrate were used for both wild type and mutant EGFR. Our synthesized inhibitors were the pre-
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incubated with the specific kinase and peptide for 2 hours. After this period, the reaction was initiated by 
the addition of ATP. The next part of the procedure involved the detection step. This was conducted by a 
Tecan Safire plate reader, which measured the fluorescence of the samples at 620 nm (Eu-labeled 
antibody) and 665 nm (XL665 labeled streptavidin) 60 μs after excitation at 317 nm. An illustration of 
this HTRF® KinEASE
TM
 assay procedure is shown in figure 86. The IC50 values were then determined by 
plotting the quotient of both readings for reactions made with eight different inhibitor concentrations, 
carried out in triplicate, against inhibitor concentration – fitted to a Hill-4 parameter equation. An 
example of a graph to determine the IC50 value is shown in figure 87. Furthermore, the EGFR inhibitors 
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5.4 Evaluation of results and discussion 
The IC50 values of the eight target compounds, obtained from the biochemical assays, are tabulated below 
(table 2). Unfortunately, the results did not show inhibitory activity for seven of these compounds at 100 
μM, and no noticeable trend with regards to structure-activity relationship studies could be identified. For 
this reason, any conclusions drawn in relation to the inhibitor activity would be speculative. Overall, the 
only compound which exhibited some inhibitory activity was 49,which demonstrated an IC50 value of 
6.09 μM and 4.35 μM against L858R and L858R_T790M, respectively. Comparing the structure of 49 to 
48, we could deduce that the aromatized, planar pyrrolocarbazole core is necessary for inhibitor activity. 
Further evidence for this reasoning can be drawn from the fact that the EGFR inhibitors, illustrated in 
figure 83, all display a high degree of aromaticity (also see section 1.6, figure 25). In addition, when 
evaluating the results of 49 and compound 29, which served as an inspiration for the design of the 
pyrrolocarbazole compounds, it is clear that the length of the carbon linker to the warhead significantly 
influences the activity of the compound. It appears as if a three carbon linker is much more beneficial 
than a two carbon linker (figure 88). Compounds 53, 104, and 105 did display some degree of inhibition 
against L858R, but at concentrations higher than 100 μM. As a result of the poor activity demonstrated 
against the EGFR WT and mutant forms, as well as time constraints, we decided against pursuing follow-
up studies and optimization of these compounds.  
Table 2 
IC50 values (μM) of the eight target compounds. 
 
IC50 EGFR [μM] (HTRF) 
  WT L858R L858R_T790M 
Gefitinib ˂0.001 ˂0.001 0.055 ± 0.048 
WZ4002 0.015 ± 0.007 0.001 0.001 
48 n.i. n.i n.i 
49 ˃10  6.09 ± 2.13 4.35 ± 1.08 
50 n.i. n.i. n.i. 
51 n.i. n.i. n.i. 
52 n.i. n.i. n.i. 
53 n.i. ˃100 n.i. 
104 n.i. ˃100 n.i. 
105 n.i. ˃100 n.i. 
n.i. no inhibition at 100 μM. 
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Comparison of the structure of our inspiration compound 29 and 49 with their respective IC50 values. 
5.5 Conclusion 
In this project, the natural product staurosporine served as a structural ‘muse’ to synthesize compounds as 
potential kinase inhibitors. The project comprised of two parts, based on the pyrrolocarbazole scaffold 
and the “open” form of the indolocarbazole core. With the initial aim in mind, six pyrrolocarbazole 
analogues were synthesized. Different warheads were incorporated into these compounds, having both 
unaromatized and planar (aromatized) driving portions. The second part of the project, primarily inspired 
by the selective kinase inhibitor enzastaurin, focused on the synthesis of bisaryl maleimides. One of the 
synthetic strategies, which proved problematic, involved a double-click approach. Another approach 
which yielded unsatisfactory results made use of click reactions on an indolyl maleimide system. 
Although some challenges were experienced in obtaining the bisaryl maleimides, a successful synthetic 
strategy based on bisamino maleimide derivatives, afforded the two final target compounds in high yields.  
Upon generating the eight target compounds, their IC50 values were measured by collaborators at the 
Technische Universität Dortmund in Germany. The biochemical assays were screened against the EGFR 
wild-type and the two mutant forms (L858R and L858R_T790M). Of these results, only one (49) of the 
eight compounds exhibited some inhibitory activity. 49 showed IC50 values of 6.09 μM and 4.35 μM 
against L858R and L858R_T790M, respectively. We suspect that the planar pyrrolocarbazole scaffold is 
necessary for activity. Furthermore, it was deduced that the carbon linker length plays a vital role in the 
inhibitor potency.  
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Although the majority of the compounds did not exhibit inhibitor activity, the natural product 
staurosporine continues to be an inspiration and viable lead structure to design kinase inhibitors with 
improved selectivity and potency. 
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CHAPTER 6 – FUTURE WORK 
6.1 Design of the pyrrolocarbazole compounds 
Upon inspection of the biochemical assay results of the eight target compounds, compound 49 proved to 
be the only structure exhibiting inhibitory activity against EGFR and its mutant forms. Comparing 49 to 
the inspiration compound 29, it was deduced that the 3-carbon linker of 29 contributed to the increased 
potency of the inhibitor. Furthermore, the aromatized form of the pyrrolocarbazole structures proved to be 
the more suitable scaffold in comparison to the unaromatized structure. For this reason, the future 
synthetic work pertaining to these compounds will focus on the design of aromatized pyrrolocarbazoles 
containing a functionalized (‘warhead’) tether composed of a longer (3/4) carbon linker (figure 89). 
 
Figure 89 
Aromatized pyrrolocarbazole derivatives containing a 3-carbon linker with warhead (R). 
6.1.1 Proposed divergent synthetic route 
Although the majority of the compounds afforded during the synthesis of the final target products were 
obtained in moderate to high yields, the route undertaken in section 3.7.4 is of particular importance. This 
interest arises from the fact that the design strategy involving the protected-N-pyrrolocarbazole is a more 
divergent route, when compared to the method followed in which N-alkylation was performed prior to the 
generation of the backbone scaffold (before DA reaction). Using this divergent route, and following the 
procedure outlined in 3.7.4.2, to afford the benzyl-protected pyrrolocarbazole derivative, various 
moieties, other than the nitrile group (3-carbon linkers with warhead), could potentially be introduced 
onto the scaffold.  
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The final step would involve the deprotection of the benzyl group to expose the essential –NH 
functionality (scheme 89). However, this N-benzyl deprotection directly from maleimide has not been 





Divergent strategy to incorporate various 3-carbon tether warheads (R). 
The unsuccessful N-benzyl deprotection reaction was attempted in section 3.7.4.4 by catalytic 
hydrogenation, using a palladium carbon catalyst in the presence of H2 gas (H2, Pd/C) under pressure. 
However, N-benzyl carboxamides are known to be notoriously difficult to hydrogenolyze even when one 
of the most robust deprotection catalysts (for example, Pearlman’s catalyst) are utilized.
[215]
 In addition, 
only R groups prone to hydrogenation under these conditions would then not be tolerated. For this reason, 
an alternative N-benzyl deprotection route will be required. An indirect method which involves an 
alkaline hydrolysis to afford maleic anhydride, followed by heating with ammonium acetate (NH4OAc) or 
urea has shown to be successful in literature.
[201, 216-217]
 Similarly, this approach could be used to attempt 
the deprotection of the benzyl group from the pyrrolocarbazole compound as shown in scheme 90. Again, 
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Proposed strategy for N-benzyl deprotection involving alkaline hydrolysis and treatment with NH4OAc or urea. 
In addition, this synthetic route furnishes an approach in which maleic anhydride could be used, instead of 
maleimide, thereby avoiding the alkaline hydrolysis step as shown in scheme 91. However, the use of 
NH4OAc or urea under the harsh reaction conditions depicted in scheme 90 and 91, could possibly alter 
the warhead functionality. This calls for the investigation of an alternative protecting group. 
 
Scheme 91 
Strategy incorporating maleic anhydride to build the scaffold in order to avoid the alkaline hydrolysis step. 
p-Nitrophenyl in the synthesis of the bisamino maleimide target compounds (see section 4.4), proved to 
be a promising protecting group for the maleimide moiety. One particular advantage of this protecting 
group was its simple cleavage by methanolic ammonia at room temperature. Hence, the strategy to 
incorporate p-nitrophenyl as a protecting group for the pyrrolocarbazole compounds could be employed 
as a potential route to avoid the difficulties experienced with N-benzyl deprotection.  
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The p-nitrophenyl protected maleimide could be easily synthesized, following a procedure in 
literature.
[218]
 This method involves treating maleic anhydride with p-nitroaniline, in AcOH at 140 ºC, for 
5 h. The outline of this proposed strategy is shown in scheme 92.The stability of this protecting group 
under previously utilized thermal Diels-Alder conditions would however still have to be determined.  
With the identification of an optimal protecting group, the introduction of side chains at the 
pyrrolocarbazole amine, as well as deprotection could then be carried out effortlessly. In this manner, a 
number of pyrrolocarbazole derivatives, with various warheads, could be synthesized as potential kinase 
inhibitors.  
 Scheme 92 
Outline of strategy utilizing p-nitrophenyl as maleimide protecting group. 
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6.2 Design of the ‘open’ structure maleimide compounds 
6.2.1 Derivatization of the aniline group 
Although target compounds 104 and 105 did not exhibit inhibitory activity against EGFR and its mutant 
strains, the synthetic route undertaken for their generation proved to be successful. This efficient 
approach, displays potential scope as it allows for the derivatization of the preliminary structures of 
compound 104 and 105 to possibly improve inhibitory activity. One such strategy that could optimize 
these structures is the incorporation of various functional groups at the ortho, meta or para position of the 
aniline ring. Specifically, the presence of a functional group (halogen or hydroxyl) at the ortho position 
could potentially distort the planarity of the aniline phenyl ring and maleimide due to steric interactions 
(scheme 93). This change in orientation could affect the interactions of the inhibitor in the active site, 
from which further information could be deduced. In addition, the possibility of incorporating various 
warheads (R) also creates the opportunity to synthesize compounds with enhanced activity.  
 
Scheme 93 
Incorporating the derivatized aniline group onto the bisamino maleimides. 
6.2.2 SB-415286 inspired 3-anilino-4-arylmalimides 
Another feature that could possibly be altered to improve the inhibitory activity of these ‘open’ maleimide 
compounds is to replace the piperazine ring with a more rigid aromatic ring. This design is inspired by the 
kinase inhibitor SB-415286, illustrated in figure 90. SB-415286 is a potent, selective inhibitor of GSK-3, 
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Structure of the kinase inhibitor SB-415286. 
An outline of a proposed synthetic strategy is shown in scheme 94, and resembles the route followed by 
Smith and co-workers.
[220]
 The design of the 3-anilino-4-arylmaleimides derivatives will start with a base-
induced condensation of an appropriate arylacetamide with dimethyl oxalate. Once the condensation 
reaction affords the desired 3-hydroxy-4-aryl maleimide, chlorination of the hydroxyl, utilizing either 
phosphorus oxychloride in N,N-dimethylaniline or oxalyl chloride in CH2Cl2, will be undertaken. Finally, 
a number of aniline derivatives could then be introduced onto the structure, where R1 is an o, m, p–
halogen or -hydroxyl group. The problematic reactivity of the warhead group R could potentially be 
overcome by initially making use of a robust group (such as a nitro group). Following certain 




Design strategy of 3-anilino-4-arylmaleimide derivatives. 
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6.2.3 Design of bisaryl maleimides utilizing click chemistry 
Once the chloro derivative of the 4-arylmaleimide is successfully synthesized, another approach would be 
to generate a class of triazole-based 4-arylmaleimides, as illustrated in scheme 95. This route would 
involve a substitution reaction using NaN3, followed by the click reaction (CuAAC). Having several 
alkynes with pre-installed warheads in hand, this would allow for the synthesis of a small library of 
triazole based, potentially irreversible ‘open’ maleimide kinase inhibitors.  
Scheme 95 
Design strategy towards the triazole-based 4-aryl maleimides utilizing CuAAC. 
6.3 Concluding remarks pertaining to the future work 
From the biochemical assay results, the synthesis of aromatized pyrrolocarbazoles having a 3-carbon 
tether warhead, seem to be the most promising compounds towards improving inhibitory activity. 
Unfortunately, no further deductions could be made from the results as to how to improve these 
compounds in future research. However, a more divergent synthesis is recommended, provided an 
optimal protecting group is identified.  
The route utilized for the synthesis of the bisamino maleimides provides a promising approach to generate 
target compounds exhibiting improved activity. It is expected that the absence of a maleimide-protecting 
group for this approach, would simplify the process as deprotection would not be necessary. In addition, 
the kinase inhibitor SB-415286 serves as a structural ‘muse’ to design various derivatives of the ‘open’ 
form of maleimide as either 3-anilino-4-arylmaleimide-or triazole-based bisaryl maleimide derivatives. In 
addition, incorporation of possible warheads that can impart inhibition in a reversible or irreversible 
manner would allow for the synthesis of potential kinase inhibitors.  
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CHAPTER 7 – EXPERIMENTAL WORK 
7.1 General information 
7.1.1 Purification of solvents and reagents 
The chemicals used were purchased from either Merck or Sigma-Aldrich, or obtained from the chemical 
stores (De Beers building). Solvents used for chromatographic purposes were distilled by means of 
conventional distillation procedures. Solvents used for reaction purposes were dried over the appropriate 
drying agents and then distilled under N2 gas. Tetrahydrofuran was distilled from sodium flakes with 
benzophenone as indicator. Toluene was distilled from sodium as well, with the absence of the 
benzophenone indicator. Dichloromethane, dimethylformamide and acetonitrile were distilled from 
calcium hydride. Triethylamine was distilled under potassium hydroxide. Diethyl ether was bought with a 
≥98% purity grade from Sigma Aldrich. Other reaction solvents were dried over the appropriate size 
activated molecular sieves. The ethyl acetate, hexane and dichloromethane, used for column 
chromatography, were distilled beforehand. Other reagents requiring purification were purified according 
to standard procedures. 
7.1.2 Chromatography 
Thin layer chromatography was performed using Merck silica gel 60 F254 coated on aluminium sheets. 
Compounds on the TLC plates were visualized under 254 nm UV light, or stained using solutions of 
KMnO4, Cerium ammonium molybdate (CAM) or ninhydrin followed by heating. All column 
chromatography was performed on Merck silica gel 60 (particle size 0.040-0.063 mm) using a 
combination of ethyl acetate, hexane, dichloromethane or/ and methanol as a solvent. 





C) were recorded on a 300 MHz Varian VNMRS (75 MHz for 
13
C), or a 400 MHz 
Varian Unity Inova (101 MHz for 
13
C). Chemical shifts (δ) are reported in ppm and J-values are given in 
Hz. Chemical shifts were recorded using the residual solvent peak as reference. All spectra were obtained 
at 25 °C. Data was processed using MestReNova. Mass spectrometry was performed on a Waters 
SYNAPT G2. Infrared spectra were recorded on a Thermo Nicolet Nexus 470 by means of Attenuated 
Total Reflectance (ATR) mode. Melting points were obtained using a Gallenkamp Melting Point 
Apparatus and are uncorrected. 
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7.1.4 Other general procedures 
All reactions were carried out under a positive pressure of N2 or Ar, unless H2O was used as solvent. 
Glassware was dried in an oven at 120 ºC for a minimum of 2 h. Heating of reaction mixtures was 
accomplished by placing the reaction flask in a paraffin oil bath. Standard Schlenk techniques were 
employed when necessary. Solvents were removed in vacuo, using a rotary evaporator, followed by 
removal of trace amounts of the remaining solvent using a high vacuum pump at ca. 0.08 mm Hg.
 
7.2 Experimental work pertaining to chapter 3 
7.2.1 1-tert-Butyl 2-ethyl 1H-indole-1,2-dicarboxylate (32) 
A 2-neck round bottom flask was charged with ethyl indole-2-carboxylate (31) (2.40 g, 13.0 mmol) and 
dissolved in dry MeCN (45 mL). Di-tert-butyl dicarbonate (3.60 mg, 16.5 mmol, 1.3 equiv) and DMAP 
(170 mg, 1.53 mmol, 0.12 equiv) were then added successively. The reaction mixture was stirred 
overnight at RT. The mixture was then concentrated in vacuo to give an oily yellow residue. The crude 
product was purified by column chromatography (EtOAc/Hexane, 1:20) to afford 1-tert-butyl 2 ethyl 1H-
indole-1,2-dicarboxylate (32) as a light yellow oil (3.1 g, 85%). The 
1
H NMR spectrum of 1-tert-butyl 2 




Rf = 0.65 (EtOAc/Hexane, 1:4);
1
H NMR (600 MHz,CDCl3) δ 8.11 (dd, 
J = 8.5, 0.6 Hz, 1H, He/h), 7.59 (d, J = 7.8 Hz, 1H, He/h), 7.41 (ddd, J = 
8.5, 5.7, 1.2 Hz, 1H, Hf/g), 7.43 – 7.37 (m, 1H, Hf/g), 7.11 (s, 1H, Hc), 





7.2.2 (1H-Indol-2-yl)methanol (34) 
LiAlH4 (0.88 g, 23 mmol, 2.2 equiv) was stirred in THF (10 mL) in a 250 mL 2-neck round bottom flask 
at 0 ºC under a N2 environment. The solution appeared blue/grey in colour. A solution of commercially 
available ethyl indole-2-carboxylate (31) (2.00 g, 10.0 mmol) in THF (10 mL) was then added drop-wise 
to the LiAlH4 solution. The ice bath was then removed and the reaction mixture was warmed to 25 ºC and 
stirred for 30 min.  
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It was cooled to 0 ºC again. H2O (2 mL) was then added drop-wise, followed by NaOH (1 M, aq., 5 mL) 
and again H2O (6 mL) successively. The solution turned white in colour. The reaction mixture was stirred 
for 30 min at RT. The solution was then filtered through Celite and washed with CH2Cl2 (100 mL). The 
filtrate was then washed with brine (100 mL) and the organic layer was dried over MgSO4. Once the 
drying agent was filtered off, the product was concentrated in vacuo. The crude product was finally 
purified by column chromatography (EtOAc/Hexane, 1:4) to afford the desired product (1H-indol-2-
yl)methanol (34) as an off-white solid (1.4 g, 93%). The 
1
H NMR spectrum of (1H-indol-2-yl)methanol 




Rf = 0.39 (EtOAc/Hexane, 4:6); 
1
H NMR (600 MHz, CDCl3) δ 8.36 (s, 1H, 
Ha), 7.59 (dd, J = 7.9, 0.8 Hz, 1H, Hh/e), 7.33 (dd, J = 8.1, 0.8 Hz, 1H, He/h), 
7.19 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H, Hg/f), 7.14 – 7.08 (m, 1H, Hf/g), 6.40 (dd, J 
= 2.0, 0.8 Hz, 1H, Hc), 4.80 (s, 2H, Hj ), 1.99 (s, 1H, Hk). 
7.2.3 1H-Indole-2-carbaldehyde (35) 
The (1H-Indol-2-yl)methanol (34) (1.42 g, 9.68 mmol) was dissolved in freshly distilled MeCN (90 mL) 
in a 2-neck round bottom flask. MnO2 (8.41 g, 96.8 mmol, 10 equiv) was added to the solution turning it 
black in colour. The mixture was then stirred at RT for 6 h. The MnO2 was then removed by filtration 
through Celite after which the reaction mixture was washed with EtOAc (50 mL). The filtrate appears 
orange in colour. The solvent was removed in vacuo to afford 1H-indole-2-carbaldehyde (35) as a 
yellow/orange solid (1.11 g, 76%) which required no further purified. The 
1
H NMR spectrum of 1H-
indole-2-carbaldehyde (35) was compared to that reported in the literature and corresponded well.
[139,149]
 
Rf = 0.77 (EtOAc/Hexane, 2:3); 
1
H NMR (300 MHz, CDCl3) δ 9.86 (s, 1H, 
Hk), 9.36 (s, 1H, Ha), 7.77 (ddd, J = 8.1, 1.5, 0.9 Hz, 1H, He/h), 7.48 (dd, J = 
8.4, 1.2 Hz, 1H, He/h), 7.40 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H, Hg/f), 7.29 (dd, J = 
2.1, 0.9 Hz, Hc), 7.19 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H, Hg/f). 
7.2.4 tert-Butyl 2-formyl-1H-indole-1-carboxylate (36) 
1H-Indole-2-carbaldehyde (35) (587 mg, 3.99 mmol) was added to a 2-neck round bottom flask and 
dissolved in 25 mL dry CH2Cl2. Di-t-butyl dicarbonate (1.13 g, 5.19 mmol, 1.3 equiv) and DMAP (53 
mg, 0.48 mmol, 0.12 equiv) were then added to the flask successively. The reaction mixture was stirred 
overnight at RT. The solution was then concentrated in vacuo to give an oily yellow residue.  
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The crude product was purified by column chromatography (EtOAc/Hexane, 1:20) to afford tert-butyl 2-
formyl-1H-indole-1-carboxylate (36) as a yellow solid (0.94 g, 88%). The 
1
H NMR spectrum of tert-butyl 
2-formyl-1H-indole-1-carboxylate (36) was compared to that reported in the literature and corresponded 
well.
[149] 
Rf= 0.75 (EtOAc/Hexane, 3:7); 
1
H NMR (300 MHz, CDCl3) δ 10.44 (s, 1H, 
Hn), 8.17 (dd, J = 8.5, 0.8 Hz, 1H, He/h), 7.67 (d, J = 8.0 Hz, 1H, He/h), 7.48 (ddd, 
J = 8.5, 7.2, 1.3 Hz, 1H, Hf/g), 7.44 (s, 1H, Hc), 7.30 (ddd, J = 8.0, 7.2, 1.3 Hz, 
1H, Hg/f), 1.72 (s, 9H, Hl). 
 
 
7.2.5 1-(Phenylsulfonyl)-1H-indole (39) 
Indole (38) (500 mg, 4.27 mmol) was added to a 2-neck round bottom flask and dissolved in dry DMF (5 
mL). The flask was placed in an ice bath and NaH (60% dispersion in oil) (204 mg, 5.13 mmol, 1.2 equiv) 
was added slowly, forming a white slurry. To this, benzenesulfonyl chloride (0.66 mL, 5.1 mmol, 1.2 
equiv) was added drop-wise and left to stir overnight. The reaction mixture was then diluted with CH2Cl2 
(120 mL) and washed with NH4Clsat (120 mL). The organic layer collected was concentrated in vacuo and 
diluted using Et2O (50 mL). This was then washed with H2O (4 × 30 mL), brine (50 mL) and dried over 
MgSO4. The solvent was finally removed in vacuo affording 1-(phenylsulfonyl)-1H-indole (39) as an 
orange solid (612 mg, 55%). No further purification was required. The 
1
H NMR spectrum of 1-





Rf= 0.31 (EtOAc/Hexane, 1:9); 
1
H NMR (300 MHz, CDCl3) δ 7.99 (ddd, J = 8.3, 
1.8, 0.8 Hz, 1H, HAr), 7.90 – 7.84 (m, 2H, HAr), 7.56 (d, J = 3.7 Hz, 1H, HAr), 7.55 
– 7.48 (m, 2H, HAr), 7.46 – 7.37 (m, 2H, HAr), 7.31 (ddd, J = 8.3, 7.3, 1.3 Hz, 1H, 
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7.2.6 1-(Phenylsulfonyl)-1H-indole-2-carbaldehyde (40) 
Dry THF (20 mL) was added to a 2-neck round bottom flask and stirred under a N2 atmosphere. TMP 
(0.20 mL, 2.3 mmol, 1.5 equiv) was added to the flask containing THF at -78 °C, followed by the drop-
wise addition of n-BuLi (1.24 mL, 1.86 mmol, 1.2 equiv). The solution was left to stir at -78 °C for 10 
min. The dry ice acetone slurry was then replaced with an ice bath and the solution was further stirred at 
0 °C for 30 min. The solution was again cooled to -78 °C and 1-(phenylsulfonyl)-1H-indole (39) (400 mg, 
1.55 mmol) was added and stirred for 1 h. The temperature was again increased to 0 °C for 20 min after 
which the dry ice slurry was again introduced. DMF (0.20 mL, 2.32 mmol, 1.5 equiv) was added to the 
yellow reaction mixture and stirred overnight at RT. The solution was then added to a flask containing 
saturated NH4Cl (50 mL) and extracted using EtOAc (2 × 50 mL). The organic layers were combined, 
washed with brine (100 mL) and dried over MgSO4. The drying salts were then filtered and the solvent 
removed in vacuo. The crude product was purified by column chromatography (EtOAc/Hexane, 5:95). 
1-(Phenylsulfonyl)-1H-indole-2-carbaldehyde (40) was obtained as an off-white solid (160 mg, 36%). 
The 
1
H NMR spectrum of 1-(phenylsulfonyl)-1H-indole-2-carbaldehyde (40) was compared to that 




Rf= 0.35 (EtOAc/Hexane, 1:9); 
1
H NMR (600 MHz, CDCl3) δ 10.53 (s, 1H, 
Ho), 8.24 (d, J = 8.6 Hz, 1H, He/h), 7.78(d, J = 8.3 Hz, 2H, Hk), 7.63 (d, J = 7.8 




7.2.7 2-Vinyl-1H-indole (41) 
Methyltriphenylphosphonium bromide (MePPh3Br ) (7.39 g, 20.7 mmol, 6 equiv) and dry THF (140 mL) 
were added to a 2-neck round bottom flask under a N2 atmosphere.The flask was placed in an ice bath and 
n-BuLi (13.5 mL, 19.0 mmol, 5.5 equiv) was added drop-wise, using a syringe, to the solution at 0 °C. 
During this time the colour of the solution changed from white to a deep yellow. The ice bath was then 
removed and the temperature increased to 30 ºC. The solution was stirred for 30 min at this temperature 
and then placed on an ice bath again. The 1H–indole-2-carbaldehyde (35) (500 mg, 3.45 mmol) was 
dissolved in THF (20 mL). This solution was then transferred drop-wise, using a syringe, to the 
methylenetriphenylphosphorane solution at 0 ºC.  
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The ice bath was removed and the mixture was stirred overnight at RT under N2 atmosphere. Et2O (80 
mL) was added to the reaction mixture and it was washed with H2O (2 × 80 mL). The aqueous layer was 
collected and was further extracted with Et2O (2 × 50 mL). The organic layers were combined, washed 
with brine (200 mL) and dried over MgSO4. The drying salts were removed by filtration and the solvent 
was removed in vacuo. Purification was done by column chromatography (EtOAc/Hexane, 5:95) and the 
product 2-vinyl-1H-indole (41) was isolated as an off-white solid (361 mg, 74%). The 
1
H NMR spectrum 
of 2-vinyl-1H-indole (41) was compared to that reported in the literature and corresponded well.
[139] 
Rf= 0.47 (EtOAc/Hexane, 1:9); 
1
H NMR (300 MHz, CDCl3 ) δ 8.15 (s, 1H, 
Ha), 7.58 (ddd, J = 8.2, 1.1, 0.9 Hz, 1H, He/h), 7.33 (ddd, J = 8.1, 1.5, 0.9 Hz, 
1H, He/h), 7.19 (ddd, J = 8.2, 7.1, 1.5 Hz, 1H, Hf/g), 7.09 (ddd, J = 8.1, 7.1, 1.1 
Hz, 1H, Hf/g), 6.75 (dd, J = 17.8, 11.2 Hz, 1H, Hj), 6.53 (d, J = 2.1Hz, 1H, Hc), 
5.55 (d, J = 17.8 Hz, 1H, Hk), 5.27 (d, J = 11.2 Hz, 1H, Hk’). 
7.2.8 4,5,6,10c-Tetrahydropyrrolo[3,4-c]carbazole-1,3(2H,3aH)-dione (42) 
2-Vinyl-1H-indole (4) (500 mg, 3.50 mmol) and maleimide (407 mg, 4.19 mmol, 1.2 equiv) were added 
neat to a small round bottom flask. The flask was placed in an oil bath which was preheated to 190 °C. As 
the temperature increased, the compounds melted at 40 °C and then solidified. The temperature was kept 
at 190 °C for 1 h. The crude product was obtained as a dark brown highly insoluble solid (840 mg) which 
was used in the following step without further purification. 
 Mp = 160-162 ºC; Rf = 0.22 (MeOH/EtOAc/Hexane, 1:1:3); IR (ATR, 
cm
-1
): 3382, 3222 (2° amine/amide, N-H str), 2961, 2943 (alkanes C-H 
str), 1703 (carbonyl, C=O str), 756,745 (aromatics C-H); (
1
H NMR 300 
MHz, DMSO) δ 10.95 (s, 1H, Ha), 7.70 (d, J = 7.2 Hz, 1H, He/h), 7.26 (d, 
J = 7.4 Hz, 1H, Hh/e), 7.07 – 6.93 (m, 2H, Hf&g), 4.17 (d, J = 8.1 Hz, 1H, 
Hp), 3.50 – 3.42 (m, 1H, Hk/j), 3.17 (d, J = 5.1 Hz, 1H, Hl), 2.77 – 2.66 (m, 





, 241.0977, found 241.0966. 
7.2.9 Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione (43) 
4,5,6,10c-Tetrahydropyrrolo[3,4-c]carbazole-1,3(2H,3aH)-dione (7) (150 mg, 0.630 mmol) was added to 
a small round bottom flask.  
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The compound was dissolved in DMSO (7 mL) and stirred at 30 ° C under a N2 atmosphere. DDQ (286 
mg, 1.26 mmol, 2 equiv) was then added and the temperature was increased to 50 °C and stirred for 2 h. 
H2O (10 mL) was then added drop-wise and a precipitate formed. The precipitate was filtered off and 
washed with Et2O, and further dried under high vacuum to afford the desired product pyrrolo[3,4-
c]carbazole-1,3(2H,6H)-dioneas a brown solid (74 mg, 40%).  
 
Mp = 250-252 ºC; Rf = 0.84 (EtOAc); IR (ATR, cm
-1
): 3186, 3057 (2° 
amine/amide, N-H str), 1697 (carbonyl, C=O str), 1451 (aromatic C-C 
str), 740 (aromatics C-H);
1
H NMR (300 MHz, DMSO) δ12.08 (s, 1H, 
HNH), 11.12 (s, 1H, HNH), 8.82 (d, J = 8.0 Hz, 1H, He/h), 7.85 (d, J = 8.2 
Hz, 1H, Hk/j), 7.79 (d, J = 8.2 Hz, 1H, Hk/j)7.65 – 7.52 (m, 2H, He/h/f/g), 
7.32 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H, Hf/g);
 13
C NMR (300 MHz, DMSO) δ 
170.4(Cm/o), 170.3 (Cm/o),144.1 (CCar), 141.5 (CCar), 128.1 (CCar), 126.7 (CCar), 124.7 (CCar), 123.8 (CCar), 





, 237.0664, found 234.2000. 
7.2.10 tert-Butyl 2,5-dioxo-2,5-dihydro-1H-pyrrole-1-carboxylate (45) 
To a 2-neck round bottom flask, under an Ar atmosphere, was added maleimide (50 mg, 0.52 mmol) and 
di-tertiary butyl-dicarbonate (123 mg, 0.567 mmol, 1.1 equiv). The mixture was dissolved in chloroform 
(5 mL) and stirred for 5 min. A spatula tip of DMAP was then added and the solution changed colour 
from clear to brown. The reaction mixture was stirred for a further 6 h at RT. The mixture was then 
washed with NaHCO3(sat) (10 mL) followed by H2O (2 × 5 mL). The aqueous layers were combined and 
extracted with CH2Cl2 (15 mL). The organic layer was then washed with brine (30 mL) and dried over 
MgSO4. The drying salts were filtered off and the solvent was finally removed in vacuo. The crude 
product was purified by column chromatography (EtOAc/Hexane, 3:7), affording the product tert-butyl 
2,5-dioxo-2,5-dihydro-1H-pyrrole-1-carboxylate (45) as an opaque solid (68 mg, 67%). The 
1
H NMR 
spectrum of tert-butyl 2,5-dioxo-2,5-dihydro-1H-pyrrole-1-carboxylate (45) was compared to that 
reported in the literature and corresponded well.
[166] 
 
Rf= 0.64 (EtOAc/Hexane, 4:6), 
1
H NMR (300 MHz, CDCl3) δ 6.78 (s, 2H, Ha), 1.57 
(s, 9H, Hb). 
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The 2-vinyl-1H-indole (100 mg, 0.699 mmol) and Boc-maleimide (138 mg, 0.700 mmol, 1 equiv) were 
added neat to a small round bottom flask. The flask was placed in an oil bath preheated to 70 °C, and 
stirred under a N2 atmosphere for 30 min. TLC indicated some 2-vinyl-1H-indole remained unreacted. 
The crude product was purified by column chromatography (EtOAc/Hexane, 3:7) affording tert-butyl1,3-
dioxo-1,3,3a,4,5,10c-hexahydropyrrolo[3,4-c]carbazole-2(6H)-carboxylate (140 mg) as an off-white solid 
and recovering 23 mg of the starting reagent 2-vinyl-1H-indole. Yield: 59% (77% brsm). 
Mp = 266-268 ºC; Rf= 0.51 (EtOAc/Hexane, 4:6); IR (ATR, cm
-1
): 
3379 (2° amine, N-H str), 2982 (alkanes C-H str), 1755 (ester C=O str), 
1709 (carbonyl, C=O str), 738 (aromatics C-H);
1
H NMR (300 MHz, 
DMSO) δ 11.07 (s, 1H, Ha), 7.69 (d, J = 7.5 Hz, 1H, He/h), 7.29 (d, J = 
7.7 Hz, 1H, He/h), 7.11 – 6.96 (m, 2H, Hf&g), 4.33 (d, J = 8.0 Hz, 1H, Hr), 
3.74 – 3.64 (m, 1H, Hl), 2.80 – 2.67 (m, 1H, Hj), 2.64 – 2.54 (m, 1H, 
Hj/k), 2.38 – 2.27 (m, 1H, Hj/k), 1.86 (ddd, J = 16.3, 10.6, 5.2 Hz, 1H, Hk), 
1.45 (s, 9H, Hp); 
13
C NMR (300 MHz, DMSO) δ 175.7 (Cq/m), 173.4 
(Cm/q), 147.1 (Cn), 136.1 (Cindole), 135.8 (CIn), 126.8 (CIn), 121.4 (CIn), 
119.5 (CIn), 119.3 (CIn), 111.4 (CIn), 101.8 (CIn), 85.6 (Co), 40.4 (2C, Cr/l), 




, 363.1321 , found 
363.1321. 
7.2.12 (2-Bromoethoxy)(tert-butyl)dimethylsilane (55) 
Imidazole (1.3 g, 19 mmol, 1.2 equiv) was added to a 2-neck round bottom flask and dissolved in dry 
MeCN (20 mL) under a N2 atmosphere. The flask was placed in an ice bath and 2-bromoethanol (54) (2.0 
g, 16 mmol) was added to the solution, followed by tert-butyldimethylsilane (2.4 g, 18 mmol, 1.1 equiv). 
The reaction mixture was stirred at RT overnight. The white precipitate formed was filtered off and the 
solvent was removed in vacuo. The crude product was re-dissolved in EtOAc, forming more precipitate, 
which was removed by filtration. The solvent was removed in vacuo, affording the product 
(2-bromoethoxy)(tert-butyl)dimethylsilane (55) as a clear oil (3.0 g, 74 %). The 
1
H NMR spectrum of 
(2-bromoethoxy)(tert-butyl)dimethylsilane (55) was compared to that reported in the literature and 
corresponded well.
[167] 
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H NMR (300 MHz, CDCl3) δ 3.89 (t, J = 6.5 Hz, 2H, Hb), 3.39 (t, J = 6.5 Hz, 2H, Ha), 








7.2.13 Ethyl 1-{2-(tert-butyldimethylsilyloxy)ethyl}-1H-indole-2-carboxylate (56) 
A dry, 2-neck round bottom flask charged with commercially available ethyl indole-2-carboxylate (1.50 
g, 7.90 mmol) was evacuated under high vacuum and filled with Ar. Dry DMF (10 mL) was added to the 
flask which was placed in an ice bath. NaH (0.37 g, 9.5 mmol, 1.2 equiv) was added in portions at 0 ° C 
and stirred for 10 min. (2-bromoethoxy)(tert-butyl)dimethylsilane (2.10 g, 8.7 mmol, 1.1 equiv) in DMF 
(5 mL) was then added drop-wiseto the reaction mixture and stirred at 40 ° C, under N2, overnight. Upon 
completion, the mixture was cooled to RT, poured onto cold H2O (50 mL) and extracted with EtOAc (50 
mL). The organic layer was then washed with brine (80 mL), dried over MgSO4 and filtered. The solvent 
was finally removed in vacuo and the crude product was purified by column chromatography 
(EtOAc/Hexane, 5:95) affording the product ethyl 1-{2-(tert-butyldimethylsilyloxy)ethyl}-1H-indole-2 
carboxylate (56) as a clear liquid (0.27 g, 73%). 
Rf = 0.88 (EtOAc/Hexane, 2:8); IR (ATR, cm
-1
): 2957, 2929, 2857 
(alkane C-H str), 1708 (ester C=O str), 1358 (alkane C-H rock), 1252 (-
Si(CH3)2-O- str), 1220, 1196, 1080 (C-O str), 835, 777, 749 (-Si(CH3)2-
O- str); 
1
H NMR (300 MHz, CDCl3) δ 7.60 (d, J = 7.9 Hz, 1H, Hh/e), 
7.44 (d, J = 8.3 Hz, 1H, He/h), 7.22 (m, 2H, Hg/f & c), 7.08 (dd, J = 10.9, 
3.9 Hz, 1H, Hf/g), 4.64 (t, J = 5.4 Hz, 2H, Hj/k), 4.32 (q, J = 7.2 Hz, 2H, 
Hp), 3.89 (t, J = 5.4 Hz, 2H, Hk/j), 1.36 (t, J = 7.2 Hz, 3H, Hq ), 0.70 (s, 
9H, Hn), -0.26 (s, 6H, Hl); 
13
C NMR (300 MHz, CDCl3) δ 162.3 (Co), 
140.2 (CIn), 127.7 (CIn) 126.0 (CIn), 124.9 (CIn), 122.5 (CIn), 120.6 (CIn), 
111.5 (CIn), 110.8 (CIn), 63.2 (Ck/j), 60.6 (Cp/j/k), 47.0 (Cj/p), 25.9 (Cn), 18.3 (Cm), 14.5 (Cq), -5.6 (Cl); 




, 348.1995, found 348.2007. 
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7.7.14 [1-{2-(tert-Butyldimethylsilyloxy)ethyl}-1H-indol-2-yl]methanol (57) 
LiAlH4 (0.22 g, 5.8 mmol, 2 equiv) was added to a 2-neck round bottom flask under an Ar atmosphere 
and stirred in dry THF (10 mL).A solution of ethyl 1-{2-(tert-butyldimethylsilyloxy)ethyl}-1H-indole-2-
carboxylate(56)(1.0 g, 2.9 mmol) dissolved in dry THF (10 mL) was added drop wise to the LiAlH4 
solution at 0 ºC. The reaction mixture was stirred for 15 min at 0 ºC. Upon complete consumption of 
starting reagent, H2O (2 mL), NaOH (1 M, aq., 5 mL) and more H2O (6 mL) were successively added 
drop-wise. The solution became white in colour when stirred at RT for 30 min. Upon completion of the 
reaction, the solution was filtered through Celite and washed with CH2Cl2 (50 mL). The filtrate was then 
washed with brine (50 mL) and the organic layer was dried over MgSO4. Once the drying agent was 
filtered off, the product was concentrated in vacuo. The crude product was purified by column 
chromatography (EtOAc/Hexane, 2:8) affording [1-{2-(tert-butyldimethylsilyloxy)ethyl}-1H-indol-2-
yl]methanol (57) as a white solid (0.85 g, 97%).  
Mp = 66-68 ºC; Rf= 0.84 (EtOAc/Hexane, 4:6); IR (ATR, cm
-1
): 3258 (O-H 
str), 2926, 2854 (alkane C-H str), 1251(-Si(CH3)2-O- str), 1111 (C-O str), 
780, 832 (-Si(CH3)2-O- str); 
1
H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 7.8 
Hz, 1H, Hh/e), 7.40 (d, J = 8 Hz, 1H, He/f), 7.30 – 7.27 (m, 1H , Hg/f), 7.24 – 
7.18 (m, 1H, Hf/g), 6.48 (s, 1H, Hc), 4.78 (s, 2H, Ho), 4.37 (t, J = 5.2 Hz, 2H, 
Hj/k), 4.00 (t, J = 5.2 Hz, 2H, Hk/j), 3.23 (s, 1H, Hp), 0.78 (s, 9H, Hn), -0.13 (d, 
J = 3.0 Hz, 6H, Hl); 
13
C NMR (400 MHz, CDCl3) δ 139.7 (Cindole), 137.0 
(Cindole), 127.9 (Cindole), 121.9 (Cindole), 121.2 (Cindole), 119.8 (Cindole), 109.5 
(Cindole), 101.8 (Cindole), 62.2 (Ck/j), 57.0 (Co/j/k), 45.7 (Cj/o/k), 25.9 (Cn), 18.5 




, 306.1889, found 306.1889. 
7.2.15 1-{2-(tert-Butyldimethylsilyloy)ethyl}-1H-indole-2-carbaldehyde (58) 
1-{2-(Tert-butyldimethylsilyloy)ethyl}-1H-indol-2-yl)methanol (2.9 g, 9.9 mmol) was dissolved in dry 
MeCN (100 mL) in a 2-neck round bottom flask. MnO2 (8.4 g, 96 mmol, 10 equiv) was added to the 
solution and the reaction was left to proceed at RT under N2 for 8 h. The reaction mixture was then 
filtered through Celite and was washed with EtOAc (80 mL). The filtrate appears orange in colour. The 
solvent was removed in vacuo affording the product 1-{2-(tert-Butyldimethylsilyloy)ethyl}-1H-indole-2-
carbaldehyde as a light yellow oily solid (2.4 g, 83%). No further purification was required.  
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Rf = 0.79 (EtOAc/Hexane, 2:8); IR (ATR, cm
-1
): 2953, 2925,2854 (alkane C-
H str), 2804, 2726 (aldehyde H-C=O: C-H str), 1668 (aldehyde C=O str), 1249 
(-Si(CH3)2-O- str), 775, 835 (-Si(CH3)2-O- str); 
1
H NMR (300 MHz, CDCl3) 
δ 9.88 (s, 1H, Hp), 7.71 (d, J = 8.1 Hz, 1H, Hh/e), 7.52 (d, J = 8.5 Hz, 1H, He/h), 
7.39 (m, 1H, Hg/f), 7.28 (s, Hc), 7.20 – 7.11 (m, 1H, Hf/g), 4.66 (t, J = 5.2 Hz, 
2H, Hj/k), 3.95 (t, J = 5.2 Hz, 2H, Hk/j), 0.73 (s, 9H, Hn), -0.23 (s, 6H, Hl); 
13
C 
NMR (300 MHz, CDCl3) δ 182.7 (Co), 141.5 (CIn), 135.4 (CIn), 126.9 (CIn), 
126.4 (CIn), 123.22 (CIn), 121.03 (CIn), 118.26 (CIn), 111.88 (CIn), 63.16 (Ck/j), 





, 304.1733, found 304.1730 
7.2.16 1-{2-(tert-Butyldimethylsilyloxy)ethyl}-2-vinyl-1H-indole (59) 
A dry, 2-neck round bottom flask charged with MePPh3Br (5.58 g, 15.6 mmol, 6 equiv) was flushed with 
N2 and placed in an ice bath. Dry THF (80 mL) was added to the flask and allowed to stir for 10 min. n-
BuLi (9.87 mL, 14.3 mmol, 5.5 equiv) was then slowly added drop-wise using a syringe at 0 °C. During 
this time the colour of the solution changed from white to yellow. The ice bath was then removed and the 
reaction mixture was stirred for 30 min at 30 ºC. 1-{2-(tert-Butyldimethylsilyloy)ethyl}-1H-indole-2-
carbaldehyde (58) (0.79 g, 2.6 mmol) was then dissolved in THF (15 mL) and transferred drop-wise using 
a syringe to the methylenetriphenylphosphorane solution at 0 ºC.The reaction mixture was then stirred at 
RT for 8 h. Upon completion, the reaction mixture was diluted with Et2O (100 mL) and washed with H2O 
(2 × 100 mL). The combined aqueous layers were further extracted with Et2O (2 × 80 mL). The organic 
layers were then combined, washed with brine (150 mL), and dried over MgSO4. After filtration the 
solvent was finally removed in vacuo. Purification of the crude product was done by column 
chromatography (EtOAc/Hexane, 3:97) affording the product 1-{2-(tert-butyldimethylsilyloxy)ethyl}-2-
vinyl-1H-indole (59) as an opaque oil (0.62 g, 79%).  
Rf = 0.75 (EtOAc/Hexane, 1:9); IR (ATR, cm
-1
): 3052 (alkene =C-H str), 
2926, 2854 (alkane C-H str), 1251 (-Si(CH3)2-O- str), 831, 774 (-Si(CH3)2-O- 
str), 731, 662 (alkene =C-H bend); 
1
H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 
7.8 Hz, 1H, Hh/e),7.23 (d, J = 8.2 Hz, 1H, He/h), 7.09 (dd, J = 8.2, 7.0 Hz, 1H, 
Hg/f), 7.03 – 6.98 (m, 1H, Hf/g), 6.77 (dd, J = 17.4, 11.2 Hz, 1H, Ho), 6.62 (s, 
1H, Hc), 5.76 (dd, J = 17.4, 1.3 Hz, 1H, Hq’), 5.26 (dd, J = 11.2, 1.3 Hz, 1H, 
Hq), 4.20 (t, J = 6.1 Hz, 2H, Hj/k), 3.81 (t, J = 6.1 Hz, 2H, Hk/j), 0.75 (s, 9H, 
Hn), -0.21 (s, 6H, Hl); 
13
C NMR (400 MHz, CDCl3) δ 138.6 (C), 137.5 (C), 
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128.0 (C), 126.4 (C), 121.7 (C), 120.6 (C), 119.9 (C), 116.4 (C), 109.6 (C), 99.0 (C), 62.3 (Ck/j), 45.6 




, 302.1940, found 301.1941. 
7.2.17 6-{2-(tert-Butyldimethylsilyloxy)ethyl}-4,5,6,10c-tetrahydropyrrolo[3,4-c]carbazole-
1,3(2H,3aH)-dione (60) 
1-{2-(tert-butyldimethylsilyloxy)ethyl}-2-vinyl-1H-indole (190 mg, 0.630 mmol) and maleimide (73 
mg0.76 mmol, 1.2 equiv) were addedneat to a small round bottom flask. The flask was placed in an oil 
bath preheated to 190 °C and stirred for 30 min. TLC indicates some 1-{2-(tert-
butyldimethylsilyloxy)ethyl}-2-vinyl-1H-indoleremained unreacted. The crude product appears as a 
red/orange oily solid together with highly insoluble red solid. Purification by column chromatography 
(EtOAc/Hexane, 3:7) afforded 6-{2-(tert-butyldimethylsilyloxy)ethyl}-4,5,6,10c-tetrahydropyrrolo[3,4-
c]carbazole-1,3(2H,3aH)-dione (60) as a light orange solid (155 mg) and recovered 40 mg of 1-{2-(tert-
butyldimethylsilyloxy)ethyl}-2-vinyl-1H-indole (59). Yield: 62% (78% brsm). 
 
Mp = 140-142 º C; Rf = 0.21 (EtOAc/Hexane, 2:8); IR (ATR, cm
-1
): 
3181 (amide N-H str), 2951, 2928, 2854 (alkane C-H str), 1700 (carbonyl 
C=O str), 1250, 837, 778 (-Si(CH3)2-O- str); 
1
H NMR (300 MHz, 
DMSO) δ 10.95 (s, 1H, Ht), 7.73 (d, J = 7.6 Hz, 1H, He/h), 7.37 (d, J = 7.9 
Hz, 1H, Hh/e ), 7.11 – 6.97 (m, 2H, Hf & g), 4.23 – 4.14 (m, 3H, Hj/k & r/q), 
3.84 – 3.76 (m, 2H, Hk/j), 3.52 – 3.39 (m, 1H, Hr/q), 2.92 – 2.80 (m, 1H, 
Ho/p), 2.55 (m, 1H, Ho/p), 2.37 – 2.22 (m, 1H, Ho/p), 1.85 – 1.69 (m, 1H, 
Ho/p), 0.70 (s, 9H, Hn), -0.27 (s, 6H, Hl); 
13
C NMR (300 MHz, DMSO) δ 
180.3 (Cu/s), 178.6 (Cs/u), 136.5 (CIn), 136.1 (CIn), 126.3 (CIn), 120.7 (CIn), 
119.5 (CIn), 118.8 (CIn), 109.5 (CIn), 102.8 (CIn), 61.8 (Ck/j), 44.7 (Cj/k), 
40.7 (Cq/r), 40.5 (Cr/q), 25.7 (Cn), 20.9 (Cm), 18.4 (Co/p), 17.9 (Co/p), -5.8 




, 399.2104, found 399.2109. 
7.2.18 6-(2-Hydroxyethyl)-4,5,6,10c-tetrahydropyrrolo[3,4-c]carbazole-1,3(2H,3aH)-dione 
(48) 
To a dry 2-neck round bottom flask was added 6-{2-(tert-butyldimethylsilyloxy)ethyl}-4,5,6,10c-
tetrahydropyrrolo[3,4-c]carbazole-1,3(2H,3aH)-dione (60) (256 mg, 0.642 mmol) and dissolved in THF 
(8 mL). The flask was placed in an ice bath and TBAF·3H2O (1.01 g 3.21 mmol, 5 equiv) was added in 
one portion. The reaction mixture was stirred at RT under N2 atmosphere for 30 min. CH2Cl2 (20 mL) 
was added to the reaction mixture and washed with NaHCO3 (sat) (20 mL).  
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The aqueous layer was collected and extracted with CH2Cl2 (2 × 20 mL). The organic layers were then 
combined and washed with brine (50 mL) and dried over MgSO4. After filtration the solvent was finally 
removed in vacuo. The crude product was purified by column chromatography (EtOAc/Hexane, 7:3) 
affording the product6-(2-hydroxyethyl)-4,5,6,10c-tetrahydropyrrolo[3,4-c]carbazole-1,3(2H,3aH)-dione 
(48) as a yellow solid (155 mg, 86%). 
Mp = 166-169 º C; Rf = 0.39 (EtOAc/Hexane, 8:2); IR (ATR, cm
-1
): 3421 
(alcohol O-H str), 1704 (carbonyl C=O str), 740 (aromatic C-H); 
1
H NMR 
(300 MHz, DMSO) δ 10.97 (s, 1H, Hr), 7.74 (d, J = 7.5 Hz, 1H, Hh/e), 7.39 
(d, J = 7.9 Hz, 1H, He/h), 7.12 – 6.97 (m, 2H, Hf&g), 4.84 (s, 1H, Hl), 4.24 – 
4.15 (m, 1H, Hp/o), 4.10 (m, 2H, Hj/k), 3.66 – 6.57 (m, 2H, Hk/j), 3.51 – 3.42 
(m, 1H, Ho/p), 2.93 - 2.80 (d, J = 16.3 Hz, 1H, Hm/n), 2.60 – 2.52 (m, 1H, 
Hm/n), 2.35 – 2.24 (m, 1H, Hn/m), 1.90 – 1.73 (m, 1H, Hn/m);
13
C NMR (300 
MHz, DMSO) δ 180.4 (Cs/q), 178.7 (Cq/s), 136.6 (CIn) , 136.2 (CIn), 126.3 
(CIn), 120.7 (CIn), 119.5 (CIn), 118.8 (CIn), 109.4 (CIn), 102.6 (CIn), 60.1 (Ck/j), 45.1 (Cj/k), 40.7 (Co/p), 40.5 




, 285.1239, found 285.1246. 
7.2.19 6-(2-Hydroxyethyl)pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione (49) 
A 2-neck round bottom flask charged with 6-(2-hydroxyethyl)-4,5,6,10c-tetrahydropyrrolo[3,4-
c]carbazole-1,3(2H,3aH)-dione (48) (188 mg, 0.661 mmol)was evacuated under high vacuum and filled 
with Ar. Dry dioxane (15 mL) was then added, followed by MnO2 (1.26 g, 14.5 mmol, 22 equiv). The 
reaction mixture was heated at reflux under a N2 atmosphere overnight. Upon cooling to RT, the MnO2 
was removed by filtration through Celite. The solvent was then finally removed in vacuo and column 
chromatography (EtOAc/Hexane, 8:2) afforded the product 6-(2-hydroxyethyl)pyrrolo[3,4-c]carbozole-
1,3(2H,6H)-dione (49) as a yellow solid (98 mg, 53%). 
Mp = 322-324 º C; Rf = 0.57 (EtOAc/Hexane, 8:2); IR (ATR, cm
-1
): 3372 
(alcohol O-H str), 1710 (carbonyl C=O str), 747 (aromatic C-H); 
1
H NMR 
(300 MHz, DMSO) δ 11.15 (s, 1H, Hr), 8.87 (d, J = 7.8 Hz, 1H, HCar), 
8.01 (d, J = 8.3 Hz, 1H, HCar), 7.84 (d, J = 8.3 Hz, 1H, HCar), 7.75 (d, J = 
8.2 Hz, 1H, HCar), 7.62 (t, J = 7.6 Hz, 1H, Hg/f), 7.36 (t, J = 7.4 Hz, 1H, 
Hf/g), 4.90 (t, J = 4.9 Hz, 1H, Hl), 4.55 (d, J = 4.4 Hz, 2H, Hj/k), 3.82 (d, J = 
4.8 Hz, 2H, Hk/j); 
13
C NMR (300 MHz, DMSO) δ 171.0 (Cq/s), 170.9 
(Cs/q), 145.3 (CCar), 142.9 (CCar), 128.7 (CCar), 127.3 (CCar), 125.4 (CCar), 
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124.5 (CCar), 120.9 (C), 120.4 (CCar), 119.9 (CCar), 118.7 (CCar), 115.2 (CCar), 111.1 (CCar), 60.2 (Ck/j), 46.4 




, 281.0926, found 281.0937 
7.2.20 1-(2-Propynyl)-2-vinyl-1H-indole (61) 
A 2-neck round bottom flask charged with 2-vinyl-1H-indole (41) (505 mg, 3.53 mmol) was evacuated 
under high vacuum and filled with Ar. Dry DMF (80 mL) was then added followed by Cs2CO3 (3.45 g, 
10.6 mmol, 3 equiv) and propargyl bromide (1.51 g, 10.6 mmol, 3 equiv). The reaction mixture was 
stirred at 60 °C for 2 d under N2. Upon completion, the solution was diluted with EtOAc (50 mL) and 
washed with H2O (3 × 50 mL). The organic layers were combined, washed with brine (150 mL) and dried 
over MgSO4. Filtration was followed by removal of the solvent in vacuo. The crude product was purified 
by column chromatography (EtOAc/Hexane, 5:95) to obtain 1-(2-propynyl)-2-vinyl-1H-indole (61) as a 
yellow solid (0.29 g, 45%). The 
1
H NMR spectrum of 1-(2-propynyl)-2-vinyl-1H-indole (61) was 
compared to that reported in the literature and corresponded well.
[168] 
Rf= 0.68 (EtOAc/Hexane, 1:9);
1
H NMR (300 MHz, CDCl3) δ 7.59 (d, J = 7.8 
Hz, 1H, He/h), 7.38 (d, J = 8.2 Hz, 1H, Hh/e), 7.26 (m, 1H, Hf/g), 7.13 (m, 1H, 
Hg/f), 6.90 (dd, J = 17.4, 11.2,Hz, 1H, Hm), 6.73 (s, 1H, Hc), 5.86 (dd, J = 17.4, 
0.7 Hz, 1H, Hn’), 5.43 (dd, J = 11.2, 0.7 Hz, 1H, Hn), 4.90 (d, J = 2.4 Hz, 2H), 
2.31 (t, J = 2.4 Hz, 1H, Hl). 
7.2.21 6-(2-Propynyl)-4,5,6,10c-tetrahydropyrrolo[3,4-c]carbazole-1,3(2H,3aH)-dione (51) 
1-(2-Propynyl)-2-vinyl-1H-indole (61) (114 mg, 0.629 mmol) and maleimide (92 mg 0.94 mmol, 1.5 
equiv) were added neat to a small round bottom flask. The flask was placed in an oil bath preheated to 
160 °C and the mixture solidified within a few seconds. The reaction was kept at this temperature for 
30 min. TLC indicated some1-(2-propynyl)-2-vinyl-1H-indole remained unreacted. The crude product 
appeared as a brown solid (soluble in CH2Cl2) which was purified by column chromatography 
(EtOAc/Hexane, 3:7) affording 48 mg of the product 6-(2-propynyl)-4,5,6,10c-tetrahydropyrrolo[3,4-
c]carbozole-1,3(2H,3aH)-dione (51) as a light yellow solid and recovering 40 mg of the starting reagent 
1-(2-propynyl)-2-vinyl-1H-indole (61). The crude product also consists of 35 mg 6-(2-propynyl)-
4,5,6,10c-tetrahydropyrrolo[3,4-c]carbazole-1,3(2H,3aH)-dione (51) of the product as a dark brown solid 




Stellenbosch University  https://scholar.sun.ac.za




Mp = 252-254 º C; Rf= 0.45 (EtOAc/Hexane, 4:8); IR (ATR, cm
-1
): 3293 
(amide N-H str), 1700 (carbonyl C=O str), 751 (aromatic C-H), 671 
(alkyne -C≡C-H); 
1
H NMR (300 MHz, DMSO) δ 11.03 (s, 1H, Hr), 7.77 
(d, J = 7.6 Hz, 1H, He/h), 7.49 (d, J = 7.9 Hz, 1H, Hh/e), 7.20 – 7.02 (m, 
2H, Hg&f), 5.00 (s, 2H, Hj), 4.21 (d, J = 7.7 Hz, 1H, Hp/o), 3.54 – 3.42 (m, 
1H, Ho/p), 3.28 (s, 1H, Hl), 2.93 – 2.81 (m, 1H, Hm), 2.64 – 2.54 (m, 1H, 
Hm/n), 2.39 – 2.24 (m, 1H, Hn/m), 1.85 (dd, J = 14.1, 9.1 Hz, 1H, Hn/m); 
13
C 
NMR (300 MHz, DMSO) δ 180.7 (Cs/q), 179.0 (Cq/s), 136.3 (CIn), 136.1 (CIn), 126.8 (CIn), 121.7 (CIn), 
120.2 (CIn), 119.8 (CIn), 109.9 (CIn), 104.4 (CIn), 79.9 (Ck), 75.2 (Cl), 41.1 (Co/p/j), 40.9 (Cp/o/j), 32.2 (Cj/o/p), 




, 279.1134, found 279.1126. 
7.2.22 6-(2-Propynyl)pyrrolo[3,4-c]carbozole-1,3(2H,6H)-dione (52) 
To a 2-neck round bottom flask was added 6-(2-propynyl)-4,5,6,10c-tetrahydropyrrolo[3,4-c]carbozole-
1,3(2H,3aH)-dione (51) (120 mg, 0.43 mmol). Dry dioxane (15 mL) was then added followed by MnO2 
(0.825, 9.49 mmol, 22 equiv). The reaction mixture was then heated to reflux for 8 h. Upon completion 
and cooling to RT, the dioxane was removed in vacuo. The crude product was triturated with CH2Cl2 and 
acetone affording 6-(2-propynyl)pyrrolo[3,4-c]carbozole-1,3(2H,6H)-dione (52) as a yellow solid (92 mg, 
72%). No further purification was required. 
 
Mp = 278-280 ºC; Rf= 0.84 (EtOAc/Hexane, 7:3); IR (ATR, cm
-1
): 3271 
(amide N-H str), 1720, 1701 (carbonyl C=O str), 745 (aromatic C-H), 657 
(alkyne -C≡C-H); 
1
H NMR (300 MHz, DMSO) δ 11.22 (s, 1H, Hr), 8.87 
(d, J = 7.9 Hz, 1H, He/h), 8.08 (d, J = 8.3 Hz, 1H, Hn/m), 7.90 (d, J = 8.3 Hz, 
1H, Hn/m), 7.83 (d, J = 8.2 Hz, 1H, He/h), 7.67 (m, 1H, Hf/g), 7.40 (m, 1H, 
Hg/f), 5.46 (s, 2H, Hj), 3.56 (s, 1H, Hl); 
13
C NMR (300 MHz, DMSO) δ 
170.1 (Cq/s), 170.1 (Cs/q), 143.6 (CCar), 141.3 (CCar), 128.4 (CCar), 126.9 
(CCar), 125.0 (CCar), 124.7 (CCar), 121.0 (CCar), 120.1(CCar), 119.8 (CCar), 118.5 (CCar), 114.3 (CCar), 110.3 




, 275.0821 , found 
275.0316. 
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7.2.23 3-(2-Vinyl-1H-indol-1-yl)propanenitrile (62) 
A 2-neck round bottom flask charged with 2-vinyl-1H-indole (41) (750 mg, 5.24 mmol) was evacuated 
under high vacuum and filled with Ar. Dry MeCN (20 mL) was added and the solution was treated with 
acrylonitrile (2.40 mL, 36.7 mmol, 7 equiv), followed by 1.8-diazabicyclo[5.4.0]under-7-ene (20 drops). 
The reaction mixture was stirred at RT under a N2 atmosphere for 8 h. The solution was then diluted with 
H2O (30 mL) and extracted with EtOAc (30 mL). The organic layer was washed with brine (50 mL) and 
dried over MgSO4. The drying salts were then filtered off and the solvent was finally removed in vacuo. 
The crude product was purified by column chromatography (EtOAc/Hexane, 1:9) affording 3-(2-vinyl-
1H-indol-1-yl)propanenitrile (62) as an opaque solid (750 mg) and recovering 98 mg of 2-vinyl-1H-
indole (41). Yield: 73% (84% brsm). 
 
Mp = 83-85 ºC; Rf= 0.22 (EtOAc/Hexane, 1:9);IR (ATR, cm
-1
): 2247 (nitrile 
C≡N str), 786, 748 (alkene =C-H), 735(aromatic C-H); 
1
H NMR (400 MHz, 
CDCl3) δ 7.59 (d, J = 7.8 Hz, 1H, He/h), 7.29 – 7.20 (m, 2H, Hf/g&e/h), 7.16 – 
7.11 (m, 1H, Hf/g), 6.76 (dd, J = 17.3, 11.2, 1H, Hm), 6.72 (s, 1H, Hc), 5.86 (d, J 
= 17.3 Hz, 1H, Hn’ ), 5.44 (d, J = 11.2 Hz, 1H, Hn), 4.47 (t, J = 7.2 Hz, 2H, Hj), 
2.73 (t, J = 7.2 Hz, 2H, Hk); 
13
C NMR (400 MHz, CDCl3) δ 137.6 (C), 136.7 
(C), 128.4 (C), 125.0 (C), 122.6 (C), 121.2 (C), 120.8 (C), 118.1 (C), 117.1 (C), 108.8 (C), 100.8 (C), 








To a solution of 3-(2-vinyl-1H-indol-1-yl)propanenitrile (62) (280 mg, 1.43 mmol) in toluene (15 mL) 
was added maleimide (208 mg, 2.14 mmol, 1.5 equiv) and SnCl2 (5.41 mg, 0.03 mmol, 0.02 equiv). The 
reaction mixture was then heated to reflux under N2 for 16 h. Upon completion, the reaction mixture was 
allowed to reach RT. NaHCO3 (sat) (30 mL) was added to the mixture and it was extracted with CH2Cl2 (2 
× 30 mL). The combined organic layers were then washed with brine (80 mL) and dried over MgSO4. 
After filtration of the drying salts the solvent was finally removed in vacuo. The crude product was 
purified by column chromatography (EtOAc/Hexane, 1:1). 50 mg of 3-(2-vinyl-1H-indol-1-
yl)propanenitrile(62)was recovered and the product 3-{1,3-Dioxo-1,2,3,3a,4,5-hexahydropyrrolo[3,4-
c]carbazol-6(10cH)-yl}propanenitrile (50) was obtained as a yellow solid (243 mg). Yield: 58% (71% 
brsm). 
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Mp = 160-162 ºC; Rf= 0.21 (EtOAc/Hexane, 6:4); IR (ATR, cm
-1
): 2246 
(nitrile C≡N str), 1703 (carbonyl C=O), 734 (aromatic C-H); 
1
H NMR 
(300 MHz, DMSO) δ 11.02 (s, 1H, Hr), 7.76 (d, J = 7.5 Hz, 1H, He/h), 
7.51 (d, J = 8.0 Hz, 1H, Hh/e), 7.17 – 7.02 (m, 2H, Hf&g), 4.43 (t, J = 6.3 
Hz, 2H, Hj/k), 4.21 (d, J = 8.0 Hz, 1H, Hp/o), 3.54 – 3.43 (m, 1H, Ho/p), 
2.92 (t, J = 6.3 Hz, 2H, Hk/j), 2.88 – 2.82 (m, 1H, Hm), 2.67 – 2.55 (m, 1H, 
Hm/n), 2.38 – 2.25 (m, 1H, Hn/m), 1.90 – 1.75 (m, 1H, Hn/m); 
13
C NMR 
(300 MHz, DMSO) δ 180.3 (Cq/s), 178.5 (Cq/s), 135.9 (CIn/l), 135.7 (CIn/l), 
126.5 (CIn/l), 121.1 (CIn/l), 119.7 (CIn/l), 119.4 (CIn/l), 118.9 (CIn/l), 109.5 
(CIn/l), 103.7 (CIn/l), 40.6 (Co/p/j), 38.7 (Cj/o/p), 38.0 (Cp/o/j), 21.1 (Cm/n/k), 




, 294.1243, found 294.1253. 
7.2.25 3-{1,3-Dioxo-2,3-dihydropyrrolo[3,4-c]carbazol-6(1H)-yl}propanenitrile (53) 
To a 2-neck round bottom flask, under an Ar atmosphere, was added 3-{1,3-Dioxo-1,2,3,3a,4,5-
hexahydropyrrolo[3,4-c]carbazol-6(10cH)-yl}propanenitrile (490 mg, 1.67 mmol). Dry dioxane (20 mL) 
was added followed by MnO2 (3.20 g, 36.8 mmol, 22 equiv). The reaction mixture was then heated to 
reflux for 8 h under N2. Upon completion and cooling to RT, the dioxane was removed in vacuo. The 
crude product was recrystallized from DMF. The yellow solid was collected, washed with hexane, and 
dried under high vacuum (145 mg, 30 %).  
Mp = 298-300 ºC; Rf = 0.32 (EtOAc/Hexane, 6:4); IR (ATR, cm
-1
): 2251 
(nitrile C≡N str), 1716, 1697 (carbonyl C=O), 747 (aromatic C-H); 
1
H 
NMR (300 MHz, DMSO) δ 11.21 (s, 1H, Hr), 8.88 (d, J = 7.8 Hz, 1H, 
He/h), 8.16 (d, J = 8.3 Hz, 1H, He/h/m/n), 7.88 (d, J = 8.5 Hz, 2H, He/h/m/n), 
7.69 – 7.60 (m, 1H, Hf/g), 7.44 – 7.35 (m, 1H, Hf/g), 4.89 (t, J = 6.3 Hz, 
2H, Hj/k), 3.10 (t, J = 6.2 Hz, 2H, Hk/j); 
13
C NMR (300 MHz, DMSO) δ 
170.1 (Cq/s) , 170.1 (Cs/q), 143.8 (CCar), 141.4 CCar), 128.3 (CCar), 126.8 
(CCar), 124.9 (CCar), 124.5 (CCar), 120.9 (CCar), 120.0 (CCar), 119.6 (CCar), 
118.7 (CCar), 118.3 (CCar), 114.4 (CCar), 110.3 (CCar), 38.6 (Cj/k), 17.0 (Ck/j); 




, 290.0930 , found 290.0928. 
 
7.2.26 1-Benzyl-1H-pyrrole-2,5-dione (64) 
To a 2-neck round bottom flask was added maleic anhydride (280 mg, 2.86 mmol) and dissolved in 
AcOH (10 mL). Benzylamine (0.25 mL, 2.3 mmol, 0.8 equiv) was then added and the reaction mixture 
was heated to reflux for 2 h.  
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The solvent was removed under reduced pressure and the crude product was purified by column 
chromatography (EtOAc/Hexane, 3:7) affording the product 1-benzyl-1H-pyrrole-2,5-dione as a white 
solid (330 mg, 62%). The 
1
H NMR spectrum of 1-benzyl-1H-pyrrole-2,5-dionewas compared to that 




Rf= 0.85 (EtOAc/Hexane, 4:6), 
1
H NMR (300 MHz, CDCl3) δ 7.24 (m, 5H, HAr), 






7.2.27 2-Benzylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione (65) 
2-Vinyl-1H-indole (41) (96 mg, 0.67 mmol) and 1-benzyl-1H-pyrrole-2,5-dione(125 mg, 0.668 mmol, 1 
equiv) were added neat to a small round bottom flask. The flask was placed in an oil bath preheated to 
140 °C and stirred for 40 min. The crude product was dissolved in dry dioxane (10 mL) and transferred to 
a 2-neck round bottom flask. MnO2 (695 mg, 7.99 mmol, 22 equiv) was then added to the solution and 
heated to reflux for 5 h. The Mn2O was then filtered off through Celite and the solvent was finally 
removed in vacuo. The crude product was purified by column chromatography (EtOAc/Hexane, 3:7) 
affording the product 2-benzylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione (65) as a yellow solid (120 mg, 
84%). 
Mp = 257-258 ºC; Rf = 0.73 (EtOAc/Hexane, 1:1); IR (ATR, cm
-1
): 3287 
(2° amine, N-H str), 2927 (alkanes C-H str), 1683 (carbonyl, C=O str), 
749, 715, 692 (aromatics C-H); (
1
H NMR (400 MHz, DMSO) δ 12.10 (s, 
1H, Ha ), 8.79 (d, J = 7.3 Hz, 1H, He/h), 7.83 (d, J = 6.5 Hz, 2H, HCar), 7.63 
– 7.52 (m, 2H, Hf&g), 7.39 – 7.21 (m, 6H, HAr&Car), 4.82 (s, 2H, Hn); 
13
C 
NMR (400 MHz, DMSO) δ 169.4 (Cs/m), 169.4 (Cm/s), 144.9 (CAr/Car), 
142.3 (CAr/Car), 137.8 (CAr/Car), 129.3 (2C,Cq/p), 129.0 (CAr/Car), 128.1 (2C, 
Cp/q), 128.0 (CAr/Car), 126.2 (CAr/Car), 125.3 (CAr/Car), 123.1 (CAr/Car), 120.9 
(CAr/Car), 120.5 (CAr/Car), 120.4 (CAr/Car), 119.1 (CAr/Car), 116.3 (CAr/Car), 
112.4 (CAr/Car), 41.4 (Cn); HRMS: calcd for C21H15N2O2
+
 [M+H], 327.1134, found 327.1131. 
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A 2-neck round bottom flask charged with 2-benzylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione (65) 
(60 mg, 0.18 mmol) was evacuated under high vacuum and filled with Ar. Dry benzene (2 mL) was added 
and the solution was treated with NaOH (50%, 1 mL), followed by tetra-N-butyl ammonium hydrogen 
sulfate (31 mg, 0.092 mmol, 0.5 equiv). The colour of the solution changed from yellow to dark red. 3-
bromopropionitrile (0.02 mL, 0.2 mmol, 1.1 equiv) was then added and the reaction mixture was stirred 
for 14 h at RT. On addition of the bromopropionitrile, the colour of the solution changed to yellow, then 
red and finally to orange. Once completed, the reaction mixture was diluted in CH2Cl2 (5 mL), washed 
with brine (10 mL) and dried over MgSO4. The drying salts were filtered off and the solvent was finally 
removed in vacuo. The crude product was purified by column chromatography (EtOAc/Hexane, 3:7) 
affording the product 3-{2-benzyl-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbazol-6(1H)-yl}propanenitrile 
(66)as a yellow solid (42 mg, 60 %). 
 
Mp = 200-202 ºC; Rf= 0.69 (EtOAc/Hexane, 4:6); IR (ATR, cm
-1
): 2949 
(alkanes C-H str), 2251 (nitrile C≡N str), 1696 (carbonyl, C=O str), 744, 
702 (aromatics C-H); 
1
H NMR (400 MHz, DMSO) δ 8.81 (dd, J = 7.8, 
4.0 Hz, 1H, He/h), 8.10 (dd, J = 8.3, 4.5 Hz, 1H, He/h), 7.89 (dd, J = 8.3, 4.5 
Hz, 1H, Hg/h), 7.83 (dd, J = 7.8, 4.5 Hz, 1H, Hg/h), 7.63 (dd, J = 11.7, 7.4 
Hz, 1H, Hk/j), 7.42 – 7.30 (m, 5H, HAr), 7.29 –7.23 (m, 1H, Hk/j), 4.91 – 
4.76 (m, 4H, Hu&n), 3.13 – 3.04 (m, 2H, Hv); 
13
C NMR (400 MHz, 
DMSO) δ 169.1 (Cs/m), 169.1 (Cm/s), 144.6 (CAr/Car), 142.1 (CAr/Car), 137.7 
(CAr/Car), 129.3 (2C, Cq/p), 129.2 (2C, Cp/q), 128.1 (CAr/Car), 128.1 (CAr/Car), 
126.2 (CAr/Car), 125.5 (CAr/Car), 123.8 (CAr/Car), 121.6 (CAr/Car), 120.5 
(CAr/Car), 120.5 (CAr/Car), 119.4 (CAr/Car), 119.2 (CAr/Car), 115.0 (CAr/Car), 
111.0 (CAr/Car), 65.7 (CAr/Car), 41.5 (Cu/n), 39.2 (Cn/u), 18.6 (CAr/Car), 17.7 
(Cv); HRMS: calcd for C24H18N3O2
+
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7.3 Experimental work pertaining to chapter 4 
7.3.1 Synthesis of the ‘double click’ products using NH-maleimides 
7.3.1.1 3,4-Dichlorofuran-2,5-dione (69) 
A 2-neck round bottom flask charged with maleic anhydride (68) (2.00 g, 20.4 mmol) was evacuated 
under high vacuum and filled with Ar (× 3). SOCl2 (20 mL) was added to the flask and it was placed in an 
ice bath. The reaction mixture was stirred under a N2 atmosphere while adding pyridine (3.31 g, 41.8 
mmol, 2.05 equiv) drop-wise to the solution at 0 °C. During this time the colour of the solution changed 
from orange to dark brown as more pyridine was added. The ice bath was then removed and the 
temperature increased to 75 °C. The reaction mixture was stirred at this temperature for 20 min. Upon 
removal of the SOCl2in vacuo, a solid residue formed. The solid was then triturated with benzene (× 4) 
and filtered. The benzene filtrate was collected and the solvent removed under reduced pressure. The 
product 3,4-dichlorofuran-2,5-dione (69) was obtained as a yellow solid (2.39 g, 70%) which required no 
further purification. The 
13
C NMR spectrum of 3,4-dichlorofuran-2,5-dione (69) was compared to that 





C NMR (400 MHz, DMSO) δ 162.0 (2C, Cb), 130.4 (2C, Ca). 
 
 
7.3.1.2 3,4-Dichloro-1H-pyrrole-2,5-dione (70) 
3,4-Dichlorofuran-2,5-dione (69) (1.50 g, 8.98 mmol), urea (567 mg, 9.43 mmol, 1.05 equiv) and NaCl 
(1.84 g, 31. 4 mmol, 3.5 equiv) were added to a mortar and mixed by grinding the solids together with a 
pestle.The mixture was added to a round bottom flask and reacted under N2 atmosphere. The flask was 
placed in an oil bath and the temperature increased to 120 °C. As the temperature increased, the solids 
fused together. The reaction mixture was left at this temperature for 20 min followed by a methanol-water 
(2:1 v/v) recrystallization. The precipitate was collected and washed with hexane, affording the product 
3,4-dichloro-1H-pyrrole-2,5-dione as a brown solid (855 mg, 57%). No further purification was required. 
The 
1
H NMR spectrum of 3,4-dichloro-1H-pyrrole-2,5-dione (70) was compared to that reported in 




Rf= 0.22 (EtOAc/Hexane, 1:9); 
1
H NMR (400 MHz, DMSO) δ 11.71 (s, Hc).
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7.3.1.3 3-Azido-4-chloro-1H-pyrrolo -2,5-dione (71) 
3,4-Dichloro-1H-pyrrole-2,5-dione (70) (200 mg, 1.21 mmol) was added to a 2-neck round bottom flask 
and dissolved in acetone (12 mL). NaN3 (78.3 mg, 1.21 mmol, 1 equiv) was dissolved in H2O (3 mL) and 
added to the flask. The reaction mixture was stirred at RT overnight under a N2 atmosphere. Upon 
completion, the acetone was removed in vacuo. The solution was then diluted with H2O (15 mL) and 
extracted with CH2Cl2 (2 × 15 mL). The organic layers were combined, washed with brine (30 mL) and 
dried over MgSO4. The drying salts were then filtered off and the solvent was finally removed under 
reduced pressure. The crude product was purified by column chromatography (EtOAc/Hexane, 1:9) 
affording the product 3-azido-4-chloro-1H-pyrrolo -2,5-dione (71) as a light yellow solid (164 mg, 79%).  
 
Mp = 125-127 ºC; Rf= 0.39 (EtOAc/Hexane, 2:8); IR (ATR, cm
-1
): 3199 (N-H str), 
2149 (N3 str), 1714 (C=O str), 659 (C-Cl str); 
1
H NMR (400 MHz, DMSO) δ 11.46 
(s, Hc); 
13
C NMR (400 MHz, DMSO) δ 165.1 (Cb/d), 164.9 (Cb/d), 136.7 (Ce), 111.0 




, 172.9866, found 172.9700. 
 
7.3.1.4 3,4-Diazido-1H-pyrrolo -2,5-dione (72) 
3,4-Dichloro-1H-pyrrole-2,5-dione (70) (120 mg, 0.723 mmol) was added to a 2-neck round bottom flask 
and dissolved in acetone (8 mL). NaN3 (141 mg, 2.17 mmol, 3 equiv) was dissolved in H2O (2 mL) and 
added to the flask. The reaction mixture was stirred at RT overnight under a N2 atmosphere. Upon 
completion, the acetone was removed in vacuo. The solution was then diluted with H2O (15 mL) and 
extracted with CH2Cl2 (2 × 15 mL). The organic layers were combined, washed with brine (30 mL) and 
dried over MgSO4. The drying salts were then filtered off and the solvent was finally removed under 
reduced pressure. The crude product was purified by column chromatography (EtOAc/Hexane, 1:9) 
affording the product 3,4-diazido-1H-pyrrolo -2,5-dione (72) as a yellow solid (86 mg, 66%).  
 
Mp = 105-106 ºC; Rf = 0.46 (EtOAc/Hexane, 2:8); IR (ATR, cm
-1
): 3209 (N-H str), 
2088 (N3 str), 1699 (C=O str);
1
H NMR (400 MHz, DMSO) δ 11.28 (s, Hc); 
13
C 





, 180.0270. The MS technique utilized did not result in detection of the 
molecular ion of compound 72. 
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7.3.1.5 3,4-bis(4-Phenyl-1H-1,2,3-triazol-1-yl)-1H-pyrrole-2,5-dione (73) 
3,4-Diazido-1H-pyrrolo-2,5-dione (72) (56 mg, 0.31 mmol) and phenyl acetylene (0.14 mL, 1.3 mmol, 
4 equiv) were added to a 2-neck round bottom flask and dissolved in MeOH (2 mL). CuSO4•5H2O (6.2 
mg, 0.025 mmol, 0.08 equiv) and Na ascorbate (50 mg, 0.25 mmol, 0.8 equiv) were then dissolved in H2O 
(1 mL) and added to the reaction mixture. The solution became cloudy in colour and was stirred for 2 d at 
40 °C under a N2 atmosphere. During this time, TLC monitoring indicated unreacted starting reagents and 
no further reaction of the materials could be observed at longer reaction time. The MeOH was then 
removed in vacuo and the reaction mixture was diluted with CH2Cl2 (10 mL). The solution was then 
washed with H2O (5 mL), NH4Cl(sat) (5 mL), brine (20 mL) and dried over MgSO4. Filtration of the drying 
salts was followed by removal of the solvent under reduced pressure. Column chromatography 
(EtOAc/Hexane, 2:8) afforded trace amounts of the product 3,4-bis(4-Phenyl-1H-1,2,3-triazol-1-yl)-1H-
pyrrole-2,5-dione (73) as a yellow solid.  
 
Rf = 0.29 (EtOAc/Hexane, 2:8);
1
H NMR (300 MHz, 
DMSO) δ 11.28 (s, 1H, Hc), 8.75 (s, 2H, Hd), 7.93 (d, 
J = 7.5 Hz, 4H, Hg), 7.84 – 7.28 (m, 6H, Hh&i);
 13
C 
NMR (300 MHz, DMSO) δ 167.3 (2C, Cb), 140.6 
(2C, Cd), 130.3 (2C), 128.9 (4C, Cg/h), 128.1 (2C), 




7.3.2 Synthesis of the ‘double click’ product using NMe-maleimides 
7.3.2.1 3,4-Dichloro-1-methyl-1H-pyrrole-2,5-dione (75) 
To a 2-neck round bottom flask was added 3,4-dichlorofuran-2,5-dione(69) (300 mg, 1.80 mmol) and 
glacial acetic acid (15 mL). The solution was stirred under a N2 atmosphere and the flask was placed in an 
ice bath. Methylamine hydrochloride (133 mg, 1.98 mmol, 1.1 equiv) followed by NaOMe (107 mg, 1.98 
mmol, 1.1 equiv) were then added to the solution. The reaction mixture was heated to reflux and stirred 
for 4 h. Once the reaction mixture cooled to RT the solution appeared orange in colour with some 
precipitate formation. The acetic acid was then removed in vacuo and EtOAc (15 mL) was added to the 
reaction mixture.  
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The solution was then washed with H2O (15 mL) and the aqueous layer extracted with EtOAc (2 × 15 
mL). The organic layers were combined, washed with brine (30 mL) and dried over MgSO4. The drying 
salts were then filtered off and the solvent was finally removed under reduced pressure. The crude 
product was purified by column chromatography (EtOAc/Hexane, 1:9) affording the product 3,4-
dichloro-1-methyl-1H-pyrrole-2,5-dione (75) as an off-white solid (201 mg, 62%). The 
1
H NMR 





Rf = 0.51 (EtOAc/Hexane, 1:9);
1






7.3.2.2 3-Azido-4-chloro-1-methyl-1H-pyrrole-2,5-dione (76) 
3,4-dichloro-1-methyl-1H-pyrrole-2,5-dione (75) (200 mg, 1.11 mmol) was added to a 2-neck round 
bottom flask and dissolved in acetone (4 ml). NaN3 (72.2 mg, 1.11 mmol, 1 equiv) was dissolved in H2O 
(1 mL) and added to the flask. The reaction mixture was stirred at RT overnight under a N2 atmosphere. 
Upon completion, the acetone was removed in vacuo. The solution was then diluted with H2O (10 mL) 
and extracted with CH2Cl2 (2 × 15 mL). The organic layers were combined, washed with brine (30 mL) 
and dried over MgSO4. The drying salts were then filtered off and the solvent was finally removed under 
reduced pressure. The crude product was purified by column chromatography (EtOAc/Hexane, 1:9) 
affording the product 3-azido-4-chloro-1-methyl-1H-pyrrole-2,5-dione (76) as an off-white solid (189 mg, 
98%).  
Mp = 110-112 ºC; Rf = 0.58 (EtOAc/Hexane, 2:8); IR (ATR, cm
-1
): 2149, 2115 (N3 
str), 1705 (C=O str), 1642 (alkene C=C str), 733 (C-Cl str);
 1
H NMR (400 MHz, 
CDCl3) δ 3.07 (s, 3H, H-NMe).
13
C NMR (400 MHz, CDCl3) δ 164.2 (Cb/d), 164.1 





187.0023. The MS technique utilized did not result in detection of the molecular ion 
of compound 76. 
7.3.2.3 3,4-Diazido-1-methyl-1H-pyrrole-2,5-dione (77) 
3,4-Dichloro-1-methyl-1H-pyrrole-2,5-dione (75) (200 mg, 1.15 mmol) was added to a 2-neck round 
bottom flask and dissolved in acetone (4 mL). NaN3 (225 mg, 3.46 mmol, 3 equiv) was dissolved in H2O 
(1 mL) and added to the flask.  
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The reaction mixture was stirred at RT overnight under a N2 atmosphere. Upon completion, the acetone 
was removed in vacuo. The solution was then diluted with H2O (10 mL) and extracted with CH2Cl2 (2 × 
15 mL). The organic layers were combined, washed with brine (30 mL) and dried over MgSO4. The 
drying salts were then filtered off and the solvent was finally removed under reduced pressure. The crude 
product was purified by column chromatography (EtOAc/Hexane, 1:9) affording the product 3,4-diazido-
1-methyl-1H-pyrrole-2,5-dione (77) as a yellow solid (146 mg, 68 %).  
 
Mp = 55-58 ºC; Rf = 0.58 (EtOAc/Hexane, 2:8); IR (ATR, cm
-1
): 2096, 2049(N3 
str);
1
H NMR (300 MHz, CDCl3) δ 3.02 (s, 3H, Hc);
13
C NMR (300 MHz, CDCl3) δ 





, 138.0304, found 138.0315. 
 
 
7.3.2.4 1-Methyl-3,4-bis(4-phenyl-1H-1,2,3-triazol-1-yl)-1H-pyrrole-2,5-dione (78) 
3,4-Diazido-1-methyl-1H-pyrrole-2,5-dione (77)(50 mg, 0.26 mmol) and phenyl acetylene (0.06 mL, 1.3 
mmol, 2.2 equiv) were added to a 2-neck round bottom flask and dissolved in MeOH (2 mL). 
CuSO4.5H2O (2.6 mg, 0.010 mmol, 0.04 equiv) and Na ascorbate (21 mg, 0.10 mmol, 0.4 equiv) were 
then dissolved in H2O (1 mL) and added to the reaction mixture. The solution became cloudy in colour 
and was stirred for 2 d at 40 °C under a N2 atmosphere. During this time, TLC monitoring indicated 
unreacted starting reagents and no further reaction of the materials could be observed at longer reaction 
times. The MeOH was removed in vacuo and the reaction mixture was diluted with CH2Cl2 (10 mL). The 
solution was then washed with H2O (5 mL), NH4Cl (sat) (5 mL), brine (10 mL) and dried over MgSO4. 
Filtration of the drying salts was followed by removal of the solvent under reduced pressure. Column 
chromatography (EtOAc/Hexane, 4:6) afforded trace amounts of the product 1-methyl-3,4-bis(4-phenyl-
1H-1,2,3-triazol-1-yl)-1H-pyrrole-2,5-dione (78) as a yellow solid.  
Rf = 0.33 (EtOAc/Hexane, 1:1);
1
H NMR (400 MHz, 
CDCl3) δ 8.75 (s, 2H, Hd), 7.94 (d, J = 7.0 Hz, 4H, 
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7.3.3 Synthesis of the ‘double click’ product using dialkynylated maleimides 
7.3.3.1 3,4-Dibromomaleic anhydride (79) 
A solution of maleic anhydride (68) (750 mg, 7.65 mmol), AlCl3 (14 mg, 0.11 mmol, 0.014 equiv), and 
Br2 (0.750 mL, 15.3 mmol, 2 equiv) was added to a Schlenk tube under an Ar atmosphere and sealed. The 
flask was placed in an oil bath preheated to 120 ° C and stirred for 16 h. The reaction mixture was left to 
reach RT and diluted with EtOAc (30 mL). It was then filtered and the filtrate was concentrated in vacuo. 
CHCl2 (20 mL) was then added and the product (79) precipitated as a white solid (1.402 g, 72%). The 
1
H 
NMR spectrum of 3,4-dibromomaleic anhydride (79) was compared to that reported in literature and 
corresponded well. 
13
C NMR (300 MHz, DMSO) δ 167.6 (2C, Cb), 163.2 (2C, Ca). 
 
 
7.3.3.2 1-Benzyl-3,4-dibromo-1H-pyrrole-2,5-dione (80) 
3,4-Dibromomaleic anhydride (79) (1.35 g, 5.28 mmol) was added to a 2-neck round bottom flask and 
dissolved in AcOH (10 mL). Benzylamine (0.63 mL, 5.8 mmol, 1.1 equiv) was slowly added to the 
solution while stirring at RT. The reaction mixture was then heated to reflux for 3 h under a N2 
atmosphere. The solvent was finally removed in vacuo and the crude product was purified by column 
chromatography (EtOAc/Hexane, 5:95) affording the product 1-benzyl-3,4-dibromo-1H-pyrrole-2,5-
dione (80) as a white solid (993 mg, 55%). The 
1
H NMR spectrum of 1-benzyl-3,4-dibromo-1H-pyrrole-
2,5-dione (80) was compared to that reported in literature and corresponded well.
[187] 
Rf = 0.69 (EtOAc/Hexane, 2:8); 
1
H NMR (400 MHz, DMSO) δ 7.44 - 7.3 (m, 5H, 
HAr), 4.8 (s, 2H, Hc). IR (ATR, cm
-1
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7.3.3.3 1-Benzyl-3,4-bis{(trimethylsilyl)ethynyl}-1H-pyrrole-2,5-dione (81) 
To a dry Schlenk tube was added dry THF (8 mL) and DIPEA (0.5 mL). Standard freeze-pump-thaw 
techniques were employed, followed by degassing with N2 to ensure an inert, O2 free environment. 
1-Benzyl-3,4-dibromo-1H-pyrrole-2,5-dione (80) (400 mg, 1.60 mmol), PdCl2(PPh3)2 (41 mg, 0.058 
mmol, 0.05 equiv) and CuI (22 mg, 0.12 mmol, 0.1 equiv) were then added successively to the Schlenk 
tube and stirred for 5 min. TMSA (0.41 mL, 2.9 mmol, 2.5 equiv) was then added to the solution and the 
reaction mixture was stirred at RT overnight under a N2 atmosphere. The solution was then washed with 
H2O (20 mL), followed by NH4Cl(sat) (20 mL). The aqueous layers were combined and extracted with 
EtOAc (2 × 30 mL). The combined organic layers were then washed with brine (80 mL) and dried over 
MgSO4. The drying slats were removed by filtration and the solvent was finally removed in vacuo. The 
crude product was purified by column chromatography (EtOAc/Hexane, 1:9) to obtain the desired product 
1-benzyl-3,4-bis{(trimethylsilyl)ethynyl}-1H-pyrrole-2,5-dione (81)as a light yellow solid (304 mg, 
68%). The 
1
H NMR spectrum of 1-benzyl-3,4-bis{(trimethylsilyl)ethynyl}-1H-pyrrole-2,5-dione (81) was 
compared to that reported in literature and corresponded well.
[176] 
Rf = 0.75 (EtOAc/Hexane, 2:8); 
1
H NMR (300 MHz, DMSO) δ 7.07 – 









7.3.3.4 1-Methyl-3,4-bis{(trimethylsilyl)ethynyl}-1H-pyrrole-2,5-dione (83) 
To a dry Schlenk tube was added dry THF (5 mL) and dry TEA (20 mL). Standard freeze-pump-thaw 
techniques were employed, followed by degassing with N2 to ensure an inert, O2 free environment. 3,4-
Dichloro-1-methyl-1H-pyrrole-2,5-dione (75) (150 mg, 0.833 mmol), PdCl2(PPh3)2 (37 mg, 0.042 mmol, 
0.05 equiv) and CuI (16 mg, 0.083 mmol, 0.1 equiv) were then added successively to the Schlenk tube 
and stirred for 5 min. TMSA (327 mg, 3.33 mmol, 4 equiv) was then added to the solution and the 
reaction mixture was stirred at RT overnight under a N2 environment.  
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The solution was then washed with H2O (50 mL), followed by NH4Cl (sat) (50 mL). The aqueous layers 
were combined and extracted with EtOAc (2 × 50 mL). The combined organic layers were washed with 
brine (100 mL) and dried over MgSO4. After filtration the solvent was finally removed in vacuo. The 
crude product was purified by column chromatography (EtOAc/Hexane, 5:95) affording the product 1-
methyl-3,4-bis{(trimethylsilyl)ethynyl}-1H-pyrrole-2,5-dione (83) as a brown oily solid (108 mg, 43%).  
Rf = 0.63 (EtOAc/Hexane, 1:9); 
1
H NMR (300 MHz, DMSO) δ 2.87 (s, 
1H, Hc), 0.26 (s, 18H, Hf); 
13
C NMR (300 MHz, DMSO) δ 166.3 (Cb), 






7.3.3.5 3,4-bis(1-Benzyl-1H-1,2,3-triazol-4-yl)-1-methyl-1H-pyrrole-2,5-dione (84) 
To a 2-neck round bottom flask was added 1-methyl-3,4-bis{(trimethylsilyl)ethynyl}-1H-pyrrole-2,5-
dione (83) (100 mg, 0.330 mmol) and dissolved in THF/MeOH (1:1, 6 mL). TBAF (1 M in THF) (174 
mg, 0.666 mmol, 2.02 equiv) was then added to the solution and stirred under N2 for 1 h. The reaction 
mixture was then treated with benzyl azide (87.8 mg, 0.659 mmol, 2 equiv), CuSO4.5H2O (3.3 mg, 0.013 
mmol, 0.04 equiv) and Na ascorbate (26 mg, 0.13 mmol, 0.4 equiv) and stirred overnight at RT under a 
N2 atmosphere. Upon completion of the reaction, the solvent was removed under reduced pressure. The 
reaction mixture was then diluted with EtOAc (10 mL) and washed with NH4Cl(sat) (2 × 10 mL), brine 
(20 mL) and dried over MgSO4. Filtration of the drying salts was followed by removal of the solvent in 
vacuo. Column chromatography (EtOAc/Hexane, 2:8) afforded the product 3,4-bis(1-benzyl-1H-1,2,3-
triazol-4-yl)-1-methyl-1H-pyrrole-2,5-dione (84) as a brown solid (7 mg, 5%).  
Rf = 0.52 (EtOAc/Hexane, 2:8);
1
H NMR (300 MHz, DMSO) δ 
8.62 (s, 2H, He), 7.84 (d, J = 7.8 Hz, 4H, Hh), 7.46 – 7.29 (m, 
6H, Hh,i&j), 5.64 (s, 4H, Hf ) Hc not found (masked by H2O peak); 
13
C NMR (300 MHz, DMSO) δ146.7 (2C, CAr/b), 136.0 (2C, 
CAr), 130.7 (2C), 128.9 (4C, Ch/i), 128.8 (4C, Ch/i), 128.2 (2C, 
CAr/e/d/a), 127.9 (4C, CAr/e/d/a), 125.2 (4C, CAr//e/d/a), 121.5 (2C, 
CAr/e/d/a), 53.0 (2C, Cf). 
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7.3.4 Synthesis of the click products using indolylmaleimides 
7.3.4.1 1-Benzyl-3,4-dichloro-1H-pyrrole-2,5-dione (85) 
A 2-neck round-bottomed flask was charged with 3,4-dichlorofuran-2,5-dione (69) (1.14 g, 6.83 mmol) 
and dissolved in AcOH (20 mL). The solution was then treated with benzylamine (804.90 mg, 7.51, 
1.1 equiv) and heated to reflux for 2 h. Upon completion the AcOH was removed under reduced pressure. 
The crude product was then purified by column chromatography (EtOAc/Hexane, 5:95) to afford the 
product 1-benzyl-3,4-dichloro-1H-pyrrole-2,5-dione (85) as an off-white solid. The 
1
H NMR spectrum of 
the product 1-benzyl-3,4-dichloro-1H-pyrrole-2,5-dione (85) was compared to that reported in literature 
and corresponded well.
[202] 
Rf = 0.41 (EtOAc/Hexane, 1:9);
1
H NMR (300 MHz, CDCl3) δ 4.73 (s, 2H, 







7.3.4.2 3-Chloro-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione (86) 
Indole (600 mg, 4.89 mmol, 1.1 equiv) and dry THF (20 mL) were added to a Schlenk tube. 3,4-Dichloro-
1-methyl-1H-pyrrole-2,5-dione (75) (800 mg, 4.45 mmol) was dissolved in another Schlenk tube in dry 
THF (15 mL). Standard freeze-pump-thaw techniques were employed to both THF solutions, followed by 
degassing with N2 to ensure an inert, O2 free environment. EtMgBr (1.66 mL, 4.98 mmol, 1.12 equiv) was 
then added drop-wise to the indole solution at 0 °C. The colour of the solution changed from clear to 
yellow on addition of the EtMgBr. After stirring for 1 h at 60 °C, the solution of 3,4-dichloro-1-methyl-
1H-pyrrole-2,5-dione (75) was added to the reaction mixture and the colour became dark red. The 
temperature was further increased to 65 °C and the mixture was stirred for 2 h. H2O (30 mL) was then 
added to the reaction mixture and it was extracted with EtOAc (2 × 30 mL). The organic layers were 
combined, washed with NH4Cl (sat), brine and dried over MgSO4. Filtration of the drying salts was 
followed by removal of the solvent in vacuo. The crude product was purified by column chromatography 
(EtOAc/Hexane, 1:9) to obtain the desired product 3-chloro-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-
dione (86) as an orange solid (679 mg, 57%). The 
1
H NMR spectrum of 3-chloro-4-(1H-indol-3-yl)-1-
methyl-1H-pyrrole-2,5-dione (86) was compared to that reported in literature and corresponded well.
[86] 
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Rf = 0.22 (EtOAc/Hexane, 2:8); 
1
H NMR (400 MHz, DMSO) δ 12.14 (s, 1H, 
Hm), 8.08 (d, J = 2.9 Hz, 1H, Hn), 7.93 (d, J = 8.0 Hz, 1H, Hk/h), 7.52 (d, J = 8.0 






7.3.4.3 1-Benzyl-3-chloro-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione (87) 
Indole (383 mg, 3.12 mmol, 1.1 equiv) and dry THF (12 mL) were added to a Schlenk tube. 1-Benzyl-
3,4-dichloro-1H-pyrrole-2,5-dione (85) (730 mg, 2.84 mmol) was dissolved in another Schlenk tube in 
dry THF (12 mL).Standard freeze-pump-thaw techniques were employed to both THF solutions, followed 
by degassing with N2 to ensure an inert, O2 free environment. EtMgBr (1.06 mL, 3.18 mmol, 1.12 equiv) 
was then added drop-wise to the indole solution at 0 °C. The colour of the solution changed from clear to 
yellow on addition of the EtMgBr. After stirring for 1 h at 60 °C, the solution of 1-benzyl-3,4-dichloro-
1H-pyrrole-2,5-dione (85) was added to the reaction mixture and the colour became dark red. The 
temperature was further increased to 65 °C and the mixture was stirred for 2 h. H2O (30 mL) was then 
added to the reaction mixture and it was extracted with EtOAc (2 × 30 mL). The organic layers were 
combined, washed with NH4Cl(sat), brine and dried over MgSO4. Filtration of the drying salts was 
followed by removal of the solvent in vacuo. The crude product was purified by column chromatography 
(EtOAc/Hexane, 1:9) to obtain the desired product 1-benzyl-3-chloro-4-(1H-indol-3-yl)-1H-pyrrole-2,5-
dione (87) as a red solid (410 mg, 43%). 
Mp = 198-200 º C; Rf = 0.24 (EtOAc/Hexane, 2:8); IR (ATR, cm
-1
): 3279 
(N-H str), 2917 (alkane C-H str), 1696 (C=O str), 1594 (Ar C-C str), 736 (Ar 
C-H), 696 (C-Cl str). 
1
H NMR (400 MHz, DMSO) δ 12.18 (s, 1H, Hq), 8.12 
(d, J = 4.5 Hz, 1H, Hr), 7.95 (dd, J = 7.8, 4.5 Hz, 1H, Hl/o), 7.52 (dd, J = 7.8, 
4.6 Hz, 1H, Ho/l), 7.38 – 7.27 (m, 5H, HAr), 7.25 – 7.21 (m, 1H, Hm/n), 7.20 – 
7.13 (m, 1H, Hm/n), 4.73 (s, 2H, Hc).
13
C NMR (400 MHz, DMSO) δ 168.4 
(Ch/b), 165.9 (Cb/h), 136.6 (C), 133.5 (C), 131.7 (C), 128.6 (2C, Cf/e), 127.5 
(C), 127.4 (2C, Ce/f), 124.7 (C), 122.7 (C), 122.1 (C), 121.5 (C), 120.7 (C), 





337.0744, found 337.0736. 
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7.3.4.4 3-(1H-Indol-3-yl)-1-methyl-4-{(trimethylsilyl)ethynyl}-1H-pyrrole-2,5-dione (88) 
To a dry Schlenk tube was added dry THF (3 mL) and TEA (9 mL). Standard freeze-pump-thaw 
techniques were employed, followed by degassing with N2 to ensure an inert, O2 free environment. 
3-Chloro-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione (86) (100 mg, 0.376 mmol), PdCl2(PPh3)2 (26 
mg, 0.038 mmol, 0.1 equiv) and CuI (7.1 mg, 0.038 mmol, 0.1 equiv) were then added successively to the 
Schlenk tube and stirred for 5 min. TMSA (0.11 mL, 0.77 mmol, 2.05 equiv) was then added to the 
solution and the reaction mixture was stirred at RT overnight. NH4Cl(sat) (20 mL) was added to the 
reaction mixture and it was extracted with ether (3 × 20 mL). The combined organic layers were then 
washed with brine and dried over MgSO4. The drying slats were removed by filtration and the solvent 
removed in vacuo. The crude product was purified by column chromatography (EtOAc/Hexane, 3:7) to 
obtain the desired product 3-(1H-indol-3-yl)-1-methyl-4-{(trimethylsilyl)ethynyl}-1H-pyrrole-2,5-dione 
(88) as a red solid (105 mg, 87%). The 
1
H NMR spectrum of 3-(1H-indol-3-yl)-1-methyl-4-
{(trimethylsilyl)ethynyl}-1H-pyrrole-2,5-dione (88) was compared to that reported in literature and 
corresponded well.
[86] 
Rf = 0.44 (EtOAc/Hexane, 4:6); 
1
H NMR (300 MHz, DMSO) δ 
12.29 (s, 1H, Hm), 8.34 – 8.29 (m, 2H, Hn/h/k), 7.52 (d, J = 8.0 Hz, 1H, 






7.3.4.5 1-Benzyl-3-(1H-indol-3-yl)-4-{(trimethylsilyl)ethynyl}-1H-pyrrole-2,5-dione (89) 
To a dry Schlenk tube was added dry THF (12 mL) and TEA (50 mL). Standard freeze-pump-thaw 
techniques were employed, followed by degassing with N2 to ensure an inert, O2 free environment. 
1-Benzyl-3-chloro-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione (87) (738 mg, 2.19 mmol), PdCl2(PPh3)2 (154 
mg, 0.219 mmol, 0.1 equiv) and CuI (42 mg, 0.22 mmol, 0.1 equiv) were then added successively to the 
Schlenk tube and stirred for 5 min. TMSA (0.64 mL, 4.5 mmol, 2.05 equiv) was then added to the 
solution and the reaction mixture was stirred at RT overnight. NH4Cl(sat) (50 mL) was added to the 
reaction mixture and it was extracted with ether (3 × 50 mL). The combined organic layers were then 
washed with brine and dried over MgSO4. The drying salts were removed by filtration and the solvent 
removed in vacuo.  
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The crude product was purified by column chromatography (EtOAc/Hexane, 3:7) to obtain the desired 
product 1-benzyl-3-(1H-indol-3-yl)-4-{(trimethylsilyl)ethynyl}-1H-pyrrole-2,5-dione (89) as a red solid 
(712 mg, 83%).  
 
Mp = 182-184 ºC; Rf = 0.35 (EtOAc/Hexane, 3:7); IR (ATR, cm
-1
): 
3335 (N-H str), 2955 (alkane C-H str), 2138 (C≡C str), 1697 (C=O 
str), 1585 (Ar C-C str), 840 (N-H wag), 741 (Ar C-H). (
1
H NMR 
(400 MHz, CDCl3) δ 8.88 (s, 1H, Hq), 8.31 (d, J = 7.9 Hz, 1H, Hl/o), 
8.12 – 8.09 (m, 1H, Hr), 7.29 – 7.23 (m, 2H, HIn), 7.20 – 7.05 (m, 
6H, HAr/m/n), 4.63 (d, J = 2.1 Hz, 2H, Hc), 0.09 (s, 9H, Hu).
13
C NMR 
(400 MHz, CDCl3) δ 170.9 (Cb/h), 169.1 (Ch/b), 138.7, 136.5, 136.4, 
131.5, 128.8 (2C, Ce/f), 128.6 (2C, Cf/e), 128.0 (C), 125.5 (C), 124.3 
(C), 123.8 (C), 121.3 (C), 113.4 (C), 112.3 (C), 111.8 (C), 108.0 (Ct), 97.2 (Cs), 42.3 (Cc), -0.2 (Cu). 




, 399.1529 , found 399.1528. 
7.3.4.6 3-(1-Benzyl-1H-1,2,3-triazol-4-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione 
(90) 
To a 2-neck round bottom flask was added 3-(1H-indol-3-yl)-1-methyl-4-{(trimethylsilyl)ethynyl}-1H-
pyrrole-2,5-dione (88) (100 mg, 0.304 mmol) and dissolved in THF/MeOH (1:1, 8 mL). TBAF (96 mg, 
0.304 mmol, 1 equiv) was then added to the solution and stirred under N2 for 30 min. The reaction 
mixture was then treated with benzyl azide (40.5 mg, 0.304 mmol, 1 equiv), CuSO4•5H2O (1.6 mg, 
0.0061 mmol, 0.02 equiv) and Na ascorbate (12 mg, 0.061 mmol, 0.2 equiv) and stirred overnight at RT. 
The solvent was removed under reduced pressure. The reaction mixture was then diluted with EtOAc 
(20 mL) and washed with NH4Cl(sat) (2 × 10 mL), brine and dried over MgSO4. Filtration of the drying 
salts was followed by removal of the solvent in vacuo. Column chromatography (EtOAc/Hexane, 3:7) 
afforded the product 3-(1-benzyl-1H-1,2,3-triazol-4-yl)-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione 
(90) as a yellow solid (22 mg, 19%).  
Rf = 0.36 (EtOAc/Hexane, 1:1); 
1
H NMR (400 MHz, 
DMSO) δ 11.92 (s, 1H, Hm), 8.56 (d, J = 3.3 Hz, 1H, Hn), 
8.20 (m, 1H, Hp/h/k), 7.75 – 7.66 (m, 1H, HIn/Ar), 7.48 – 7.28 
(m, 5H, H Ar/In), 7.15-7.09 (m, 1H, HIn/Ar), 6.83 (m, 1H, HIn/Ar), 
5.70 (d, J = 2.7 Hz, 2H, Hq), 3.02 (s, 3H, Hc). 
13
C NMR (400 
MHz, DMSO) δ 170.9 (Cb/d), 170.8 (Cd/b), 136.5 (C), 136.0 
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(C), 132.3 (C), 131.8 (C), 128.8 (2C, Cs/t), 128.1 (C), 127.7 (2C, Ct/s), 126.0 (C), 125.0 (C), 122.0 (C), 
121.6 (C), 119.9 (C), 119.8 (C), 112.1, 104.7 (C), 52.8 (Cq), 24.1 (Cc). 
7.3.4.7 1-Benzyl-3-(1-benzyl-1H-1,2,3-triazol-4-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione 
(91) 
To a 2-neck round bottom flask was added 1-benzyl-3-(1H-indol-3-yl)-4-{(trimethylsilyl)ethynyl}-1H-
pyrrole-2,5-dione (89) (50 mg, 0.304 mmol) and dissolved in THF/MeOH (1:1, 6 mL). TBAF·3H2O (40 
mg, 0.13 mmol, 1 equiv) was added to the solution and stirred under N2 for 30 min. The reaction mixture 
was treated with benzyl azide (17 mg, 0.13 mmol, 1 equiv), CuSO4.5H2O (0.64 mg, 0.0026 mmol, 0.02 
equiv) and Na ascorbate (5 mg, 0.03 mmol, 0.2 equiv) and stirred overnight atRT. The solvent was 
removed under reduced pressure. The reaction mixture was then diluted with CH2Cl2 (20 mL) and washed 
with NH4Cl (sat) (2 × 10 mL), brine and dried over MgSO4. Filtration of the drying salts was followed by 
removal of the solvent in vacuo. Column chromatography (EtOAc/Hexane, 4:6) afforded the product 1-
benzyl-3-(1-benzyl-1H-1,2,3-triazol-4-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione (91) as an orange solid 
(12 mg, 20%).  
Rf = 0.38 (EtOAc/Hexane, 4:6); 
1
H NMR (400 MHz, 
DMSO) δ 12.0 (s, 1H, Hq), 8.6 (d, J = 6.0 Hz, 1H, Hr/t), 8.2 
(s, 1H, Hr/t), 7.5 – 7.4 (m, 1H, HIn), 7.4 – 7.3 (m, 11H, HIn/Ar), 
7.1 (s, 1H, HIn), 6.9 – 6.8 (m, 1H, HIn), 5.7 (d, J = 5.6 Hz, 2H, 




7.3.4.8 3-Ethynyl-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione (92) 
To a 2-neck round bottom flask was added 3-(1H-indol-3-yl)-1-methyl-4-{(trimethylsilyl)ethynyl}-1H-
pyrrole-2,5-dione (88) (380 mg, 1.16 mmol). The solid was dissolved in THF/NH4Cl(sat) (1:1, 15 mL) and 
stirred for 5 min. TBAF·3H2O (547 mg, 1.73 mmol, 1.5 equiv) was then added to the solution and stirred 
in the dark under N2, overnight. H2O (10 mL) was added to the reaction mixture and extracted with 
CH2Cl2 (2 × 30 mL). The combined organic layers were then washed with brine and dried over MgSO4. 
Filtration of the drying salts was followed by removal of the solvent in vacuo. The crude product was 
purified by column chromatography (EtOAc/Hexane, 3:7) to afford the desired product 3-ethynyl-4-(1H-
indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione (92) as a red solid (131 mg, 44%). 
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Rf = 0.49 (EtOAc/Hexane, 4:6); 
1
H NMR (400 MHz, DMSO) δ 12.25 (s, 
1H, Hm), 8.30 (d, J = 2.4 Hz, 1H, Hn), 8.24 (d, J = 7.7 Hz, 1H, Hh/k), 7.53 
(d, J = 8.0 Hz, 1H, Hk/h), 7.25 (m, 1H, Hi/j), 7.17 (m, 1H, Hi/j), 5.10 (s, 1H, 
Hp), 2.97 (s, 3H, Hc).
13
C NMR (400 MHz, DMSO) δ 170.3 (Cb/d), 168.8 
(Cd/b), 139.7 (C), 136.8 (C), 132.6 (C), 124.9 (C), 122.9 (C), 122.8 (C), 
120.7 (C), 112.5 (C), 109.6 (C), 106.0 (C), 96.1 (C), 76.7 (Co/p) 24.3 (Cc).  
 
 
7.3.4.9 1-Benzyl-3-ethynyl-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione (93) 
To a 2-neck round bottom flask was added 1-benzyl-3-(1H-indol-3-yl)-4-{(trimethylsilyl)ethynyl}-1H-
pyrrole-2,5-dione (89) (552 mg, 1.42 mmol). The solid was dissolved in THF/NH4Cl(sat) (1:1, 30 mL) and 
stirred for 5 min. TBAF·3H2O (670 mg, 2.12 mmol, 1.5 equiv) was then added to the solution and stirred 
in the dark at RT, under N2, overnight. H2O (50 mL) was added to the reaction mixture and extracted with 
CH2Cl2 (2 × 50 mL). The combined organic layers were then washed with brine and dried over MgSO4. 
Filtration of the drying salts was followed by removal of the solvent in vacuo. The crude product was 
purified by column chromatography (EtOAc/Hexane, 3:7) to afford the desired product 1-benzyl-3-
ethynyl-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione (93) as a red solid (274 mg, 59%). 
 
Rf = 0.59 (EtOAc/Hexane, 4:6);
1
H NMR (400 MHz, DMSO) δ 12.2 (s, 
1H, Hq), 8.1 (s, 1H, Hr), 7.9 (d, J = 7.9 Hz, 1H, Hl/o), 7.5 (d, J = 7.9 Hz, 
1H, Ho/l), 7.4 – 7.2 (m, 5H, HAr), 7.3 – 7.2 (m, 1H, Hm/n), 7.2 (m, 1H, Hn/m), 







To a 2-neck round bottom flask was added 3-ethynyl-4-(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione 
(92) (40 mg, 0.16 mmol) and dissolved in THF/MeOH (1:1, 4 mL). To the solution was then added N-(4-
azidophenyl)acrylamide (37 mg, 0.19 mmol, 1.2 equiv), CuSO4.5H2O (1.6 mg, 0.0062 mmol, 0.04 equiv) 
and Na ascorbate (12 mg, 0.062 mmol, 0.4 equiv) and stirred overnight at RT.  
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The solvent was removed under reduced pressure. The reaction mixture was then diluted with CH2Cl2 (15 
mL) and washed with NH4Cl(sat) (2 × 15 mL), brine and dried over MgSO4. Filtration of the drying salts 
was followed by removal of the solvent in vacuo. Column chromatography (EtOAc/Hexane, 7:3) afforded 
the product N-(4-[4-{4-(1H-indol-3-yl)-1-methyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl}-1H-1,2,3-
triazol-1-yl]phenyl)- acrylamide (94) as an orange solid (18 mg, 26%).  
Rf = 0.72 (EtOAc/Hexane, 8:2); 
1
H NMR (400 
MHz, DMSO) δ 11.92 (s, 1H, Hm/u), 9.92 (s, 1H, 
Hm/u), 8.48 (d, J = 3.7 Hz, 1H, Hn), 8.18 (s, 1H, 
Hp), 7.50 – 7.44 (m, 2H, Hr/s ), 7.40 – 7.32 (m, 
1H, Hindole), 7.26– 7.20 (m, 1H, Hindole ), 7.15 – 
7.09 (m, 1H, Hindole), 7.05 – 7.01 (m, 1H, Hindole), 
6.89 – 6.86 (m, 2H, Hr/s), 6.53 – 6.43 (m, 1H, 
Hw), 6.27 (m, 1H, Hx/x’), 5.78 (m, 1H, Hx/x’), 3.02 
(s, 3H, Hc).
 13
C NMR (400 MHz, DMSO) δ 
171.0 (Cb/d), 170.8 (Cb/d), 163.8 (Cv), 137.0 (C), 136.5 (C), 135.4 (C), 132.1 (C), 131.8 (C), 131.4 (C), 
130.3 (C), 128.7 (C), 128.4 (C), 127.2 (C), 126.2 (C), 126.1 (C), 125.8 (C), 125.1 (C), 122.0 (C), 121.7 
(C), 119.9 (C), 119.8 (C), 112.1 (C), 104.8 (C), 24.1 (Cc). 
7.3.5 Synthesis of the bisamino maleimide target compounds 104 and 105 
7.3.5.1 3,4-Dibromo-1-(4-nitrophenyl)-1H-pyrrole-2,5-dione (96) 
A 2-neck round bottom flask charged with 3,4-dibromomaleic anhydride (79) (2.15 g, 8.40 mmol), was 
evacuated under high vacuum and filled with Ar. It was then dissolved in AcOH (30 mL), followed by the 
addition of p-nitroaniline (1.28 g, 9.24 mmol, 1.1 equiv). The reaction mixture was then heated to reflux 
for 8 hours under a N2 atmosphere. Upon completion, the solvent was removed in vacuo and the crude 
product was purified by column chromatography (EtOAc/Hexane, 3:7) to afford the product 3,4-dibromo-
1-(4-nitrophenyl)-1H-pyrrole-2,5-dione (96) as a light yellow solid (2.16 g, 69%). The 
1
H NMR spectrum 
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Rf = 0.77 (EtOAc/Hexane, 4:6); 
1
H NMR (300 MHz, DMSO) δ 8.39 (d, J = 8.9 Hz, 
2H, He), 7.69 (d, J = 8.9 Hz, 2H, Hd); 
13
C NMR (75 MHz, DMSO) δ 163.3 (2C, Cb), 






7.3.5.2 3-Bromo-1-(4-nitrophenyl)-4-(phenylamino)-1H-pyrrolo-2,5-dione (97) 
A Schlenk tube charged with 3,4-dibromo-1-(4-nitrophenyl)-1H-pyrrole-2,5-dione (96) (474 mg, 1.27 
mmol) was evacuated under high vacuum and filled with Ar. Dry THF (3.5 mL) was added to the Schlenk 
and it was stirred in an ice bath for 5 min. A solution of aniline (0.12 mL, 1.3 mmol, 1.05 equiv), THF (11 
mL) and TEA (0.44 mL, 3.2 mmol, 2.5 equiv) was then prepared, stirred and added drop-wise to the 
Schlenk solution at 0 °C. The reaction mixture was stirred overnight at RT under a N2 atmosphere. Upon 
completion, the mixture was diluted with CH2Cl2 (20 mL), washed with H2O (20 mL) and brine. It was 
then dried over MgSO4 salts, filtered and the solvent was removed in vacuo. The mixture was purified by 
column chromatography (EtOAc/Hexane, 2:8) to afford the product 3-bromo-1-(4-nitrophenyl)-4-
(phenylamino)-1H-pyrrolo-2,5-dione (97) as a yellow solid (386 mg, 79%).  
Mp = 210-212 º C; Rf = 0.70 (EtOAc/Hexane, 4:6); IR (ATR, cm
-
1
):3326 ( amine N-H str), 1708 (carbonyl C=O str), 666 (C-Br str), 1519, 
1314 (nitro N-O str); 
1
H NMR (400 MHz, DMSO) δ 10.11 (s, 1H, Hi), 
8.37 (d, J = 8.1 Hz, 2H, He), 7.75 (d, J = 8.1 Hz, 2H, Hd ), 7.44 – 7.36 
(m, 2H, Hl), 7.29 – 7.20 (m, 3H, Hk&m); 
13
C NMR (400 MHz, DMSO) δ 
165.8 (Cb/g), 164.3 (Cb/g), 145.5 (Cf/c/h/j), 141.9 (Cf/c/h/j), 137.7 (Cf/c/h/j), 
136.3 (Cf/c/h/j), 128.2 (2C, Ce/d/k/l), 126.3 (2C, Ce/d/k/l), 125.6 (Cm), 124.8 
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Piperazine (98) (1.54 g, 17.9 mmol, 1.8 equiv) was added to a 2-neck round bottom flask and dissolved in 
MeOH (40 mL). The flask was placed in an ice bath and the solution was stirred for 5 min. A solution of 
di-tert-butyl dicarbonate (2.17 g, 9.95 mmol) in MeOH (20 mL) was then added drop-wise at 0 ° C to the 
flask containing the piperazine solution. The reaction mixture was stirred at RT for 2 days. The MeOH 
was then removed in vacuo and the mixture was diluted with Et2O (60 mL). The aqueous solution was 
then obtained by extracting the organic solution with 1M citric acid (3 × 30 mL) and washing it with 
EtOAc (3 × 30 mL), removing the disubstituted byproduct.1 M NaOH was then added to the aqueous 
solution until the pH was adjusted to 11. The solution was then extracted with EtOAc (3 × 50 mL). The 
organic layers were combined, washed with brine and dried over MgSO4. After filtration of the drying 
salts and removal of the solvent under reduced pressure, the desired product N-Boc-piperazine (99) was 
obtained as an off-white solid (1.09 g, 59%). The 
1
H NMR spectrum of N-Boc-piperazine (99) was 




H NMR (300 MHz, CDCl3) δ 3.45 – 3.28 (m, 4H, Hc), 2.86 – 2.72 (m, 4H, Hb), 2.22 (s, 










A Schlenk tube charged with 3-bromo-1-(4-nitrophenyl)-4-(phenylamino)-1H-pyrrolo-2,5-dione (97) 
(750 mg, 1.95 mmol) was evacuated under high vacuum and filled with Ar. Dry THF (15 mL) was added 
to the Schlenk and it was stirred in an ice bath for 5 min. A solution of N-Boc-piperazine(99)(549 mg, 
2.93 mmol, 1.5 equiv), THF (30 mL) and TEA (0.68 mL, 4.9 mmol, 2.5 equiv) was prepared, stirred and 
added drop-wise to the Schlenk solution at 0 °C. The reaction mixture was stirred overnight at 55 °C. 
Upon completion, the solvent was removed in vacuo and diluted with CH2Cl2 (50 mL). The solution was 
washed with H2O (2 × 30 mL). The organic layers were combined, washed with brine and dried over 
MgSO4. Once the drying salts were removed by filtration, the solvent was removed in vacuo.  
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Purification by column chromatography (EtOAc/Hexane; 2:8) afforded 174 mg of the starting reagent 
(97) and 590 mg of the desired product tert-butyl 4-{1-(4-nitrophenyl)-2,5-dioxo-4-(phenylamino)-2,5-
dihydro-1H-pyrrol-3-yl}piperazine-1-carboxylateas (100) an orange solid. Yield: 62% (80% brsm). 
Mp = 115-117 ºC; Rf = 0.64 (EtOAc/Hexane, 4:6), IR (ATR, 
cm
-1
): 3332 (amine N-H str),1689 (carbonyl C=O str), 1517, 1334 
(nitro N-O str);
1
H NMR (300 MHz, DMSO) δ 8.34 (d, J = 8.7 Hz, 
2H, He/d), 8.25 (s, 1H, Hi), 7.70 (d, J = 8.7 Hz, 2H, He/d), 7.29 – 
7.20(m, 2H, Hl ), 6.88 (d, J = 8.3 Hz, 2H, Hk ), 6.86 – 8.80(m, 1H, 
Hm), 3.30 – 3.25 (m, 4H, Hn/o), 3.18 – 3.10 (m, 4H, Hn/o), 1.36 (s, 
9H, Hr).
13
C NMR (75 MHz, DMSO) δ 166.8 (Ch/g), 165.9 (Cg/h), 
153.7 (Cp), 144.9 (C), 141.9 (C), 137.9 (C), 128.7 (C), 128.6 (2C, 
Ce/d/k/l), 125.9 (2C, Ce/d/k/l), 124.1 (2C, Ce/d/k/l), 119.9 (C), 117.1 (2C, 





, 494.2040, found 494.2043. 
7.3.5.5 1-(4-Nitrophenyl)-3-(phenylamino)-4-(piperazin-1-yl)-1H-pyrrole-2,5-dione (101) 
tert-Butyl 4-{1-(4-nitrophenyl)-2,5-dioxo-4-(phenylamino)-2,5-dihydro-1H-pyrrol-3-yl}piperazine-1-car-
boxylate (100) (220 mg, 0.449 mmol) was added to a 2-neck round bottom flask and dissolved in CH2Cl2 
(20 mL). The flask was placed in an ice bath and the solution was stirred for 5 min under a N2 
atmosphere.TFA (0.71 mL, 9.0 mmol, 20 equiv), diluted in CH2Cl2 (4 mL), was then added drop-wise at 
0 °C. The reaction mixture became dark red in colour. The ice bath was then removed and the reaction 
mixture was stirred overnight at 35 °C. The solution was then transferred to a flask containing 
NaHCO3 (sat) (40 mL) and stirred at 0 °C. The addition of K2CO3 adjusted the pH to 10. The product was 
then obtained by extracting with CH2Cl2 (3 × 20 mL). The organic layers were combined, washed with 
brine and dried over MgSO4. The drying salts were removed by filtration and the solvent was removed 
under reduced pressure. Column chromatography (MeOH/CH2Cl2; 1:9) afforded the desired product 1-(4-
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Mp = 200-202 ºC; Rf = 0.47 (MeOH:CH2Cl2, 1:9), IR (ATR, cm
-1
): 
3329 (amine N-H str), 1689 (carbonyl C=O str), 1494, 1335 (nitro N-O 
str);
1
H NMR (300 MHz, DMSO) δ 8.33 (d, J = 8.8 Hz, 2H, He), 8.10 (s, 
1H, Hi), 7.70 (d, J = 8.8 Hz, 2H, Hd), 7.27 – 7.17 (m, 2H, Hl), 6.90 – 6.78 
(m, 3H, Hk/m), 3.95 –3.71 (s, 5H, Hp), 3.39 (s, 4H, Hn), 2.64 (s, 4H, 
Ho).
13
C NMR (300 MHz, DMSO) δ 166.9 (Cg/b), 165.8 (Cg/b), 144.9 
(Cf/c/h/j), 142.7 (Cf/c/h/j), 138.0 (Cf/c/h/j), 130.3 (Cf/c/h/j), 128.6 (2C, Ce/d/k/l), 
125.8 (2C, Ce/d/k/l), 124.1 (2C, Ce/d/k/l), 119.4 (Cf/c/h/j), 116.5 (2C, Ce/d/k/l), 





, 394.1515, found 394.1510. 
7.3.5.6 3-(4-Acryloylpiperazin-1-yl)-1-(4-nitrophenyl)-4-(phenylamino)-1H-pyrrole-2,5-
dione (102) 
To a 2-neck round bottom flask was added 1-(4-nitrophenyl)-3-(phenylamino)-4-(piperazin-1-yl)-1H-
pyrrole-2,5-dione (101) (85 mg, 0.22 mmol) and dissolved in a mixture of THF and DMF (10 mL: 10 
mL). The flask was placed in an ice bath and TEA (0.09 mL, 0.65 mmol, 3 equiv) was added to the 
solution. The reaction mixture was stirred for 10 min at 0 °C, followed by the drop-wise addition of 
acryloyl chloride (0.05 mL, 0.65 mmol, 3 equiv) diluted in THF (2 mL). The reaction mixture was stirred 
at RT for 2 h. The THF was then removed in vacuo and the mixture was diluted in Et2O (30 mL). The 
organic layer was then washed with H2O (5 × 20 mL), brine and dried over MgSO4. The drying salts were 
then removed by filtration and the solvent was removed in vacuo. Purification by column chromatography 
(EtOAc/Hexane, 1:1) afforded the desired product 3-(4-acryloylpiperazin-1-yl)-1-(4-nitrophenyl)-4-
(phenylamino)-1H-pyrrole-2,5-dione (102) as an orange solid (59 mg, 61%).  
Mp = 195-197 ºC; Rf = 0.47 (EtOAc/Hexane, 1:1), IR (ATR, cm
-1
): 
3391, 3295 (amine N-H str), 3073 (alkene C=C-H), 1694 (carbonyl C=O 
str), 1503, 1343 (nitro N-O str); 
1
H NMR (300 MHz, cdcl3) δ 8.30 (d, J 
= 8.8 Hz, 2H, He), 7.70 (d, J = 8.8, 2H, Hd), 7.38 – 7.29 (m, 2H, Hl), 7.10 
– 7.02 (m, 1H, Hm), 6.91 (d, J = 7.8 Hz, 2H, Hk), 6.47 (dd, J = 16.8, 10.4 
Hz, 1H, Hr), 6.37 (s, 1H, Hi), 6.26 (d, J = 16.8 Hz, 1H, Hs’), 5.68 (d, J = 
10.4 Hz, 1H, Hs), 3.36 (m, 8H, Hn/o). 
13
C NMR (300 MHz, CDCl3) δ 
167.0 (Cb/g), 166.7 (Cg/b), 165.5 (Cq), 145.6 (C), 139.1 (C), 137.7 (C), 
129.2 (2C, Ce/d/k/l), 128.6 (C), 127.1 (C), 124.9 (2C, Ce/d/k/l), 124.5 (2C, 
Ce/d/k/l), 123.10 (C), 122.5 (C), 119.2 (2C, Ce/d/k/l), 118.1 (C), 48.4 (Cn/o), 
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, 448.1621, found 448.16.1612 
7.3.5.7 1-(4-Nitrophenyl)-3-(phenylamino)-4-(4-(prop-2-yn-1-yl)piperazin-1-yl)-1H-pyrrole-
2,5-dione (103) 
To a 2-neck round bottom flask was added 1-(4-nitrophenyl)-3-(phenylamino)-4-(piperazin-1-yl)-1H-
pyrrole-2,5-dione (101) (205 mg, 0.521 mmol) and dissolved in DMF (15 mL). TEA (0.11 mL, 0.78 
mmol, 1.5 equiv) was then added to the solution, followed by the drop-wise addition of propargyl 
bromide (80% in toluene) (112 mg, 0.782 mmol, 1.5 equiv). The reaction mixture was stirred for 2 h at 
50 °C. Upon completion, the reaction mixture was taken up in Et2O (50 mL) and washed with H2O (6 × 
25 mL). The organic layer was then washed with brine and dried over MgSO4 salts. The drying salts were 
removed by filtration and the solvent was removed in vacuo.Purification by column chromatography 
(EtOAc/Hexane, 4:6) afforded the desired product 1-(4-nitrophenyl)-3-(phenylamino)-4-(4-(prop-2-yn-1-
yl)piperazin-1-yl)-1H-pyrrole-2,5-dione (103) as an orange solid (160 mg, 71%).  
Mp = 192-194 ºC; Rf =0.29 (EtOAc/Hexane, 4:6), IR (ATR, cm
-1
): 3253 
(amine N-H str), 1698 (carbonyl C=O str), 1495, 1334 (nitro N-O), 684 ( 
alkyne C≡C-H);
1
H NMR (300 MHz, CDCl3) δ 8.29 (d, J = 9.1 Hz, 2H, 
He), 7.70 (d, J = 9.1 Hz, 2H, Hd), 7.36 – 7.25 (m, 2H, Hl), 7.03 - 6.95 (m, 
1H, Hm), 6.84 (d, J = 7.7 Hz, 2H, Hk), 6.09 (s, 1H, Hi), 3.54 – 3.43 (m, 2H, 
Hn/o), 3.24 (d, J = 2.3 Hz, 2H, Hq), 2.47 – 2.38 (m, 2H, Hn/o), 2.25 (m, 1H, 
Hs). 
13
C NMR (300 MHz, CDCl3) δ 167.4 (Cb/g), 166.4 (Cb/g), 145.5 (C), 
140.7 (C), 137.9 (C), 129.3 (2C, Ce/d/k/l), 126.1 (C), 124.9 (2C, Ce/d/k/l), 
124.4 (2C, Ce/d/k/l), 122.1 (C), 118.0 (2C, Ce/d/k/l), 115.0 (C), 78.4 (Cr), 73.6 





, 432.1672, found 432.16.1666. 
7.3.5.8 3-(4-Acryloylpiperazin-1-yl)-4-(phenylamino)-1H-pyrrole-2,5-dione (104) 
A Schlenk tube charged with 3-(4-acryloylpiperazin-1-yl)-1-(4-nitrophenyl)-4-(phenylamino)-1H-
pyrrole-2,5-dione (102) (60 mg, 0.13 mmol) was evacuated under high vacuum and filled with Ar. A 
mixture of CH2Cl2 and MeOH (3 mL: 3 mL) was added to the Schlenk and the solution was then saturated 
with NH3 by bubbling NH3 gas through the liquid for 5 min. The reaction mixture was stirred for 8 h at 
RT under a N2 atmosphere. The solvent was removed in vacuo and purification by column 
chromatography (EtOAc/Hexane, 1:1) afforded the desired product 3-(4-acryloylpiperazin-1-yl)-4-
(phenylamino)-1H-pyrrole-2,5-dione (104) as an orange solid (38 mg, 86%). 
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Mp = 161-163 ºC; Rf = 0.24 (EtOAc/Hexane, 1:1), IR (ATR, cm
-1
): 3317, 
3141 (amine N-H str), 3036 (alkene C=CH2 str), 1698 (carbonyl C=O 
str);
1
H NMR (300 MHz, CDCl3) δ 8.16 (s, 1H, Hc), 7.34 – 7.24 (m, 2H, 
Hi), 7.02 - 6.94 (m, 1H, Hj), 6.84 (d, J = 8.0 Hz, 2H, Hh), 6.48 (dd, J = 
16.8, 10.4 Hz, 1H, Hn), 6.37 (s, 1H, Hf), 6.27 (dd, J = 16.8, 1.5 Hz, 1H, 
Ho/o’), 5.69 (dd, J = 10.4, 1.5 Hz, 1H, Ho/o’), 3.53 – 3.21 (m, 8H, Hk/l).
13
C 
NMR (300 MHz, CDCl3) δ 169.3 (Cb/d), 169.0 (Cb/d), 165.5 (Cm), 140.1 
(Cg), 129.0 (2C, Ch/i), 128.5 (C), 127.1 (C), 124.4 (C), 122.0 (C), 118.2 





, 327.1457, found 327.1447. 
3.7.5.9 3-(Phenylamino)-4-(4-(prop-2-yn-1-yl)piperazin-1-yl)-1H-pyrrole-2,5-dione (105) 
A Schlenk tube charged with 1-(4-nitrophenyl)-3-(phenylamino)-4-(4-(prop-2-yn-1-yl)piperazin-1-yl)-
1H-pyrrole-2,5-dione (103) (90 mg, 0.21 mmol) was evacuated under high vacuum and filled with Ar. A 
mixture of CH2Cl2 and MeOH (4 mL: 4 mL) was added to the Schlenk tube and the solution was saturated 
with NH3 by bubbling NH3 gas through the liquid for 5 min. The reaction mixture was stirred for 10 h at 
RT under a N2 atmosphere. The solvent was removed in vacuo and purification by column 
chromatography (EtOAc/Hexane, 4:6) afforded the desired product 3-(phenylamino)-4-(4-(prop-2-yn-1-
yl)piperazin-1-yl)-1H-pyrrole-2,5-dione (105) as an orange solid (59 mg, 91%). 
Mp = 82-84 ºC; Rf = 0.35 (EtOAc/Hexane, 1:1); IR (ATR, cm
-1
): 3277, 2920 
(amine N-H str) 1694 (carbonyl C=O str), 691 (alkyne C≡C-H str);
1
H NMR 
(300 MHz, CDCl3) δ 7.79 (s, 1H, Hc), 7.30 – 7.22 (m, 2H, Hh), 6.95 – 6.89 (m, 
1H, Hj), 6.74 (d, J = 7.8 Hz, 2H, Hi), 5.90 (s, 1H, Hf), 3.55 – 3.40 (m, 4H, Hk/l), 
3.22 (d, J = 2.3 Hz, 2H, Hm), 2.48 – 2.35 (m, 4H, Hk/l), 2.28 – 2.24 (m, 1H, 
Ho).
13
C NMR (300 MHz, CDCl3) δ 169.6 (Cb/d), 168.5 (Cd/b), 141.9 (C), 129.2 
(2C, Ch/i), 128.5 (C), 121.1 (C), 117.1 (2C, Ch/i), 113.4 (C), 78.3 (Cn), 73.7 (Co), 





, 311.1508, found 311.1497. 
 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 8 – References  
204 
 
CHAPTER 8 – REFERENCES 
 
[1] Olson, J. S., Making Cancer History: Disease and Discovery at the University of Texas M. D. 
Anderson Cancer Center, Houston, Texas, Johns Hopkins University Press, 2009. 
[2] Galgut, C., Murray, J., Coulter, C., The Psychological Impact of Breast Cancer: A Psychologist's 
Insights as a Patient, Oxfordshire, Radcliffe Publishing, 2010. 
[3] Anand, P., Kunnumakara, A., Sundaram, C., Harikumar, K., Tharakan, S., Lai, O. S., Sung, B., 
Aggarwal, B. B., Pharmaceutical Research 2008, 25, 2097-2116. 
[4] Roberts, M., BBC News Health, 2014. http://www.bbc.com/news/health-26031748 (accessed 
04/0914).  
[5] Gallagher, J., BBC News Health, 2014. http://www.bbc.com/news/health-26014693 (accessed 
04/09/14). 
[6] International Agency for Research on Cancer, Central European Journal of Public Health, 2014. 
http://www.iarc.fr/en/media-centre/pr/2014/pdfs/pr224_E.pdf (accessed 04/09/2014). 
[7] DeVita, V. T., Rosenberg, S. A., New England Journal of Medicine 2012, 366, 2207-2214. 
[8] Hanahan, D., Weinberg, R. A., Cell 2000, 100, 57-70. 
[9] Hanahan, D., Weinberg, R. A., Cell 2011, 144, 646-674. 
[10] Cutter, M. A., Sigstedt, J., Venne, V., Cell Biology and Cancer: NIH Curriculum Supplement 
Series, 1999. http://science.education.nih.gov/supplements/nih1/cancer/guide/understanding1.htm  
(accessed 08/09/2014). 
[11] National Cancer Institute, 2014. http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer 
(accessed 08/09/2014). 
[12] Downward, J., Jain, R., Kouzarides, T., Sawyers, C., Sebolt-Leopold, J., Norvatic Oncology, 
2005. http://www.nature.com/nrc/posters/pathways/index.html (accessed 08/09/2014) 
[13] Frantz, S., Nature Milestones 2006, 8, 22-23. 
[14] Abou-Jawde, R., Choueiri, T., Alemany, C., Mekhail, T., Clinical Therapeutics 2003, 25, 2121-
2137. 
[15] Strebhardt, K., Ullrich, A., Nature Reviews Cancer 2008, 8, 473-480. 
[16] Chabner, B. A., Roberts, T. G., Nature Reviews Cancer 2005, 5, 65-72. 
[17] Goldman, J. M., Melo, J. V., New England Journal of Medicine 2003, 349, 1451-1464. 
[18] Pierotti, M. A., Negri, T., Tamborini, E., Perrone, F., Pricl, S., Pilotti, S., Molecular Oncology 
2010, 4, 19-37. 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 8 – References  
205 
 
[19] Zuccotto, F., Ardini, E., Casale, E., Angiolini, M., Journal of Medicinal Chemistry 2009, 53, 
2681-2694. 
[20] Stout, T. J., Foster, P. G., Matthews, D. J., Current Pharmaceutical Design 2004, 10, 1069-1082. 
[21] Kalyn, R., Journal of Oncology Pharmacy Practice 2007, 13, 199-205. 
[22] Gerber, D. E., American Family Physician 2008, 77, 311-319. 
[23] Cohen, P., Nature Cell Biology 2002, 4, E127-E130. 
[24] Ubersax, J. A., Ferrell Jr, J. E., Nature Reviews Molecular Cell Biology 2007, 8, 530-541. 
[25] Manning, G., Whyte, D. B., Martinez, R., Hunter, T., Sudarsanam, S., Science 2002, 298, 1912-
1934. 
[26] Blume-Jensen, P., Hunter, T., Nature 2001, 411, 355-365. 
[27] Hanks, S. K., Genome Biology 2003, 4, 1-7. 
[28] Hanks, S. K., Quinn, A. M., Hunter, T., Science 1988, 241, 42-52. 
[29] Hanks, S. K., Hunter, T., The FASEB Journal 1995, 9, 576-596. 
[30] Sciences’s signal transduction knowledge environment, American Association for the 
Advancement of Science, 2002. 
http://www.sciencemag.org/content/suppl/2002/12/13/298.5600.1912.DC2/KinomePoster.pdf 
(accessed 11/09/2014). 
[31] Hunter, T., Cold Spring Harbor Perspectives in Biology 2014, 6, 1-4. 
[32] Gschwind, A., Fischer, O. M., Ullrich, A., Nature Reviews Cancer 2004, 4, 361-370. 
[33] Goodsell, D., RCSB Protein Data Bank, 2010. 
http://www.rcsb.org/pdb/101/motm.do?momID=126 (accessed 15/09/2014). 
[34] Lemmon, M. A., Experimental Cell Research 2009, 315, 638-648. 
[35] Robinson, K., Sandler, A., Current Oncology Reports 2013, 15, 396-404. 
[36] Taylor, S. S., Kornev, A. P., Trends in Biochemical Sciences, 36, 65-77. 
[37] Taylor, S. S., Keshwani, M. M., Steichen, J. M., Kornev, A. P., Philosophical Transactions of the 
Royal Society B: Biological Sciences 2012, 367, 2517-2528. 
[38] Ghose, A. K., Herbertz, T., Pippin, D. A., Salvino, J. M., Mallamo, J. P., Journal of Medicinal 
Chemistry 2008, 51, 5149-5171. 
[39] Irie, T., Fujii, I., Sawa, M., Bioorganic & Medicinal Chemistry Letters 2012, 22, 591-596. 
[40] Garuti, L., Roberti, M., Bottegoni, G., Current Medicinal Chemistry 2011, 18, 2981-2994. 
[41] Noble, M. E. M., Endicott, J. A., Johnson, L. N., Science 2004, 303, 1800-1805. 
[42] Simard, J. R., Getlik, M., Grütter, C., Pawar, V., Wulfert, S., Rabiller, M., Rauh, D., Journal of 
the American Chemical Society 2009, 131, 13286-13296. 
[43] Johnson, L. N., Noble, M. E. M., Owen, D. J., Cell 1996, 85, 149-158. 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 8 – References  
206 
 
[44] Hubbard, S. R., Nature Structural Biology 1999, 6, 711. 
[45] Fedorov, O., Müller, S., Knapp, S., Nature Chemical Biology 2010, 6, 166-169. 
[46] Cohen, P., Nature Reviews Drug Discovery 2002, 1, 309-315. 
[47] Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., Gray, N. S., ACS Chemical Biology 
2014, 9, 1230-1241. 
[48] Fang, Z., Grütter, C., Rauh, D., ACS Chemical Biology 2012, 8, 58-70. 
[49] Liu, Y., Gray, N. S., Nature Chemical Biology 2006, 2, 358-364. 
[50] Zhang, J., Yang, P. L., Gray, N. S., Nature Reviews Cancer 2009, 9, 28-39. 
[51] Bogoyevitch, M. A., Fairlie, D. P., Drug Discovery Today 2007, 12, 622-633. 
[52] Carmi, C., Mor, M., Petronini, P. G., Alfieri, R. R., Biochemical Pharmacology 2012, 84, 1388-
1399. 
[53] Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., Gray, N. S., Chemistry & 
Biology 2013, 20, 146-159. 
[54] Singh, J., Petter, R. C., Baillie, T. A., Whitty, A., Nature Reviews Drug Discovery 2011, 10, 307-
317. 
[55] Klüter , S., Simard , J. R., Rode, H. B., Grütter, C., Pawar, V., Raaijmakers, H. C., Barf, T. A., 
Rabiller, M., van Otterlo W. A. L., Rauh, D., ChemBioChem 2010, 11, 2557-2566. 
[56] Leproult, E., Barluenga, S., Moras, D., Wurtz, J.-M., Winssinger, N., Journal of Medicinal 
Chemistry 2011, 54, 1347-1355. 
[57] Michalczyk, A., Klüter, S., Rode, H. B., Simard, J. R., Grütter, C., Rabiller, M., Rauh, D., 
Bioorganic & Medicinal Chemistry 2008, 16, 3482-3488. 
[58] Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., 
Labenski, M., Zhu, Z., Wang, Z., Sheets, M., St Martin, T., Karp, R., van Kalken, D., Chaturvedi, 
P., Niu, P., Nacht, M., Petter, R. C., Westlin, W., Lin, K., Jaw-Tsai, S., Raponi, M., van Dyke, T., 
Etter, J., Weaver, Z., Pao, W., Singh, J., Simmons, A. D., Harding, T. C., Allen, A., Cancer 
Discovery 2013, 3, 1404-1415. 
[59] Doebele, R. C., Oton, A. B., Peled, N., Camidge, D. R., Bunn, P. A., Jr., Lung Cancer, 69, 1-12. 
[60] Schwartz, P. A., Kuzmic, P., Solowiej, J., Bergqvist, S., Bolanos, B., Almaden, C., Nagata, A., 
Ryan, K., Feng, J., Dalvie, D., Kath, J. C., Xu, M., Wani, R., Murray, B. W., Proceedings of the 
National Academy of Sciences 2014, 111, 173-178. 
[61] Ward, R. A., Anderton, M. J., Ashton, S., Bethel, P. A., Box, M., Butterworth, S., Colclough, N., 
Chorley, C. G., Chuaqui, C., Cross, D. A. E., Dakin, L. A., Debreczeni, J. E., Eberlein, C., Finlay, 
M. R. V., Hill, G. B., Grist, M., Klinowska, T. C. M., Lane, C., Martin, S., Orme, J. P., Smith, P., 
Wang, F., Waring, M. J., Journal of Medicinal Chemistry 2013, 56, 7025-7048. 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 8 – References  
207 
 
[62] Antonello, A., Tarozzi, A., Morroni, F., Cavalli, A., Rosini, M., Tarrozi, A., Tumiatti, V., 
Melchiorre, C., Journal of Medicinal Chemistry 2006, 49, 6642-6645. 
[63] Darling, D., The Worlds of David Darling - Encyclopedia of science, 1999. 
http://www.daviddarling.info/encyclopedia/A/Aristotle.html (accessed 16/09/2014). 
[64] Poupon, E., Nay, B., Biomimetic Organic Synthesis, Vol. 2, Wiley-VCH, 2011. 
[65] Cragg, G. M., Newman, D. J., Biochimica et Biophysica Acta 1830 2013, 3670-3695. 
[66] Butler, M. S., Natural Product Reports 2008, 25, 475-516. 
[67] Mishra, B. B., Tiwari, V. K., European Journal of Medicinal Chemistry 2011, 46, 4769-4807. 
[68] Liu, J., Hu, Y., Waller, D. L., Wang, J., Liu, Q., Natural Product Reports 2012, 29, 392-403. 
[69] Lachance, H., Wetzel, S., Kumar, K., Waldmann, H., Journal of Medicinal Chemistry 2012, 55, 
5989-6001. 
[70] Wetzel, S., Bon, R. S., Kumar, K., Waldmann, H., Angewandte Chemie International Edition 
2011, 50, 10800-10826. 
[71] Newman, D. J., Journal of Medicinal Chemistry 2008, 51, 2589-2599. 
[72] Pfisterer, P. H., Wolber, G., Efferth, T., Rollinger, J. M., Stuppner, H., Current Pharmaceutical 
Design 2010, 16, 1718-1741. 
[73] Bon, R. S., Waldmann, H., Accounts of Chemical Research 2010, 43, 1103-1114. 
[74] Augen, J., Drug Discovery Today 2002, 7, 315-323. 
[75] Kaiser, M., Wetzel, S., Kumar, K., Waldmann, H., Cellular and Molecular Life Sciences 2008, 
65, 1186-1201. 
[76] Hübel, K., Leßmann, T., Waldmann, H., Chemical Society Reviews 2008, 37, 1361-1374. 
[77] Mann, J., Nature Reviews Cancer 2002, 2, 143-148. 
[78] Bharate, S. B., Sawant, S. D., Singh, P. P., Vishwakarma, R. A., Chemical Reviews 2013, 113, 
6761-6815. 
[79] Giddings, L.-A., Newman, D., Journal of Industrial Microbiology & Biotechnology 2013, 40, 
1181-1210. 
[80] Omura, S., Iwai, Y., Hirano, A., Nakagawa, A., Awaya, J., Tsuchya, H., Takahashi, Y., Masuma, 
R., The Journal of Antibiotics 1977, 30, 275-282. 
[81] Nakano, H., Omura, S., The Journal of Antibiotics 2009, 62, 17-26. 
[82] Tamaoki, T., Nomoto, H., Takahashi, I., Kato, Y., Morimoto, M., Tomita, F., Biochemical and 
Biophysical Research Communications 1986, 135, 397-402. 
[83] Gescher, A., Critical Reviews in Oncology/Hematology 2000, 34, 127-135. 
[84] Tanramluk, D., Schreyer, A., Pitt, W. R., Blundell, T. L., Chemical Biology & Drug Design 2009, 
74, 16-24. 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 8 – References  
208 
 
[85] Acero, N., Braña, M. F., Añorbe, L., Domínguez, G., Muñoz-Mingarro, D., Mitjans, F., Piulats, 
J., European Journal of Medicinal Chemistry 2012, 48, 108-113. 
[86] Gu, G., Wang, H., Liu, P., Fu, C., Li, Z., Cao, X., Li, Y., Fang, Q., Xu, F., Shen, J., Wang, P. G., 
Chemical Communications 2012, 48, 2788-2790. 
[87] Kolb, H. C., Finn, M. G., Sharpless, K. B., Angewandte Chemie International Edition 2001, 40, 
2004-2021. 
[88] Kolb, H. C., Sharpless, K. B., Drug Discovery Today 2003, 8, 1128-1137. 
[89] Moses, J. E., Moorhouse, A. D., Chemical Society Reviews 2007, 36, 1249-1262. 
[90] Bock, V. D., Hiemstra, H., van Maarseveen, J. H., European Journal of Organic Chemistry 2006, 
2006, 51-68. 
[91] Tornøe, C. W., Christensen, C., Meldal, M., The Journal of Organic Chemistry 2002, 67, 3057-
3064. 
[92] Meldal, M., Tornøe, C. W., Chemical Reviews 2008, 108, 2952-3015. 
[93] Rostovtsev, V. V., Green, L. G., Fokin, V. V., Sharpless, K. B., Angewandte Chemie 
International Edition 2002, 114, 2708-2711. 
[94] Zhang, L., Chen, X., Xue, P., Sun, H. H. Y., Williams, I. D., Sharpless, K. B., Fokin, V. V., Jia, 
G., Journal of the American Chemical Society 2005, 127, 15998-15999. 
[95] Worrell, B. T., Malik, J. A., Fokin, V. V., Science 2013, 340, 457-460. 
[96] Himo, F., Lovell, T., Hilgraf, R., Rostovtsev, V. V., Noodleman, L., Sharpless, K. B., Fokin, V. 
V., Journal of the American Chemical Society 2004, 127, 210-216. 
[97] Agalave, S. G., Maujan, S. R., Pore, V. S., Chemistry – An Asian Journal 2011, 6, 2696-2718. 
[98] Li, F., Park, Y., Hah, J.-M., Ryu, J.-S., Bioorganic & Medicinal Chemistry Letters 2013, 23, 
1083-1086. 
[99] Kalesh, K. A., Liu, K., Yao, S. Q., Organic & Biomolecular Chemistry 2009, 7, 5129-5136. 
[100] Poot, A. J., van Ameijde, J., Slijper, M., van den Berg, A., Hilhorst, R., Ruijtenbeek, R., Rijkers, 
D. T. S., Liskamp, R. M. J., ChemBioChem 2009, 10, 2042-2051. 
[101] Arioli, F., Borrelli, S., Colombo, F., Falchi, F., Filippi, I., Crespan, E., Naldini, A., Scalia, G., 
Silvani, A., Maga, G., Carraro, F., Botta, M., Passarella, D., ChemMedChem 2011, 6, 2009-2018. 
[102] Song, D., Park, Y., Yoon, J., Aman, W., Hah, J.-M., Ryu, J.-S., Bioorganic & Medicinal 
Chemistry 2014, 22, 4855-4866. 
[103] Elsberger, B., Critical reviews in Oncology/Hematology 2014, 89, 343-351. 
[104] Gargalionis, A. N., Karamouzis, M. V., Papavassiliou, A. G., International Journal of Cancer 
2014, 134, 2019-2029. 
[105] Kumar, A., Wang, Y., Lin, X., Sun, G., Parang, K., ChemMedChem 2007, 2, 1346-1360. 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 8 – References  
209 
 
[106] Kumar, A., Ahmad, I., Chhikara, B. S., Tiwari, R., Mandal, D., Parang, K., Bioorganic & 
Medicinal Chemistry Letters 2011, 21, 1342-1346. 
[107] Paydas, S., Critical Reviews in Oncology/Hematology 2014, 89, 242-247. 
[108] Food and Drug Administration, 2012. 
http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm318203.htm (accessed 
12/11/2014). 
[109] Kumar, D., Reddy, V. B., Kumar, A., Mandal, D., Tiwari, R., Parang, K., Bioorganic & 
Medicinal Chemistry Letters 2011, 21, 449-452. 
[110] Rao, V. K., Chhikara, B. S., Shirazi, A. N., Tiwari, R., Parang, K., Kumar, A., Bioorganic & 
Medicinal Chemistry Letters 2011, 21, 3511-3514. 
[111] Parikh, R. A., Wang, P., Beumer, J. H., Chu, E., Appleman, L. J., Oncotargets and Therapy 2014, 
7, 969-983. 
[112] Maroun, C. R., Rowlands, T., Pharmacology & Therapeutics 2014, 142, 316-338. 
[113] Furlan, A., Colombo, F., Kover, A., Issaly, N., Tintori, C., Angeli, L., Leroux, V., Letard, S., 
Amat, M., Asses, Y., Maigret, B., Dubreuil, P., Botta, M., Dono, R., Bosch, J., Piccolo, O., 
Passarella, D., Maina, F., European Journal of Medicinal Chemistry 2012, 47, 239-254. 
[114] Colombo, F., Tintori, C., Furlan, A., Borrelli, S., Christodoulou, M. S., Dono, R., Maina, F., 
Botta, M., Amat, M., Bosch, J., Passarella, D., Bioorganic & Medicinal Chemistry Letters 2012, 
22, 4693-4696. 
[115] Trembley, J. H., Zhong, C., Unger, G., Slaton, J., Kren, B. T., van Waes, C., Ahmed, K., 
Biofactors 2010, 36, 187-195. 
[116] Świder, R., Masłyk, M., Martín-Santamaría, S., Ramos, A., de Pascual-Teresa, B., Molecular and 
Cellular Biochemistry 2011, 356, 117-119. 
[117] Goumans, M.-J., Lebrin, F., Valdimarsdottir, G., Trends in Cardiovascular Medicine 2003, 13, 
301-307. 
[118] Buijs, J. T., Stayrook, K. R., Guise, T. A., Cancer Microenvironment 2011, 4, 261-281. 
[119] Veronique Calleja, M. L., Gloria de las Heras-Martinez, Peter J. Parker, Jose Requejo-Isidro and, 
Larijani, B., Biochemical Society Transactions 2014, 42, 1435-1440. 
[120] Medina, J. R., Journal of Medicinal Chemistry 2013, 56, 2726-2737. 
[121] Merkul, E., Klukas, F., Dorsch, D., Grädler, U., Greiner, H. E., Müller, T. J. J., Organic & 
Biomolecular Chemistry 2011, 9, 5129-5136. 
[122] Suchaud, V., Gavara, L., Giraud, F., Nauton, L., Théry, V., Anizon, F., Moreau, P., Bioorganic & 
Medicinal Chemistry 2014, 22, 4704-4710. 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 8 – References  
210 
 
[123] Letribot, B., Akué-Gédu, R., Santio, N. M., El-Ghozzi, M., Avignant, D., Cisnetti, F., Koskinen, 
P. J., Gautier, A., Anizon, F., Moreau, P., European Journal of Medicinal Chemistry 2012, 50, 
304-310. 
[124] Akué-Gédu, R., Rossignol, E., Azzaro, S., Knapp, S., Filippakopoulos, P., Bullock, A. N., Bain, 
J., Cohen, P., Prudhomme, M., Anizon, F., Moreau, P., Journal of Medicinal Chemistry 2009, 52, 
6369-6381. 
[125] Parker, B. C., Engels, M., Annala, M., Zhang, W., The Journal of Pathology 2014, 232, 4-15. 
[126] Le Corre, L., Girard, A.-L., Aubertin, J., Radvanyi, F., Benoist-Lasselin, C., Jonquoy, A., 
Mugniery, E., Legeai-Mallet, L., Busca, P., Le Merre, Y., Organic & Biomolecular Chemistry 
2010, 8, 2164-2173. 
[127] Rees, D. C., Congreve, M., Murray, C. W., Carr, R., Nature Reviews Drug Discovery 2004, 3, 
660-672. 
[128] Merckx, A., Echalier, A., Langford, K., Sicard, A., Langsley, G., Joore, J., Doerig, C., Noble, M., 
Endicott, J., Structure 2008, 16, 228-238. 
[129] Leroy, D., Doerig, C., Trends in Pharmacological Sciences 2008, 29, 241-249. 
[130] Dar, A. C., Lopez, M. S., Shokat, K. M., Chemistry & Biology 2008, 15, 1015-1022. 
[131] Pan, Z., Scheerens, H., Li, S.-J., Schultz, B. E., Sprengeler, P. A., Burril, C., Mendonca, R. V., 
Sweeney, M. D., Scott, K. C. K., Grothaus, P. G., Jeffrey, D. A., Spoerke, J. M., Honigberg, L. 
A., Young, P. R., Dalrymple, S. A., Palmer, J. T., ChemMedChem 2007, 2, 58-61. 
[132] Klein, M., Dinér, P., Dorin-Semblat, D., Doerig, C., Grøtli, M., Organic & Biomolecular 
Chemistry 2009, 7, 3421–3429. 
[133] Roffey, J., Rosse, C., Linch, M., Hibbert, A., McDonald, N. Q., Parker, P. J., Current Opinion in 
Cell Biology 2009, 21, 268-279. 
[134] Jain, K., Ajay, D., Sobhia, M. E., Molecular Informatics 2011, 30, 329-344. 
[135] Carmi, C., Galvani, E., Vacondio, F., Rivara, S., Lodola, A., Russo, S., Aiello, S., Bordi, F., 
Costantino, G., Cavazzoni, A., Alfieri, R. R., Ardizzoni, A., Petronini, P. G., Mor, M., Journal of 
Medicinal Chemistry 2012, 55, 2251-2264. 
[136] Cha, M. Y., Lee, K.-O., Kim, J. W., Lee, C. G., Song, J. Y., Kim, Y. H., Lee, G. S., Park, S. B., 
Kim, M. S., Journal of Medicinal Chemistry 2009, 52, 6880-6888. 
[137] Singh, J., Petter, R. C., Kluge, A. F., Current Opinion in Chemical Biology 2010, 14, 475-480. 
[138] Stock, N. S., Bain, G., Zunic, J., Li, Y., Ziff, J., Roppe, J., Santini, A., Darlington, J., 
Prodanovich, P., King, C. D., Baccei, C., Lee, C., Rong, H., Chapman, C., Broadhead, A., 
Lorrain, D., Correa, L., Hutchinson, J. H., Evans, J. F., Prasit, P., Journal of Medicinal Chemistry 
2011, 54, 8013-8029. 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 8 – References  
211 
 
[139] Waser, J., Gaspar, B., Nambu, H., Carreira, E. M., Journal of the American Chemical Society 
2006, 128, 11693-11712. 
[140] An, J., Chang, N.-J., Song, L.-D., Jin, Y.-Q., Ma, Y., Chen, J.-R., Xiao, W.-J., Chemical 
Communications 2011, 47, 1869-1871. 
[141] Takuya, K., Shin-ichiro, N., Yukiko, H., Hiroaki, K., Lemin, D., Nakanishi, W., Ishikawa, T., 
Heterocycles 2008, 76, 1155-1170. 
[142] Neosome Life Sciences, LLC., Patent: US2012/302578 A1, 2012. 
[143] Schering Corporation, Patent:US 20040010013 A1, 2004. 
[144] Tsotinis, A., Afroudakis, P. A., Davidson, K., Prashar, A., Sugden, D., Journal of Medicinal 
Chemistry 2007, 50, 6436-6440. 
[145] Zheng, C., Lu, Y., Zhang, J., Chen, X., Chai, Z., Ma, W., Zhao, G., Chemistry – A European 
Journal 2010, 16, 5853-5857. 
[146] Nystrom, R. F., Brown, W. G., Journal of the American Chemical Society 1947, 69, 1197-1199. 
[147] Burke, S. D., Danheiser, R. L., Handbook of Reagents for Organic Synthesis, Chichester, John 
Wiley & Sons, 1999. 
[148] Clayden, J., Greeves, N., Warren, S., Wothers, P., Organic Chemistry, Oxford, Oxford University 
Press, 2001. 
[149] Mo, F., Li, F., Qiu, D., Zhang, Y., Wang, J., Chinese Journal of Chemistry 2012, 30, 2297-2302. 
[150] Nunes Silva da Júnior, E., Synlett 2008, 149-150. 
[151] Tojo, G., Fernández, M., Oxidation of Alcohols to Aldehydes and Ketones: A Guide to Current 
Common Practice, New York, Springer, 2006. 
[152] Gritter, R. J., Dupre, G. D., Wallace, T. J., Nature 1964, 202, 179-181. 
[153] Johnson, A. W., Ylides and Imines of Phosphorus, New York, John Wiley & Sons, 1993. 
[154] Kolodiazhnyi, O. I., Phosphorus Ylides, Weinheim, Wiley-VCH, 1999. 
[155] Johnson, A. W., Ylid Chemistry, New York-London, Academic Press Inc., 1966. 
[156] Kocienski, P. J., Protecting Groups, 3rd ed., New York, Thieme, 2005. 
[157] Abid, M., Teixeira, L., Török, B., Tetrahedron Letters 2007, 48, 4047-4050. 
[158] Saulnier, M. G., Gribble, G. W., The Journal of Organic Chemistry 1982, 47, 757-761. 
[159] Bregman, H., William, D. S., Meggers, E., Synthesis 2005, 1521 -1527. 
[160] Tao, M., Park, C. H., Bihovsky, R., Wells, G. J., Husten, J., Ator, M. A., Hudkins, R. L., 
Bioorganic & Medicinal Chemistry Letters 2006, 16, 938-942. 
[161] Nicolaou, K. C., Snyder, S. A., Montagnon, T., Vassilikogiannakis, G., Angewandte Chemie 
International Edition 2002, 41, 1668-1698. 
[162] Corey, E.J., Angewandte Chemie International Edition 2002, 41, 1650-1667. 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 8 – References  
212 
 
[163] Sauer, J., Angewandte Chemie International Edition in English 1966, 5, 211-230. 
[164] Fernández, I., Bickelhaupt, F. M., Journal of Computational Chemistry 2014, 35, 371-376. 
[165] Stoos, F., Roček, J., Journal of the American Chemical Society 1972, 94, 2719-2723. 
[166] Siemens Aktiengesellschaft, Patent: US5194629 A1, 1993. 
[167] Wu, R., Lodwig, S. N., Schmidt, J. G., Williams, R. F., Silks, L. A. P., Journal of Labelled 
Compounds and Radiopharmaceuticals 2012, 55, 211-222. 
[168] Perez-Serrano, L., Casarrubios, L., Dominguez, G., Gonzalez-Perez, P., Perez-Castells, J., 
Synthesis 2002, 13, 1810-1812. 
[169] Smaill, J. B., Baker, E. N., Booth, R. J., Bridges, A. J., Dickson, J. M., Dobrusin, E. M., Ivanovic, 
I., Kraker, A. J., Lee, H. H., Lunney, E. A., Ortwine, D. F., Palmer, B. D., Quin, J., Squire, C. J., 
Thompson, A. M., Denny, W. A., European Journal of Medicinal Chemistry 2008, 43, 1276-
1296. 
[170] Bruson, H. A., Organic Reactions, John Wiley & Sons, Inc., 2004. 
[171] Muthusamy, S., Arulananda Babu, S., Gunanathan, C., Synthetic Communications 2002, 32, 
3247-3254. 
[172] Caballero, E., Adeva, M., Calderón, S., Sahagún, H., Tomé, F., Medarde, M., Fernández, J. L., 
López-Lázaro, M., Jesús Ayuso, M.,  Bioorganic & Medicinal Chemistry 2003, 11, 3413-3421. 
[173] Robertson, A., Philp, D., Spencer, N., Tetrahedron 1999, 55, 11365-11384. 
[174] Liu, Q., Luedtke, N. W., Tor, Y., Tetrahedron Letters 2001, 42, 1445-1447. 
[175] Wuts, P. G. M., Greene, T. W., Greene's Protective Groups in Organic Synthesis, New Jersey, 
John Wiley & Sons, 2012. 
[176] Souffrin, A., Croix, C., Viaud-Massuard, M.-C., European Journal of Organic Chemistry 2012, 
2012, 2499-2502. 
[177] Relles, H. M., The Journal of Organic Chemistry 1972, 37, 3630-3637. 
[178] Chow, Y. L., Naguib, Y. M. A., Journal of the Chemical Society Perkin Transactions 1 1984, 
1165 -1171. 
[179] Edge, S., Charlton, A., Hansen, T. K., Varma, K. S., Underhill, A. E., Becher, J., 
Kathirgamanathan, P., Khosravi, E., Journal of Polymer Science Part A: Polymer Chemistry 
1992, 30, 2773-2780. 
[180] Nirogi, R., Dwarampudi, A., Kambhampati, R., Bhatta, V., Kota, L., Shinde, A., Badange, R., 
Jayarajan, P., Bhyrapuneni, G., Dubey, P. K., Bioorganic & Medicinal Chemistry Letters 2011, 
21, 4577-4580. 
[181] Chinchilla, R., Nájera, C., Chemical Reviews 2007, 107, 874-922. 
[182] Deore, P. S., Argade, N. P., Synthesis 2014, 46, 281-289. 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 8 – References  
213 
 
[183] Chinchilla, R., Nájera, C., Chemical Society Reviews 2011, 40, 5084-5121. 
[184] Sonogashira, K., Tohda, Y., Hagihara, N., Tetrahedron Letters 1975, 16, 4467-4470. 
[185] Sonogashira, K., Journal of Organometallic Chemistry 2002, 653, 46-49. 
[186] Castañeda, L., Maruani, A., Schumacher, F. F., Miranda, E., Chudasama, V., Chester, K. A., 
Baker, J. R., Smith, M. E. B., Caddick, S., Chemical Communications 2013, 49, 8187-8189. 
[187] Cheng, C.-F., Lai, Z.-C., Lee, Y.-J., Tetrahedron 2008, 64, 4347-4353. 
[188] Sun, S., Zhu, C., Song, D., Li, F., Hu, A., Polymer Chemistry 2014, 5, 1241-1247. 
[189] Pajak, B., Orzechowska, S., Gajkowska, B., Orzechowski, A., Advances in Medical Sciences 
2008, 53, 21. 
[190] Peifer, C., Alessi, D. R., ChemMedChem 2008, 3, 1810-1838. 
[191] Seyferth, D., Organometallics 2009, 28, 1598-1605. 
[192] Gary S. Silverman, P. E. R., Handbook of Grignard Reagents, New York, Marcel Dekker Inc., 
1996. 
[193] Powers, J. C., Meyer, W. P., Parsons, T. G., Journal of the American Chemical Society 1967, 89, 
5812-5820. 
[194] Heacock, R. A., Kašpárek, S., Advances in Heterocyclic Chemistry, Vol. 10, Academic Press, 
1969, pp. 43-112. 
[195] Marminon, C., Pierré, A., Pfeiffer, B., Pérez, V., Léonce, S., Pierré, A., Pfeiffer, B., Renard, P., 
Prudhomme, M.,  Journal of Medicinal Chemistry 2003, 46, 609-622. 
[196] Ye, Q., Xu, G., Lv, D., Cheng, Z., Li, J., Hu, Y., Bioorganic & Medicinal Chemistry 2009, 17, 
4302-4312. 
[197] Delarue-Cochin, S., McCort-Tranchepain, I., Organic & Biomolecular Chemistry 2009, 7, 706-
716. 
[198] Brenner, M., Rexhausen, H., Steffan, B., Steglich, W., Tetrahedron 1988, 44, 2887-2892. 
[199] Holz, J., Zayas, O., Jiao, H., Baumann, W., Spannenberg, A., Monsees, A., Riermeier, T. H., 
Almena, J., Kadyrov, R., Börner, A., Chemistry – A European Journal 2006, 12, 5001-5013. 
[200] Teller, S., Eluwa, S., Koller, M., Uecker, A., Beckers, T., Baasner, S., Böhmer, F. D., Mahboobi, 
S., European Journal of Medicinal Chemistry 2000, 35, 413-427. 
[201] Stewart, S. G., Polomska, M. E., Lim, R. W., Tetrahedron Letters 2007, 48, 2241-2244. 
[202] Awuah, E., Capretta, A., The Journal of Organic Chemistry 2011, 76, 3122-3130. 
[203] Jo, Y. S., van der Vlies, A. J., Gantz, J., Thacher, T. N., Antonijevic, S., Cavadini, S., Demurtas, 
D., Stergiopulos, N., Hubbel, J. A.,  Journal of the American Chemical Society 2009, 131, 14413-
14418. 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 8 – References  
214 
 
[204] Yin, K.-H., Hsieh, Y.-H., Sulake, R. S., Wang, S.-P., Chao, J.-I., Chen, C., Bioorganic & 
Medicinal Chemistry Letters 2014, 24, 5247-5250. 
[205] Ohashi, K., Maruvka, Y. E., Michor, F., Pao, W., Journal of Clinical Oncology 2013, 31, 1070-
1080. 
[206] Ai, X., Sun, Y., Wang, H., Lu, S., Amino Acids 2014, 46, 1635-1648. 
[207] Remon, J., Morán, T., Majem, M., Reguart, N., Dalmau, E., Márquez-Medina, D., Lianes, P., 
Cancer Treatment Reviews 2014, 40, 93-101. 
[208] Vallath, S., Hynds, R. E., Succony, L., Janes, S. M., Giangreco, A., European Respiratory 
Journal 2014, erj01464-02013. 
[209] Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, 
M., Eck, M. J., Proceedings of the National Academy of Sciences 2008, 105, 2070-2075. 
[210] Costa, D. B., Schumer, S. T., Tenen, D. G., Kobayashi, S., Journal of Clinical Oncology 2008, 
26, 1182-1184. 
[211] Kolb, A. J., Kaplita, P. V., Hayes, D. J., Park, Y.-W., Pernell, C., Major, J. S., Mathis, G., Drug 
Discovery Today 1998, 3, 333-342. 
[212] Harbert, C., Marshall, J., Soh, S., Steger, K., Current Chemical Genomics 2008, 1, 20. 
[213] Degorce, F., Card, A., Soh, S., Trinquet, E., Knapik, G.P., Xie, B., Current Chemical Genomics 
2009, 3, 22-32. 
[214] Engel, J., Technische Universität Dortmund, Germany, 2014. 
[215] Johnson, D. C., Widlanski, T. S., Tetrahedron Letters 2004, 45, 8483-8487. 
[216] Sasaki, S., Hashimoto, T., Obana, N., Yasuda, H., Uehara, Y., Maeda, M., Bioorganic & 
Medicinal Chemistry Letters 1998, 8, 1019-1022. 
[217] Xie, G., Gupta, R., Atchison, K., Lown, J. W., Journal of Medicinal Chemistry 1996, 39, 1049-
1055. 
[218] Nascimento-Júnior, N. M., Mendes, T. C. F., Leal, D. M., Corrêa, C. M. N., Sudo, R. T., Zapata-
Sudo, G., Barreiro, E. J., Fraga, C. A. M., Bioorganic & Medicinal Chemistry Letters 2010, 20, 
74-77. 
[219] Coghlan, M. P., Culbert, A. A., Cross, D. A. E., Corcoran, S. L., Yates, J. W., Pearce, N. J.,  
Rausch, O. L., Murphy, G. J., Carter, P. S., Cox, L. R., Mills D., Brown, M. J., Haigh, D., Ward, 
R. W., Smith, D. G., Murray, K. J., Reith A. D., and J. C., Holder, Chemistry & Biology 2000, 7, 
793-803. 
 
[220] Smith, D. G., Buffet, M., Fenwick, A. E., Haigh, D., Ife, R. J., Saunders, M., Slingsby, B. P., 
Stacey, R., Ward, R. W., Bioorganic & Medicinal Chemistry Letters 2001, 11, 635-639. 
Stellenbosch University  https://scholar.sun.ac.za




Stellenbosch University  https://scholar.sun.ac.za
